



#4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Aerts et al.

Serial No.: 10/004,219

Filed: November 2, 2001

For: A MAMMALIAN MUCINASE, ITS RECOMBINANT PRODUCTION, AND ITS USE IN THERAPY OR PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS INVOLVED OR INFECTIOUS DISEASES

Examiner: To be assigned

Group Art Unit: 1645

Attorney Docket No.: 2183-5136US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C.F.R. § 1.8(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

May 29, 2002
Date of Deposit

Betty Vowles
Signature of registered practitioner or other person having reasonable basis to expect mailing to occur on date of deposit shown pursuant to 37 C.F.R. § 1.8(a)(1)(ii)

Betty Vowles
Typed/printed name of person whose signature is contained above

THIRD PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced patent application on the merits, entry of the amendments as set forth herein is respectfully solicited.

Serial No.: 10/004,219

IN THE SPECIFICATION:

Pursuant to 37 C.F.R. §§ 1.121 and 1.125 (as amended to date) please enter the substitute specification in clean form and including paragraph numbers [0001] through [0137], References and Abstract attached hereto as Appendix A. A marked-up substitute specification to clearly identify amendments to the specification as required by 37 C.F.R. § 1.121(b)(3)(iii) is attached hereto as Appendix B. It is respectfully submitted that the substitute specification does not introduce new matter into the above-referenced patent application.

Please also insert the enclosed Sequence Listing after Page 47 of the as-filed substitute specification.

Serial No.: 10/004,219

REMARKS

The application has been amended to include a Sequence Listing in conformity with 37 C.F.R. §§ 1.821-1.825. Submitted herewith is the Sequence Listing, a copy of the Sequence Listing in computer readable form (CRF), as well as a Statement under 37 C.F.R. §§ 1.821(f) and 1.825. Appendices A and B also include the Sequence Listing.

The application further has been amended to cancel drawing figures 2 and 8A (*see*, attached Proposed Amendment to Drawing Figures). The sequences that were contained in these drawing figures have been incorporated into the text of the specification. Drawing figure 8B has been amended to increase the font size of the sequences contained therein and now is presented as figure 8.

It is respectfully requested that no new matter has been added by the amendment. However, if any questions remain after consideration of the instant amendments, the Office is kindly requested to contact applicants' attorney at the address or telephone number given herein.

Respectfully submitted,



Tawni L. Wilhelm
Registration No. 47,456
Attorney for Applicant
TRASKBRITT, PC
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: May 29, 2002

ACT/TLW/csw

N:\2183\5136\3rd preliminary amendment wpd



APPENDIX A

(CLEAN VERSION OF SUBSTITUTE SPECIFICATION EXCLUDING CLAIMS)

(Serial No. 10/004,219)



PATENT
Attorney Docket 5136US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL 740547479 US

Date of Deposit with USPS: November 2, 2001

Person making Deposit: Blake Johnson

APPLICATION FOR LETTERS PATENT

for

**A MAMMALIAN MUCINASE, ITS RECOMBINANT PRODUCTION, AND ITS USE
IN THERAPY OR PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS
INVOLVED OR INFECTIOUS DISEASES**

Inventors:
J.M.F.G. Aerts
R.G. Boot

Attorney:
Allen C. Turner
Registration No. 33,041
TRASKBRITT
P.O. Box 2550
Salt Lake City, Utah 84110
(801) 532-1922

TITLE OF THE INVENTION

A MAMMALIAN MUCINASE, ITS RECOMBINANT PRODUCTION, AND ITS USE IN
THERAPY OR PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS
INVOLVED OR INFECTIOUS DISEASES

TECHNICAL FIELD

[0001] The invention relates to the field of medicine. More specifically, the invention relates to therapeutic or prophylactic treatment of an individual against a disease in which mucus is involved and/or an infection disease. The invention also relates to the preparation of a mucinase suitable for the treatment.

BACKGROUND

[0002] Mucus as protective barrier. Mucins form part of the dynamic, interactive defensive system of mammals at mucosal surfaces in, for example, the gastrointestinal tract, the respiratory tract, and reproductive organs. Mucins are highly glycosylated proteins occurring either as secretory or membrane-bound forms. They have a unique molecular structure and chemical properties. The polypeptide backbone (apomucin) is rich in hydroxy amino acids, serine and threonine, which together with glycine, alanine and proline comprise nearly 50% of total amino acid residues of the protein and are present as tandemly repeated sequences. The threonine and serine residues are the targets of O-glycosylation machinery and the extent of glycosylation is such that carbohydrates account for 50-85% of the dry weight of mucins. Secretory mucins are the major constituents of mucus secretions, lining the epithelial cells of digestive, respiratory and reproductive tracts (Gendler et al., 1995, Gum 1995). They are capable of forming gels at very low concentration by forming long thread-like polymers resulting from the formation of disulphide linkages between monomers and intramolecular interactions of sugar side chains. Membrane-bound mucins are present on the surface of various cell types and, unlike secretory mucins, do not form oligomers and are hence smaller in size than their secretory counterparts (Gendler et al., 1995, Gum 1995). The membrane-bound mucins also have O-glycosylated serine and threonine-rich regions, but they lack tandem repeat sequences. The primary function of secretory mucins is to provide protection to the apical epithelial cell layers in digestive, respiratory and urinogenital tracts against environmental factors like acidic pH, hydrolytic enzymes and pathogens. The cell

surface mucins, in addition to their protective role, have a shielding effect on various surface receptors, thereby helping in the regulation of their activity (Strous and Dekker 1992). So far, twelve human mucin genes have been identified, designated as MUC1-4, MUC5AC, MUC5B, MUC6-9, and MUC11-12 (Gendler et al., 1995, Gum 1995, Gum et al., 1990, Lan et al., 1990, Moniaux et al., 1999, Shankar et al., 1997, Williams et al., 1999). They can be divided into secreted and membrane-associated forms, each with characteristic protein domains and tissue-specific glycosylation. Eight human mucin genes have been well characterized: MUC2, MUC5AC, MUC5B, MUC6 map to 11p15.5 and encode secretory gel-forming mucins while MUC1, MUC3, MUC4, MUC7 are scattered on different chromosomes and encode membrane-bound or secreted mucins.

[0003] Historically, purified mucins have been identified by their amino and carbohydrate composition consisting of a high percentage of serine, threonine, proline, alanine, glycine, and a large proportion of O-linked oligosaccharides (up to 80% of the total mass). Biosynthetic pathways have been described for the secreted and membrane-associated mucins and their eventual degradation and turnover. Mucins are present at all mucosal surfaces throughout the body in typical combinations and relate to the demands of organ function. Patterns of MUC gene expression with gastrointestinal site-specific glycosylation are clearly important but are not yet well defined. The mucosal surface throughout the gastrointestinal tract must resist the aggressive elements from the external environment present in the diet and encountered during normal function. This defensive system is based on fundamental characteristics shared with the barrier found at other mucosal surfaces. The stable protective barrier enabling exchange between the epithelial cells of the gut lumen for the purposes of nutrition and protection is made up of a layer of secreted mucus and a cell-surface membrane glycocalyx. The mucus defensive barrier forms the first line of defense to the external environment and contains both innate and adaptive immune elements.

[0004] Mucin expression. Mucins are present at all mucosal surfaces throughout the body. The specific functional requirements for mucus at each site are reflected in the appearance of different mucins in the cells at different sites in the body. The main population of specially adapted cells producing secreted mucins are the goblet cells. The proportion of goblet cells increases through the gastrointestinal tract (GI tract) with maximal numbers in the rectum. Goblet cells in the respiratory tract are present in the trachea and, to a lesser extent, in the bronchi. They are rarely found in bronchioles less than 1 mm in diameter (Jeffery et al., 1992). Mucins have a tissue-specific glycosylation at each site in the gastrointestinal tract. As carbohydrate constitutes the major part of all mature mucins and is

represented by vast arrays of different oligosaccharide structures, the potential for multiple functions related to bulk carbohydrate or individual structures must be examined. Most of the oligosaccharides in mucins are attached by O-links. However, a much smaller number of N-linked chains are also present, linked to asparagine residues in the mucin polypeptide through an N-glycosidic bond to N-acetyl-D-glucosamine. N-linked oligosaccharides contain a branched trimannosyl-chitobiose pentasaccharide core attached to the peptide.

[0005] Mucus degradation. The adherent mucus barrier and the glycocalyx are constantly being turned over as part of their protective functions at the mucosal surface. Thus, degradation of mucus is a normal feature of an equilibrium between mucosal synthesis, secretion and the breakdown of the existing adherent gel. This balance must be regulated to ensure continual mucosal protection against potentially damaging compounds and organisms entering in the diet. The first stage in mucus degradation is conversion of the mucus gel to a viscous fluid. The viscoelastic properties of the secreted, adherent gel layer are governed by the mucins, and they are responsible for the gel-forming properties. The non-mucin components of mucus may influence gel formation or affect gel strength. They are implicated in pathological situations where alterations in the normal composition of mucus are made. Mucinase activity of bacteria has been described and is well known from observations of mucin carbohydrate release, sequestration and metabolic conversion by bacteria in the large intestine. A population of mucin oligosaccharide-degrading (MOD) bacterial strains capable of specific and complete degradation of mucins has been identified. Bacterial mucinase enzymes have been shown to act on the mucus gel to reduce it to a viscous fluid, probably through the action of proteinases or peptidases, to act further on the accessible peptide backbone, not blocked by oligosaccharide substitution, and to cleave the individual sugars from the oligosaccharide chains. Bacterial mucinase activity has been measured in fecal extracts using electrophoretic assessment of mucin degradation and by direct mucinase assays with purified biotinylated mucins.

[0006] Mucin-associated diseases. Changes in mucus are frequent in inflammatory diseases of the epithelia. High levels of secretion of the mucin proteins is a common factor in, for instance, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), chronic bronchitis, asthma, tuberculosis, and carcinomas. Conversely, in Inflammatory Bowel Disease such as Crohns disease and ulcerative colitis, the mucus barrier is decreased. Furthermore, mucus appears to play a role in infection by mucus-containing pathogens.

[0008] A variety of symptoms, the most common ones being salty-tasting sweat and skin, persistent cough, wheezing, and failure to thrive (due to intestinal defects, malnutrition and anorexia), characterize the disease. The usual complications in the respiratory tract are: hemoptysis (blood in the sputum); pneumothorax (collapsed lung); atelectasis (air resorption leaving the lobe or segment airless) caused by complete mucus plugging; dilated bronchioles and bronchi and weakened bronchioles and bronchi walls; fibrosis (scar tissue); and low oxygen levels. Respiratory failure in CF is usually at the end of a long process where frequently there is no longer enough healthy lung tissue left to eliminate CO₂. It is widely believed that the respiratory sequela in CF and progressive deterioration of respiratory function are the result of persistent bacterial colonization (culminating with chronic *P. aeruginosa* infections) and chronic inflammation. The major cause of high morbidity and mortality in CF remains the chronic respiratory infections (most notably with *P. aeruginosa*) which account for more than 90 percent of CF mortality.

[0009] Cystic fibrosis (CF) is a multiorgan disease that is the result of a genetic defect of a single gene. The gene, CF transmembrane conductance regulator (CFTR), was identified in 1989 (Riordan et al., 1989). The gene encodes a membrane glycoprotein that functions as a cAMP-regulated chloride channel in exocrine glands and secretory epithelia.

[0010] As a result, thick and adhesive mucus is present in the airways and gastrointestinal tract of cystic fibrosis patients, leading to respiratory symptoms, recurrent infections, and progressive lung destruction, as well as nutritional deficiencies. The viscosity of CF mucus is determined by the presence of mucins. In addition, purulent mucus of CF patients contains as much as 3-14 mg/ml DNA (Chernick and Barbero 1959, Potter et al., 1960). This DNA, derived from inflammatory cells and epithelial cells, contributes (together with actin) to the viscosity of purulent CF sputum. Therefore, mucus transport by mucociliary activity and/or cough is hampered. In addition, the viscous DNA-containing mucus may also cause reduced effectiveness of aminoglycoside antibiotics. These two aspects of CF mucus viscosity result in persistent, recurring infections and progressive lung destruction.

[0011] As the pathogenesis of cystic fibrosis is complex, treatment for CF consists of several approaches. The pulmonary disease is managed by combinations of physiotherapy,

antibiotics (especially to contain *Pseudomonas aeruginosa* infections, which is an important cause of death in CF patients), mucolytics (n-acetylcysteine, recombinant human DNase I), bronchodilators and anti-inflammatory agents such as oral corticosteroids. The nutritional support mainly consists of the administration of pancreatic enzyme preparations to help food digestion, which is hampered by obstruction of the pancreatic ducts.

[0012] The aerosol route can be used to deliver mucoactive medications locally. These mucoactive medications comprise mucolytics, mucokinetic agents, mucoregulatory medications and expectorants and ion channel modifiers.

[0013] Several studies have focused on the use of recombinant human DNase (rhuDNase) I to reduce the viscosity of cystic fibrosis sputum. In *in vitro* assays, the viscosity of purulent CF sputum as well as its adhesiveness was shown to decrease after treatment with recombinant human DNase I (Pulmozyme®, Genentech), and the mucociliary transportability of CF sputum is increased (Shak et al., 1990, Zahm et al., 1995). This is due to the degradation of DNA but also to the depolymerization of F-actin (Vanscellos et al., 1994) Phase 3 clinical trials have shown that treatment with aerosolized recombinant human DNase I results in a 28-37% reduction in respiratory exacerbations and an improvement of 5.6-5.8% in FEV1, a measure for lung function (Fuchs et al., 1994, Shak et al., Chest 1995).

[0014] COPD. Chronic Obstructive Pulmonary Disease (COPD) is a physiologically defined group of conditions characterized by the presence of persistent airflow obstruction. COPD is defined as a disease state characterized by the presence of airflow obstruction due to chronic obstructive bronchitis or emphysema.

[0015] One of the hallmarks of bronchitis is hyperproduction of mucus as well as loss of mucociliary clearance. Even though an effect of rhuDNase has been shown to reduce chronic bronchitis sputum viscosity (Puchelle et al., 1996), mucus in chronic bronchitis contains 10-fold less DNA than in CF sputum (Kim et al., 2001). This indicates that Pulmozyme, which is a human DNase that is used to reduce viscosity of CF sputum, is not equally effective as a mucolytic for bronchitis mucus. Chronic bronchitis is currently treated with bronchodilators, β -adrenergic agents, methylxanthines, corticosteroids, and mucolytics, mostly with n-acetylcysteine. N-acetylcysteine has mucolytic activity *in vitro*; this activity, however, has not been demonstrated convincingly *in vivo* (Celli et al., 1995)

[0016] Asthma. In chronic asthma, as in CF and bronchitis, decreased mucociliary clearance caused by mucus hypersecretion and/or rheological changes and permanent changes in ciliary structure and function occur. Airway inflammation plays a

[0017] Tuberculosis. Another disease in which airway mucus viscosity is increased and acetylcysteine is used as a mucolytic is pulmonary tuberculosis. Tuberculosis is an infectious disease caused by *Mycobacterium tuberculosis*, which is transmitted by aerosols of saliva and mucus released by coughing. Pulmonary tuberculosis is associated with persistent cough and expectoration of bloody mucus. The disease is generally treated by long-term therapy with combinations of antibiotics.

[0018] Intensive care medicine (respiration). Patients in intensive care that are attached to a respirator also have problems clearing airway mucus. The airways of these patients need to be cleared regularly to prevent stasis and opportunistic infections. To this aim, these patients get antibiotics prophylactically.

[0019] Carcinoma. Mucins are thought to promote tumor-cell invasion and metastasis. In many human carcinomas, the expression profile of mucins is altered, with certain mucins like MUC1 being upregulated while others show a downregulated expression. The glycosylation process is disrupted in cancer, leading to aberrantly glycosylated, mostly underglycosylated mucins. In gastric carcinomas, the alterations of the mucin expression have been the subject of several studies. The expression of MUC5AC, a secretory mucin present in normal gastric mucosa, is downregulated and can be found in only 60% of the intestinal carcinomas. At the same time, the expression of MUC1 and MUC2 in gastric carcinomas was upregulated. The decrease in the amount of glycosylation of MUC1 with the progression of carcinogenesis was shown with a panel of antibodies binding with different affinities to glycosylated and unglycosylated forms of MUC1. Furthermore, in cancer cells the expression of MUC1 was distributed over the entire cell membrane, while it was limited to the apical region of normal gastric mucosa cells.

[0020] The expression pattern of the mucin genes is complex in normal airways involving six genes, mainly MUC5AC and MUC5B in mucus-producing cells and MUC4 in a wide array of epithelial cells. MUC5AC overexpression in metaplasia, dysplasia and normal epithelium adjacent to squamous cell carcinoma provides additional arguments for a mucous cell origin of preneoplastic squamous lesions. MUC5AC and MUC5B expression is related to mucus formation in adenocarcinomas. Mucinous bronchiolalveolar carcinoma (BAC) has a particular pattern of mucin gene expression indicating that it has sustained a well-differentiated phenotype similar to the goblet cell, correlated with distinctive features, i.e., a noninvasive pattern and a better prognosis than nonBACs. MUC4 is the earlier mucin gene

expressed in the foregut, before epithelial differentiation, and is expressed independently of mucus secretion both in normal adult airways and carcinomas. These findings are in favor of the histogenetic theory of non-small-cell carcinoma originating from a pluripotent mucous cell.

[0021] Several arguments suggest that mucins play a role in tumor-cell invasion and metastasis, resulting in prognostic implications. MUC1 is a transmembrane molecule with a large extracellular domain protruding high above the cell surface thought to reduce cell-cell and extracellular matrix (ECM)-cell adhesion in cancer cells (Jentoft 1990, Hudson et al., 1996) but direct evidence for a role of specific mucin genes in tumor progression is lacking. One study shows that splenic-portal inoculation in athymic mice of MUC2 antisense construct in highly metastatic human colon cancer cells resulted in a reduction in MUC2 levels and a marked decrease in liver colonization (Sternberg et al., 1999). Sialomucin complex (SMC), a rat homologue of the human mucin MUC4 isolated from highly metastatic ascites 13762 mammary adenocarcinoma cells is thought to potentiate metastasis by sterical disruption of molecular interactions for cell-cell and cell-ECM adhesions and by suppression of anti-tumor immunity by inhibition of interactions between cytotoxic lymphocytes and target tumor cells (Carraway et al., 2000). One recent study shows that *in vivo*, subcutaneous injection of SMC-overexpressing cells results in substantially greater lung metastasis than injection of SMC-repressed cells. Moreover, injection of A375 human melanoma cells followed by *in vivo* induction of SMC overexpression within the solid tumor resulted in spontaneous distant metastasis (Komatsu et al., 2000).

[0022] Mucus-containing pathogens. Mucins and mucin-like molecules have recently been described in several protozoan parasites, at different stages of the life cycle. These include kinetoplastid (*Trypanosoma*, *Leishmania*), apicomplexan (*Cryptosporidium*) and amoebic (*Entamoeba*) parasites (Schenkman et al., 1993, Almeida et al., 1994, Ilg et al., 1999, Barnes et al., 1998, Strong et al., 2000). These share many structural and compositional features with mammalian mucins, but vary in several other aspects. It is now becoming evident that mucins in a parasite are involved in cell-cell interaction and cell surface protection, thus helping the parasite to establish infection.

[0023] Currently, several pharmaceutical compounds against diseases in which mucus is involved are used. Those compounds have, however, limited beneficial effects. A major reason for this is the fact that the targets of therapeutic compounds, like, for instance, lung epithelial cells, can hardly be reached because of the barrier of thick and adhesive mucus which is present in the airways and gastrointestinal tract of the patient. After administration

of a certain pharmaceutical composition, only a small percentage of the composition is actually capable of performing its beneficial effect. Higher doses often do not improve treatment; essentially no more targets can be reached. Furthermore, higher doses often lead to more harmful side effects. A major part of administered pharmaceutical composition therefore often leaves the body before any beneficial effect could be performed.

[0024] The incapability of current therapeutic compounds to reach their target efficiently is a major drawback of current treatment.

[0025] Mucus thus provides an important defensive barrier which forms the first line of defense to the external environment. However, several diseases involve a disturbed generation of mucus, resulting in thick and adhesive mucus. This mucus forms an unwanted barrier hampering the uptake of, for instance, nutrition and/or medicines by a patient. This is, for instance, a major problem for patients suffering from cystic fibrosis, COPD, asthma, bronchitis, and tuberculosis. Uptake of nutrients in the gastrointestinal tract is insufficient because of the decreased permeability of the mucus layer covering the epithelial cells. This often results in failure to thrive. Likewise, pharmaceutical compositions are less able to reach their target, for instance, in the lungs, because of a thick mucus layer. This reduces the efficiency of current treatment. Therefore, there is a need for a means of decreasing the mucus barrier in a mammal.

SUMMARY OF THE INVENTION

[0026] The present invention provides a recombinant or substantially isolated or purified mammalian mucinase, or a modified form thereof having a substantially similar mucin-hydrolyzing activity. The invention also provides a recombinant or substantially isolated or purified mucinase, the mucinase being a mucinase having an amino acid sequence essentially corresponding to the amino acid sequence shown in Table I below (SEQ ID NO:1), or a modified form of the mucinase having a substantially similar mucin-hydrolyzing activity. A mucinase of the invention is particularly suitable for degrading mucus. The mucinase is particularly suitable of degrading mucus in a mammal, because a mammal naturally comprises a mucinase of the invention, which is endogenously present in the mammal. Therefore, a mucinase of the invention does not provoke severe side-effects and harmful immune responses in the mammal.

[0027] Table I. Human AMCase amino acid sequence (SEQ ID NO:1) deduced from cDNA sequence. The characteristic hydrophobic signal peptide (amino acids 1-21) is underlined with a single line.

MTKLILLTGLVLILNLQLGSAYQLTCYFTNWAQYRPGLG
 RFMPDNIDPCLCLTHLIYAFAGRQNNEITTIEWNDVTLYQ
 AFNGLKNKNSQLKTLLAIGGWNGTAPFTAMVSTPENR
 QTFITSVIKFLRQYEFDGLDFDWEYPGSRGSPQDKHLFT
 VLVQEMREAFEQEAKQINKPRLMVTAAVAAGISNIQSG
 YEIPQLSQYLDYIHVMTYDLHGSWEGYTGENSPLYKYP
 TDTGSNAYLNVDYVMNYWKDNGAPAELKLVGFPTYGH
 NFILSNPSNTGIGAPTSGAGPAGPYAKESGIWAYYEICTF
 LKNGATQGWDAPQEVPYAYQGNVWVGYDNIKSFDIKA
 QWLKHMKFGGAMVWAIDLDDFTGTFCNQGKFPLISTLK
 KALGLQSASCTAPAQPIEPITAAPSGSGNGSGSSSSGGSS
 GGSGFCAVRANGLYPVANNRNAFWHCVNGVTYQQNC
 QAGLVFDTSCDCCNWA

[0028] With a mucinase of the invention, it is now, for instance, possible to efficiently decrease an unwanted mucus barrier in the respiratory tract and/or gastrointestinal tract of a patient suffering from a disease in which mucus is involved without harmful side-effects. On the one hand, degrading mucus improves the capability of the patient to take up oxygen and/or nutrients. On the other hand, by (partially) degrading a thick mucus layer, delivery of other pharmaceutical compositions becomes easier, and mucociliary clearance improves, resulting in fewer persistent infections. It has also become possible to selectively counteract tumor cells which have a different mucus expression pattern as compared to normal cells. Additionally, it is possible to at least in part degrade microorganisms comprising mucus.

[0029] The invention also provides a mucinase produced by a host or host cell and isolated from the host or host cell or medium in which the host cell is cultured. In one embodiment, the amino acid sequence of the mucinase is encoded by a nucleotide sequence essentially corresponding to the nucleotide sequence shown in Table II below (SEQ ID NO:2). The mucinase is called AMCase. Preferably, the mucinase has a molecular weight of about 50 kDa.

[0030] Table II. Human AMCase cDNA sequence (SEQ ID NO:2) (GenBank Accession Number AF290004).

gcttccagtctgggtgaatcctccatagtctgaagccttgtataaccacagaatcag
 aacatataaaaagctcgcccactggtgctgactgcaccaatgacaaagcttattctcct
 cacaggcttgcctatactgaattgcagctcggtctgcctaccagctgacatgctactt

caccaactggcccagtaccggccaggectgggcgttcatgcctgacaacatcgac
ccctgcctctgtacccacctgtactcgccttgctggaggcagaacaacgagatcacc
accatcgaaatggaaacgtgtactcttccaagttcaatggctgaaaataagaaca
gccagctgaaaactctctggccattggaggctggaaacttcggactgccccttcactg
ccatggttctactctctgagaaccgcagacttcatcacctcagtcataatctcgcc
cagtagatgttgcacggctggactttgactggagttaccctggctctgtggggccctc
ctcaggacaaggcatcttcactgtctggcaggaaatgcgtgaagctttgagcagga
ggccaaggcagatcaacaagcccaggctgtatgtactgtcgtactgtcgtact
ccaatatccatgtggctatgagatccccactgticacagtacactggactacatccatgtc
atgacctacgacccatgtggctctggagggtacactggagagaacagccctcta
caaataccgactgacaccggcagcaacgcctactcaatgtggattatgtcatgaacta
ctggaaaggacaatggagcaccagctgagaagctcatgttggatccctacctatggaca
caacttcatctgagcaacccctcaacacttggaaattggccccccacctctggctgg
cctgtggccctatgccaaggagtctggatctggctactacgagatctgtaccc
tggaaaatggagccactcaggatggatgcctcaggaaatgccttatgcctatc
ggcaatgttgttgtggctatgacaacatcaagagcttcgatattaaggctcaatggctta
agcacaacaaatggagggccatgttccctaatctccacccctgaagaaggccctggc
cttctgcacccaggcaagttccctaatctccacccctgaagaaggccctggc
gagtgcacgttgcacggccatgttccctaatctccacccctgaagaaggccctggc
cagcgggaacgggagcgggagtagcagctctggaggcagctggaggcagttggat
tctgtgtcagagccaaacggccatccctgtggcaataacagaaatgcctctggc
actcgtaatgggtacgttccctaatctccacccctgaagaaggccctggc
agctgtgttgcacgttgcataaacctgacctgtatattccctagagttccagtc
cttttgttggacatgttgcacccctacctaaagtctcaataaaatcagcagtc

[0031] By “a mucinase” is meant herein a proteinaceous molecule which is capable of, at least in part, hydrolyzing a mucin. This results in the cleavage of at least one sugar moiety bond of the mucin. Preferably, a sugar moiety, such as a β .1-4 linked N-acetylglucosamine, is cleaved. In terms of the invention, by “substantially isolated or purified” is meant that the mucinase is removed from an environment in which it naturally occurs, or that a sample, comprising the mucinase, is enriched for the mucinase. The sample may be obtained from a mammal, for instance, from a mouse or a human individual, because mammals endogenously comprise a mucinase of the invention.

[0032] By “a recombinant mucinase” is meant a mucinase which has artificially been made, as opposed to mucinases which are naturally generated in living organisms. A recombinant mucinase can, for instance, be generated by expression, either *in vitro* or *in vivo*, of a vector comprising a nucleic acid sequence encoding the mucinase.

[0033] In terms of the invention, “a sequence essentially corresponding to” means that variations of the sequence are allowed, as long as the variations do not alter the properties of the sequence in kind. The properties may, however, be somewhat altered in amount. For amino acid sequences, the variations, for instance, include a conservative

substitution: a substitution of an amino acid residue with another amino acid residue with generally similar properties (such as size and hydrophobicity) such that the functioning of the amino acid sequence remains the same in kind, not necessarily in amount. Additionally, an amino acid residue may be deleted without significantly altering the function of the amino acid sequence. Generally, the sequence variations will be limited to less than 35%, preferably less than 20%, more preferably less than 10%. Therefore, the variants will generally have a homology of 65%, preferably 80 %, more preferably 90%. An amino acid sequence essentially corresponding to a mucinase, for instance, has the same kind of mucin-hydrolyzing property as the mucinase, though not necessarily in amount. Likewise, a nucleotide sequence essentially corresponding to a nucleotide sequence shown in Table II (SEQ ID NO:2) has the same kind of properties as that of the nucleotide sequence shown in Table II (SEQ ID NO:2). It encodes, for instance, a mucinase.

[0034] By "a modified form of the mucinase having a substantially similar mucine-hydrolyzing activity" is meant a molecule having substantially similar mucine-hydrolyzing activity, although the modified form may differ significantly from the mucinase. The modified form may, for instance, comprise a functional part of the mucinase. In terms of the invention, a functional part of a mucinase is defined as a part which has a substantially similar mucin-hydrolyzing activity as the mucinase. The functional part could, for instance, consist of the catalytic domain of the mucinase. The modified form may also be a functional derivative, wherein several domains are deleted and/or substituted and/or added. For instance, the modified form may comprise a fusion protein. The fusion protein, which is also herewith provided, preferably comprises a mucinase of the invention and/or a functional part thereof, and a protection moiety. The protection moiety allows for a longer half-life as compared to an unprotected mucinase of the invention and/or an unprotected functional part thereof. The protection moiety, for instance, comprises at least part of an immunoglobulin chain, preferably a constant region of the chain. In one embodiment of the invention, a fusion protein of the invention comprises a human mucinase of the invention and/or a functional part thereof. A fusion protein of the invention preferably retains mucinase biological activity, both *in vitro* and *in vivo*, and preferably has an improved pharmakinetics when administered *in vivo* as compared to an unprotected mucinase of the invention and/or an unprotected functional part thereof. The fusion protein can also comprise several copies of a desirable domain of the mucinase, and/or an additional domain which is not derived from the mucinase.

[0035] By "a substantially similar mucin-hydrolyzing activity" is meant herein the same mucin-hydrolyzing activity in kind, not necessarily in amount. Like mucinase, a compound with a substantially similar mucin-hydrolyzing activity is capable of cleaving at least one sugar moiety bond of mucin. The substantially similar mucin-hydrolyzing activity does not necessarily comprise additional (enzymatic) activities against other kinds of compounds. If, for instance, a mucinase of the invention comprises other catalytic activities besides its mucin-cleavage activity, a compound comprising a substantially similar mucin-hydrolyzing activity does not necessarily comprise the other catalytic activities.

[0036] In one aspect, the invention provides a pharmaceutical composition comprising an effective amount of a mucinase of the invention and a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition is particularly suitable for therapeutic or prophylactic treatment of an individual against a disease in which mucus is involved, such as, for instance, cystic fibrosis, COPD, asthma, bronchitis, tuberculosis, a mucin-producing tumor and/or infection by a protozoan parasite. Preferably, the pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of a second pharmaceutical composition, such as human DNase1, a mucolytic (*e.g.*, n-acetylcysteine), an antibiotic (*e.g.*, Tobramycin), a pancreatic enzyme supplement, an antifungal drug (*e.g.*, itraconazole, caspofungin), an antihistamine, a bronchodilator, a leukotriene inhibitor, and/or a corticosteroid.

[0037] In terms of the invention, a disease in which mucus is involved means that the disease is either associated with an altered mucin expression pattern in a patient or associated with a microorganism comprising mucus such as a protozoan parasite. The altered mucin expression pattern may lead to a thick mucus layer in the respiratory tract and/or gastrointestinal tract hampering the uptake of oxygen and/or nutrients and facilitating infections. Alternatively, the altered mucin expression pattern may only be induced locally. This is, for instance, the case with carcinoma cells having an altered expression pattern as compared to normal cells.

[0038] The invention further comprises a composition comprising a mucinase of the invention and a carrier or diluent. For instance, the composition can be a medium for culturing cells, or a cosmetic, dental or food product.

[0039] Furthermore, the invention provides a method of therapeutic or prophylactic treatment of an individual against a disease in which mucus is involved, such as cystic fibrosis, COPD, asthma, bronchitis, tuberculosis, a mucin-producing tumor and/or

infection by a protozoan parasite, comprising administering to the individual a pharmaceutical composition of the invention. The mucinase present in a pharmaceutical composition of the invention is capable of cleaving mucins. Therefore, with a method of the invention, it has, for instance, become possible to decrease an unwanted mucus barrier in the respiratory tract and/or gastrointestinal tract of a patient suffering or at risk of suffering from a disease in which mucus is involved. It has also become possible to specifically bind and/or cleave mucus of tumor cells having an altered mucus expression pattern. Once bound, the tumor cell can be subject to additional treatment by conventional pharmaceuticals. As another example, it has now also become possible to protect and/or treat an individual against a mucus-comprising pathogen, by prophylaxis and/or treatment according to a method of the invention.

[0040] The invention also provides a process for preparing a mucinase of the invention, or a modified form thereof having a substantially similar mucin-hydrolyzing activity, comprising growing a host or a host cell capable of producing the mucinase or modified form thereof and isolating the mucinase produced from the host or host cell or from medium in which the host cell is cultured. In one aspect of the invention, the host or host cell is genetically engineered. Preferably, the amino acid sequence of the mucinase is encoded by a nucleotide sequence essentially corresponding to the nucleotide sequence shown in Table II (SEQ ID NO:2).

[0041] In another aspect of the invention, a mucinase of the invention is provided which further comprises a chitin-hydrolyzing activity. By “a chitin-hydrolyzing activity” is meant herein a capability of cleaving at least one bond of chitin. The mucinase is very suitable for degrading chitin, for instance, chitin from pathogenic microorganisms. Therefore, the invention also provides a pharmaceutical composition for therapeutic or prophylactic treatment of an individual against infection by a chitin-containing pathogen, comprising a therapeutically or prophylactically effective amount of a mucinase of the invention and a pharmaceutically acceptable carrier or diluent. The invention also provides a method of therapeutic or prophylactic treatment of an individual against infection by a chitin-containing pathogen, comprising administering to the individual the pharmaceutical composition. The method is, for instance, very suitable for treating a CF-patient comprising *Aspergillus* species in its respiratory tract. With a method of the invention, a thick mucus layer and *Aspergillus* species can be degraded in the respiratory tract simultaneously, because of both mucus-hydrolyzing as well as chitin-hydrolyzing activity of the pharmaceutical composition. The

method is also suitable for treatment of other pathogens in a mucosal lining, like, for instance, vulvovaginitis and ringworm.

[0042] A composition comprising a mucinase of the invention and a carrier or diluent is also herewith provided. For instance, the composition may be a medium for culturing cells, in particular human cells, or a cosmetic, dental, or food product. Furthermore, the invention provides a chitin-based article of manufacture comprising a chitin-hydrolyzing amount of a mucinase of the invention. The chitin-based article of manufacture may be a drug-containing carrier, an implant for controlled drug release or a transient functional implant.

[0043] An isolated host cell capable of producing a mammalian mucinase of the invention is also herewith provided, as well as a recombinant nucleic acid comprising a nucleotide sequence encoding, or complementary to a nucleotide sequence encoding, an expressible mammalian mucinase of the invention. The mucinase may comprise an amino acid sequence essentially corresponding to the amino acid sequence shown in Table I (SEQ ID NO:1). Preferably, the nucleotide sequence essentially corresponds to, or essentially is complementary to, the nucleic acid sequence shown in Table II (SEQ ID NO:2). By “a nucleotide sequence encoding an expressible mucinase” is meant herein a nucleotide sequence encoding a mucinase that at least in part can be obtained by transcription and/or translation of the nucleotide sequence. By “essentially complementary to a nucleic acid sequence” is meant that a particular nucleic acid can bind by hybridization to the nucleic acid sequence, especially under stringent conditions. By “essentially corresponds to the nucleic acid sequence shown in Table II (SEQ ID NO:2)” is meant herein that a nucleotide sequence codes for the same amino acid sequence that is encoded by the nucleic acid sequence shown in Table II (SEQ ID NO:2), and/or codes for a modified form of the amino acid sequence having a substantially similar mucin-hydrolyzing activity. A nucleotide sequence coding for the same amino acid sequence can, for instance, utilize a different codon usage.

[0044] Also provided herewith is an oligonucleotide of at least about 8 nucleotides having a nucleotide sequence corresponding to, or complementary to, a nucleotide sequence shown in Table II (SEQ ID NO:2) and being capable of binding by hybridization under stringent hybridization conditions to nucleic acid coding for a mucinase of the invention. The oligonucleotide is useful for different purposes. For instance, the oligonucleotide can be used as a probe in a hybridization analysis, or as a primer in a nucleic acid amplification method such as PCR, NASBA, etc. The invention also provides a peptide

of at least about 8 amino acid residues having an amino acid sequence derived from the amino acid sequence shown in Table I (SEQ ID NO:1) and representing or mimicking an epitope of a mucinase of the invention, in particular those having an amino acid sequence corresponding to an amino acid sequence shown in Table I (SEQ ID NO:1) and having antigenicity. Usually, such peptides will have a length of at least about 10, or even at least about 15, or at least about 40 amino acid residues. Preferably, the peptide comprises a length of about 30 amino acid residues. The peptides are, for instance, suitable for diagnostic purposes, or in immunization protocols to raise mammalian mucinase-specific antibodies.

[0045] An antibody capable of binding to a mucinase of the invention is also herewith provided. Preferably, the antibody is a monoclonal antibody. An antibody of the invention can be used for many purposes, for instance, for isolating and/or purifying (*e.g.*, by affinity chromatography) a mucinase of the invention.

[0046] In yet another aspect, the invention provides a diagnostic kit comprising an antibody of the invention, and/or a peptide of the invention, and/or a diagnostically effective amount of a mucinase of the invention, and a conventional component of diagnostic kits for detecting an antigen or an antibody. Also provided is a diagnostic kit comprising an oligonucleotide of the invention and/or a recombinant nucleic acid of the invention, and a conventional component of diagnostic kits for detecting a nucleic acid.

[0047] Furthermore, the invention provides a method of decomposing mucin comprising contacting the mucin with a mucinase of the invention under mucin-hydrolyzing conditions. The invention also provides a method of decomposing chitin comprising contacting the chitin with a mucinase of the invention which further comprises a chitin-hydrolyzing activity, under chitin-hydrolyzing conditions.

LEGENDS OF THE DRAWINGS

[0048] FIG. 1. Isoelectric focusing profile of chitinolytic activity in mouse lung extract. Isoelectric focusing was performed as described in experimental procedures. Chitinolytic activity was measured using 4MU-chitotrioside substrate. The enzyme activity present in the different isoelectric focusing fractions is expressed as a percentage of the total activity present in all fractions.

[0049] FIG. 2. Degradation products with colloidal chitin as substrate. The FACE technique (described in experimental procedures) was used to visualize the cleavage products of recombinant human chitotriosidase and recombinant mouse AMCase using colloidal chitin

as substrate. Lane 1, no enzyme added. Lane 2, products formed after incubation with 50 kDa recombinant human chitotriosidase with chitin. Lane 3, products formed with recombinant mouse AMCase and chitin. Lane 4, human chitotriosidase incubated without substrate. Lane 5, mouse AMCase incubated without substrate. Marker lane is indicated with M (sugar polymers are indicated on the right-hand side).

[0050] FIG. 3. Electrophoretic behavior of chitinases.

Panel A: Purified recombinant human chitotriosidase and mouse AMCase were separated on a 12.5% SDS-PAGE gel in the presence or absence of a reducing agent and visualized by silver staining as described in experimental procedures (panel A). Lane 1, recombinant mouse AMCase under reducing conditions. Lane 2, recombinant human chitotriosidase under reducing conditions. Lane 3, recombinant human chitotriosidase under non-reducing conditions. Lane 4, recombinant mouse AMCase under non-reducing conditions. M indicates the molecular weight standards (mass (kDa) indicated at the left-hand side).

Panel B: The same purified recombinant enzymes as described in panel A were separated on a 10% SDS-PAGE gel containing glycol-chitin as described in experimental procedures. Chitinolytic activity was visualized as clearing zones in the gel. Lane 1, recombinant human 39 kDa chitotriosidase. Lane 2, recombinant human 50 kDa chitotriosidase. Lane 3, recombinant mouse AMCase (mass (kDa) indicated at the right-hand side).

[0051] FIG. 4. Effects of acidic pH.

Panel A: pH activity profile of the different chitinases. The pH optima were determined by monitoring enzyme activity at the indicated pH in McIlvaine buffer. Purified human recombinant chitotriosidase (closed lozenge), purified mouse AMCase (closed circle).

Panel B: Effects of acidic pre-incubation. Purified recombinant human chitotriosidase and mouse AMCase were pre-incubated for 30 minutes at the indicated pH in McIlvaine buffer prior to enzyme activity measurement at the assay pH (see experimental procedures). Activity prior to incubation at the indicated pH is defined as 100%.

Panel C: Precipitation by trichloroacetic acid (TCA). Purified recombinant human chitotriosidase and mouse AMCase were incubated with the indicated percentages of TCA. The amount of remaining enzyme activity after centrifugation is shown as a percentage of initial amounts.

[0052] FIG. 5. Tissue distribution of mouse AMCase mRNA.

Panel A: The relative expression levels of mouse AMCase in various mouse tissues as determined by dot blot analysis using an RNA Master Blot (Clontech) as described in experimental procedures. The highest level of expression is defined as 100%.

Panel B: Northern blot of RNA isolated from the indicated mouse tissues. 15 micrograms total of RNA was separated on an agarose gel as described in experimental procedures. The full-length mouse AMCase cDNA was used as probe. As a control for RNA loading, a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe was used (data not shown). The position of the 18S ribosomal RNA band is indicated.

[0053] FIG. 6. Tissue distribution of human AMCase mRNA. The relative expression levels of human AMCase in various human tissues were determined by dot blot analysis using an RNA Master Blot (Clontech) using the oq35c04,s1 EST clone (GenBank Accession Number AA976830) as probe. The highest level of expression is defined as 100%. Several tissues were excluded from the figure since they did not result in a detectable signal: amygdala, caudate nucleus, cerebellum, cerebral cortex, frontal lobe, hippocampus, medulla oblongata, occipital lobe, putamen, substantia nigra, temporal lobe, thalamus, nucleus accumbens, spinal cord, fetal brain, fetal heart, fetal kidney, fetal liver, fetal spleen and fetal thymus.

[0054] FIG. 7. The effect of AMCase on glycoproteins was studied by evaluating the effect of mouse AMCase on mucin, a type of glycoproteins expressed on mucosal surfaces in the airways and gastrointestinal tract. Bovine submaxillary gland mucin (Sigma) 125 µg was dissolved in 40 µl 0.05M NaAc pH 5.0 in the presence or absence of 500 ng mouse AMCase. After overnight incubation at 37°C, the mucin was electrophorized on an SDS-PAGE gel 7.5%, followed by silver staining. As is shown in FIG. 7, the mucin was degraded substantially by treatment with the AMCase (left lane), but not when it was treated with control buffer (right lane).

[0055] FIG. 8. Amino acid sequence comparison of mature (without signal peptide) human (h) (SEQ ID NO:14) and mouse (m) (SEQ ID NO:9) AMCase and human chitotriosidase (SEQ ID NO:10). Residues conserved among at least two out of the three sequences are in bold.

DETAILED DESCRIPTION OF THE INVENTION

[0056] Mucus provides an important defensive barrier which forms the first line of defense to the external environment. However, several diseases involve a disturbed

generation of mucus, resulting in thick and adhesive mucus. This leads, among others, to problems according to the uptake of oxygen and nutrients by a patient. Additionally, because of the thick adhesive mucus, current pharmaceutical compounds have a reduced capability to reach their targets (for instance, epithelial cells or DNA present in the mucus), and opportunistic infections occur as a result of impaired mucociliary clearance.

[0057] Furthermore, infections with mucus-containing pathogens like protozoan parasites can induce severe complications. The same applies to several other pathogens present in mucosal linings of an individual, for instance, the fungus *Aspergillus*, in the lungs.

[0058] Although pharmaceutical compositions are currently used to counteract diseases in which mucus is involved, there is yet no efficient and satisfactory method to degrade unwanted mucus.

[0059] For cystic fibrosis and COPD, the most widely used mucolytic agents are n-acetylcysteine or acetylcysteine and recombinant human DNase. Other mucolytics used in clinic include guaifenesin, carbocisteine lysine, citiolone, sobrerol, ambroxol, myrtol, iodinated glycerol, isobutyrylcysteine, and letosteine.

[0060] N-acetylcysteine is an aerosolized mucolytic agent often used as adjunctive therapy for pulmonary complications of cystic fibrosis. The viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucin and DNA. N-acetylcysteine acts to split the sulfide bonds between DNA and mucins, thereby decreasing mucus viscosity. The action of N-acetylcysteine is pH dependent. Mucolytic action is significant at ranges of pH 7.9 (Kastrup et al., 1998).

[0061] Adverse effects reported with acetylcysteine include stomatitis, nausea, vomiting, hemoptysis, and severe rhinorrhea. Acetylcysteine has an unpleasant, pungent odor that may lead to an increased incidence of nausea. Bronchoconstriction has also been reported with acetylcysteine therapy. N-acetylcysteine has mucolytic activity *in vitro*; this activity has, however, not been demonstrated convincingly *in vivo* (Celli et al., 1995). A possible explanation for this finding is a pH in the airways that is lower than 7.0. Even though the normal tracheal mucus pH ranges from 6.9-9.0, in infection, pH values can become as low as pH 5.8 in mucus (Buhrmester 1933). An acidic pulmonary environment has been reported for at least two mucus-associated lung diseases, namely asthma (Hunt et al.) and cystic fibrosis (Choi et al.). A similar decreased pH may also be present in the lungs of COPD patients, as they have respiratory acidosis (Plant et al.).

[0062] DNA is a factor that contributes to viscous mucus in CF patients. This high extracellular DNA (as high as 3-14 mg/ml, Chernick and Barbero 1959, Potter et al., 1960) content further thickens airway secretions. Recombinant human DNase (Pulmozyme) has been demonstrated to reduce the viscosity of sputum in CF patients by hydrolyzing the extracellular DNA (Shak et al., 1990, Zahm et al., 1995). DNase is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme that selectively cleaves DNA. Studies have demonstrated that daily administration of recombinant human DNase resulted in definite improvement in pulmonary function, as assessed by FEV1, above baseline (Fuchs et al., 1994, Shak et al., 1995). Recombinant human DNase is indicated in the management of patients with CF to improve pulmonary function and decrease the frequency of respiratory infections. Safety and efficacy have not been demonstrated in children less than 5 years of age. The recommended dose of recombinant human DNase for most patients with CF is 2.5 mg by nebulization once daily. Adverse effects include voice alteration, pharyngitis, laryngitis, rash, and chest pain. As DNase only targets the DNA present in viscous sputum, the mode of action of AMCase is independent of DNase, and possibly synergistic. In addition, for indications as COPD, where less DNA is present in the sputum, AMCase is more effective.

[0063] Although pharmaceutical compositions are currently used to counteract diseases in which mucus is involved, it has to be concluded that there is an unmet need for more sophisticated agents to degrade thick, adhesive mucus and to treat and/or prevent chronic infections with pathogens in epidermal and mucosal body linings. Preferably, such agents should be highly specific and effective and should not be prone for developing resistance there against and neither cause toxic side effects.

[0064] It was previously disclosed that bacterial chitinase preparations, which are expected to be highly immunogenic when administered to humans, can degrade human ocular mucus (Argueso et al., 1998). Here it is disclosed that mammals naturally comprise a mucinase. The mammalian mucinase, endogenously present at mucosal surfaces in mammals, provides the solution for the above-mentioned problems concerning diseases in which mucus is involved. A mucinase of the invention is capable of cleaving mucus. In one embodiment, a specific mouse (nucleotide sequence SEQ ID NO:3 (*see*, Table III, below) and amino acid sequence SEQ ID NO:4 (*see*, Table IV, below)) and human mucinase (nucleotide sequence SEQ ID NO:2 (*see*, Table II, above) and amino acid sequence SEQ ID NO:1 (*see*, Table I, above) is provided, called AMCase. It has a catalytically active 39 kDa domain

which is connected via a hinge region with a C-terminal mucin-binding domain. To show its mucus-degrading property, we have incubated a mixture of submaxillary gland mucins with recombinant 50 kDa AMCase. The effect of the incubation was examined by analysis with SDS-PAGE and silver staining. FIG. 7 shows that a remarkable reduction in size of the mucins occurs. It was noted that the viscosity of the mucin solution was markedly reduced following incubation with AMCase. The flow rate of the mucin solution, as measured in a vertically positioned glass pipette, was increased with almost a factor of 2.

[0065] Table III. Mouse AMCase cDNA sequence (SEQ ID NO:3) (GenBank Accession Number AF290003).

```

atggccaagctacttctcgacaggctggcttcgtgaatgctcagctgggtctgc
ctacaatctgtatgtatttcaccaactggcccgatcggccaggctggggagctc
aaggcctgtacatctaaccctgcgtgtactcacctgtatgccttgctggatgca
gaacaatgagatcaccaccataagaatgaaatgtttactctataaaagcttcaatgactt
aaaaaacaggaacagecaaactaaaaaccctctggcaattggaggctggaaatttggaa
ctgctcccttcaactaccatgggttccacttctcagaaccggccagacctcattaccctcagtc
caaatttctgcgtcagtatgggttgtatggactggactctggacttggaaataccaggctca
cgtgggagccctcaggacaagcatcttcactgtccttgtaaggaaatgcgtgaa
ctttttagcaggaggctttagagagcaacaggcccagactgtgggtactgcgtctgt
gtctgggtggatttccaacatccaggctggctatggacttctgaacttctaagtacctgg
tttcatccatgtcatgacatatgacccatggctctggggctacactggggagaat
agtcctcttacaataccctactggacttggtagcaatgcctaccatgtggattatgtc
atgaactattggagaacaatggagccccagctgagaagctatgtggattccagag
tatggacacacccatcttgcggacttggatggacttggggatggggatggggatgg
tgatggccctgctggccctataccagacaggctgggtctggggactatggggatgg
acccttctgagaagtggggccactggacttggggatggggatggggatggggatgg
tataaggccaaacgagtggctggctatgacaatatcaagagcttgcgttggatgg
ggcttcaagcagaacaatttggggatggggatggggatggggatggggatggggatgg
ggctcttctgtatggggatggggatggggatggggatggggatggggatggggatgg
ccacttgcggacttggggatggggatggggatggggatggggatggggatggggatgg
gtggggatggggatggggatggggatggggatggggatggggatggggatggggatgg
caaaggcagatggcccttgcggacttggggatggggatggggatggggatggggatgg
gaaatcaatccaggcggcattgtcaagcaggctgttttgcgttggatggggatggggatgg
caactggccatgaacctaatttgcatttccaggaaatttgcacttccttactccatca
aaagtaactatccctttaacccttatgcaataaaatttgcgttggatggggatggggatgg

```

[0066] Table IV. Mouse AMCase amino acid sequence (SEQ ID NO:4) deduced from cDNA sequence (SEQ ID NO:3). The characteristic hydrophobic signal peptide (amino acids 1-21) is underlined with a single line. The putative chitin-binding domain (amino acids 426-473) is underlined with a double line. The hinge region separating the catalytic domain from the chitin-binding domain (amino acids 392-425) is underlined with a dashed line. The part of the protein purified from mouse intestine that was determined by Edman sequencing (amino acids 22-43) is italicized.

MAKLLLVTGLALLN AQLGSAYNLICYFTNWAQYRPGLG
SFKPDDINPCLCI THLIYA FAGMQNNEITTIEWNDVTLYK
AFNDLKNRNSKLKTLLAIGGWNFGTAPFTMVSTSQR
QTFITSVIKFLRQYGF DGLLDWEYPGRSGSPPQDKHLF
TVLVKEMREAFEQEAIESNRPRLMVTAAVAGGISNIQAG
YEIPELSKYLDI HVMTYDLHGSWEGYTGENSPLYKYPT
ETGSNAYLNVDYVMNYWKNNGAPA EKLIVGFPEYGH
FILRNPSDNGIGAPTSGDGPAGAYTRQAGFWAYYEICTF
LRSGATEVWDASQEVPYAYKANEWLGYDNIKSF SVKA
QWLKQNNFGGAMIWAIDLDDFTGSFC DQGKFPLTSTLN
KALGISTEGCTAPDVPSEPVTTPPGSGSGGGSSGGSSGGS
GFCADKADGLYPVADDRNAFWQCINGITYQQHCQAGL
VFDTSCNCCNW P

[0067] A thick and adhesive mucus layer in the respiratory tract and/or gastrointestinal tract of an individual with, for instance, CF, COPD, or asthma can be, at least in part, degraded by administration of a mucinase of the invention to the respiratory tract and/or gastrointestinal tract of an individual. (Partly) degradation of the thick mucus layer enhances oxygen and/or nutrient uptake by the individual. Additionally, it enhances the capability of other medicaments to reach their target and prevents the occurrence of persistent chronic infections. Because a mucinase of the invention is endogenously present in mammals, it does not provoke severe immunological reactions after additional administration of the mucinase to the mammals.

[0068] A pharmaceutical composition or commercial formulation typically comprises a certain percentage of Active Pharmaceutical Ingredient, i.e., purest achievable form of a mucinase of the invention, as well as a suitable carrier that ensures the composition to be an appropriate delivery vehicle to the area of disease. Examples are a cream or ointment for skin infections, tablet or capsule formulations for the digestive tract, and an inhalation formulation for the pulmonary airways. Appropriate doses will be formulated such that these are the Maximum Effective Dose with the appropriate safety and tolerability profile.

[0069] In order to use a mammalian mucinase, like AMCase, as a pharmaceutical agent against thick mucus layers, the mammal has to be tolerant for the mucinase. Because a mucinase of the invention occurs naturally in the mammalian body, no strong immune response is elicited by additional administration of the enzyme to the mammal.

[0070] Another requirement in the application of an enzyme as a therapeutic agent is its ability to survive and to be functional in the body. This requirement is met because a mucinase of the invention is a remarkably stable enzyme. For instance, mouse AMCase can

endure incubation at acidic (pH 2) up to quite basic conditions (pH 8). The enzyme is quite resistant against various proteases.

[0071] A mucinase of the invention preferably has a low pH optimum. For instance, mouse AMCase shows a pronounced pH optimum at pH 2.3 and a less pronounced optimum at pH 4.7. A mucinase of the invention with a low pH optimum is very suitable, especially because it is pH stable, for enhancing food digestion and normal bowel movement in patients with a thick mucus layer in the gastrointestinal tract, like, for instance, cystic fibrosis patients. It can, for instance, well perform its catalytic action in the acidic stomach, whereas many other pharmaceutical compounds are inactivated.

[0072] A mucinase of the invention can be combined with existing medicaments. Once (part of) a thick mucus layer is cleaved and/or bound by mucinase, other pharmaceuticals are more capable of reaching their targets. In one embodiment, the invention therefore provides a mucinase conjugate comprising a mucinase of the invention and a second molecule, like, for instance, a second pharmaceutical compound and/or an immunoglobulin chain. The mucinase is preferably bound to the second molecule. The conjugate is suitable for a combined therapy. For instance, the conjugate can cleave mucus in the lungs and/or gastrointestinal tract of a patient with its mucin-hydrolyzing catalytic domain, after which the second pharmaceutical compound is capable of performing its therapeutic task. Alternatively, the conjugate can bind mucus with its mucus-binding domain without cleaving the mucus, after which the second pharmaceutical compound is capable of performing its therapeutic task.

[0073] Possible AMCase combination therapies are:

CF: DNase 1 (pulmozyme, Genentech) and AMCase

Oral AMCase and pancreatic enzyme supplements

AMCase and antibiotics

AMCase and gene therapy

CF with ABPA: itraconazole (or other antifungal treatments, for ABPA itraconazole is most often used) with AMCase (+ other CF medication) +/- oral corticosteroids

Asthma: AMCase with antihistamines, bronchodilators or corticosteroids.

Asthma with ABPA: itraconazole (or other antifungal treatments, for ABPA itraconazole is most often used) with AMCase +/- antihistamines, bronchodilators or corticosteroids

ABPA without asthma or CF: oral corticosteroids and AMCase (topical administration)

Chronic obstructive pulmonary disease with bronchitis: AMCase alone, or in combination with bronchodilators, β -adrenergic agents, methylxanthines, corticosteroids, or mucolytics, (mostly with n-acetylcysteine: fluimocyl or mucomyst) is efficacious.

[0074] Systemic indications for a mucinase of the invention are also foreseen. These include but are not limited to mucus-producing benign and malignant tumors. Mucinase can be administered alone or in combination with other treatments.

[0075] A mammalian mucinase can additionally comprise chitin-hydrolyzing activity. For instance, we have found that mouse and human AMCase also comprise chitin-hydrolyzing activity. This is an important finding, because 6% of the human individuals are deficient for the only human chitin-hydrolyzing enzyme known, chitotriosidase. In those individuals, an endogenous mucinase can take over that function.

[0076] Next to cellulose, chitin is the most abundant glycopolymer on earth, being present as a structural component in coatings of many species, such as the cell wall of most fungi (Debono and Gordeu 1994), the microfilarial sheath of parasitic nematodes (Fuhrman and Piessens 1985, Araujo et al., 1993), the exoskeleton of all types of arthropods (Neville et al., 1976) and in the lining of guts of many insects (Shahabuddin and Kaslow 1994). Chitinases (EC 3.2.1.14) are endo- β -1,4-N-acetylglucosaminidases that can fragment chitin and have been identified in several organisms (Flach et al., 1992). Until a few years ago it was generally assumed that man lacks the ability to produce a functional chitinase.

[0077] Chitin-containing pathogens like fungi constitute a common treat of infection of mammals. The mammalian immune system governs a broad array of defense mechanisms against systemic fungal infections. However, the incidence of life-threatening systemic fungal infections is rapidly increasing as the result of increasing active suppression of the immune system of patients during medical interventions, for example, during chemotherapies and transplantations, as well as due to viral suppression of the immune system, for example, during AIDS. Present antifungal agents show serious limitations such as the increasing resistance among the major human pathogenic fungi against existing drugs like azoles or because of the limited efficacy and toxic side effects of antifungal compounds like amphotericins. It is therefore to be concluded that there is an unmet need for more sophisticated agents to treat and/or prevent chronic infections with chitin-containing pathogens in epidermal and mucosal body linings. Preferentially, such agents should be

highly specific and effective and should not be prone for developing resistance there against and neither cause toxic side effects.

[0078] The features of a mucinase of the invention which further comprises chitin-hydrolyzing activity (endogenous production in mucosal body linings, extreme acid pH stability and protease resistance, potent fungistatic action) make the mucinase an ideal candidate for use as a drug against topical/mucosal infections with chitin-containing pathogens such as fungi.

[0079] As chitin-containing pathogens such as fungi enter the body via accessible sites such as the nose, mouth, lungs, ears, eyes, skin, urethra, bladder, topical infections of these sites occur frequently. These sites are in contact with the outside world, and as a result, topical administration of antifungal drugs may be necessary to achieve optimal efficacy.

[0080] Prominent topical fungal infections for AMCase indication are, for instance, allergic bronchopulmonary aspergillosis (ABPA), vaginal infection with candida (vulvovaginitis: Low pH; a mucinase of the invention is active whereas chitotriosidase is not), dermatophytosis (ringworm of skin, scalp, nails and athlete's foot), and other topical fungal infections in body linings (including nonallergic lung aspergillosis).

[0081] Current treatment of fungal infections include allylamines (mostly topical applications) antimetabolites (oral, IV), azoles (topical, oral, IV), glucan synthesis inhibitors (IV), polyene macrolides (mostly IV, amphotericin B and derivatives, nystatin topical, pimaricin ophthalmic), and other drugs (systemic: Griseofulvin, topical: ciclopiroxolamine, haloprogin, tolnaftate, undecylenate). Many of these drugs, especially the ones for invasive and systemic infections, are hampered by serious side effects. Such side effects are less likely if a mucinase of the invention which further comprises chitin-hydrolyzing activity, which is endogenously expressed, is used as a protein drug. Thus, a mucinase of the invention which further comprises chitin-hydrolyzing activity is very suitable for treatment of lung infections in, for instance, cystic fibrosis and COPD.

[0082] Allergic bronchopulmonary aspergillosis (ABPA) is a syndrome seen in patients with severe obstructive lung disease, most commonly in asthma and cystic fibrosis (Cockrill & Hales 1999). Chronic colonization of the airways by *Aspergillus* is apparent in these patients, accompanied by *Aspergillus*-specific IgE antibody production and eosinophilia. ABPA is generally treated by using oral corticosteroids such as prednisone to suppress the inflammatory component of the disease. Antifungal therapy, such as treatment with the orally active itraconazole, has been reported. However, no controlled trials have

been reported. In addition, as itraconazole is used for systemic treatment, *Aspergillus* in the airway lumen may not be treated as efficiently. Therefore, novel treatments need to be developed to treat fungal infections in these pulmonary diseases. A mucinase of the invention which further comprises chitin-hydrolyzing activity is suitable for use for this indication.

[0083] A mucinase of the invention which further comprises chitin-hydrolyzing activity is also suitable in the event of resistance to current antifungal therapies. For instance, flucytosine resistance is common, especially when used as monotherapy for candida. Adverse effects are displayed as well.

[0084] Resistance to ketoconazole described with prolonged treatment of AIDS patients, adverse effects indications mucosal candidiasis, mycoses, histoplasmosis, dermatophytes. Resistance to flucanazole is increasing in AIDS patients, and adverse effects are displayed. The indications are mucosal candidiasis and vulvovaginal candidiasis. Resistance to itraconazole is not clear. There are few side effects. There is an indication of candida histoplasmosis, mycoses, aspergillosis, sporotrichosis, candida Terbinafine, especially to dermatophytes.

[0085] A mucinase of the invention which further comprises chitin-hydrolyzing activity can also be administered in combination with another current pharmaceutical. The invention therefore also provides a mucinase conjugate, comprising a mucinase of the invention which further comprises chitin-hydrolyzing activity and a second molecule, for instance, a second pharmaceutical compound and/or an immunoglobulin chain. Preferably, the mucinase is bound to the second molecule. The mucinase conjugate can bind chitin with its chitin-binding domain after which the second pharmaceutical compound is capable of performing its therapeutic task. The mucinase can also cleave the chitin with its chitin-hydrolyzing catalytic domain, but this is not necessary. A possible combination therapy for treatment of a fungus infection is: azoles, antimetabolites, glucan synthesis inhibitors, griseofulvin (all with intracellular activity) together with a mucinase of the invention which further comprises chitin-hydrolyzing activity, like, for instance, AMCase. Of course, the several pharmaceutical compositions do not necessarily have to be administered at the same time. They can be administered together or separately, with either the same or different administration doses and administration intervals.

[0086] In one aspect, the invention provides a mucinase of the invention which has a low pH optimum. A major advantage of a mucinase of the invention which has a low

pH optimum is that the mucinase even withstands the harsh conditions in the gastrointestinal tract and can therefore be administered orally.

[0087] A mucinase of the invention which has a low pH optimum is also suitable for use as a topical agent. For instance, athlete's foot, a topical infection caused by trichophyton or epydermophyton, involves a local decrease of pH. Therefore, a mucinase of the invention which has a low pH optimum and which has a chitin-hydrolyzing activity is particularly suitable for topical treatment of athlete's foot and for topical treatment of any pathogen involving a low pH, like, for instance, a vaginal infection by *Candida albicans*. For instance, incubation of hyphae of *Candida albicans* with recombinant AMCase results in selective lysis of the growing tip, similar to the effect of chitotriosidase.

[0088] Additional important advantages of a mucinase of the invention which further comprises chitin-hydrolyzing activity compared to classic antifungal agents are the following. In the first place, since a mucinase of the invention which further comprises chitin-hydrolyzing activity is an endogenous protein, its administration will not result in a severe immune reaction. In the second place, resistance of fungi against chitinases has not been developed so far and seems intrinsically difficult given the fact that, despite the evolutionary pressure, plant fungal pathogens have remained sensitive to chitinases.

[0089] To counteract chitin-containing pathogens, like fungi, a mucinase of the invention which further comprises chitin-hydrolyzing activity, like AMCase, can be administered locally as a crème, for instance, on the skin. It may also be used for treatment of local ear-infections or vagina-infections, such as vulvovaginitis. Especially the latter also involves an acidic environment, in which a mucinase of the invention which further comprises chitin-hydrolyzing activity and a low pH optimum, like AMCase, is very well capable to perform its catalytic actions.

[0090] Body locations of a mucinase of the invention have led us to the conclusion that the mucinase can perform additional functions next to mucus degradation and defense against chitin-containing pathogens. For instance, the remarkably high concentration of AMCase in the gastrointestinal tract involves a role in food processing during the evolution of mammals.

[0091] A chitin-hydrolyzing capability of a mammalian mucinase, for instance, AMCase, can also be exploited as a tool to degrade injected or implanted chitin-based structures for medical purposes. For instance, drugs can be incorporated in chitin-based capsules. The concomitant presence of well-defined amounts of a mammalian mucinase,

which further comprises chitin-hydrolyzing activity, in the capsule ensures a controlled release of drugs. A slow but gradual release of drugs is particularly envisioned when the drugs are trapped in a chitin matrix. The use of a mucinase in such a system results in ultimate destruction of the chitin-based capsule and does not elicit an immunological response. The drugs used in such a system can vary from small compounds to protein and DNA fragments for the purpose of enzyme and gene therapy. Chitin (or analogues thereof) is already employed as a carrier for drugs.

[0092] Another application is the use of a mammalian mucinase which further comprises chitin-hydrolyzing activity for the swift degradation of implants that contain chitin as a structural component. This is useful in the case of implants that only temporarily have to fulfill a function and can be conveniently degraded by administration of a mammalian mucinase which further comprises chitin-hydrolyzing activity, like AMCase.

[0093] A mucinase of the invention which further comprises chitin-hydrolyzing activity and a low pH optimum, like AMCase, is especially suitable for the above-mentioned applications in the case that an acid environment is involved, or additional mucus degradation is required.

[0094] A mammalian mucinase which further comprises chitin-hydrolyzing activity can also be used *ex vivo* for degradation of mucus-containing and/or chitin-containing microorganisms. For instance, as a preventive measure, a mucinase of the invention can be added to a culture medium of cells. The cells may preferably be cultured in the absence of antibiotics. Examples are the *ex vivo* culture of cells for the purpose of gene therapy and the *ex vivo* culture of keratinocytes to be used in connection with wound healing.

[0095] A mucinase of the invention is as well suitable as an additive in toothpaste and body lotions in order to prevent infections with mucus-containing and/or chitin-containing microorganisms. Additionally, a mucinase of the invention can be used as a food preservative. For instance, it can inhibit growth of mucus-containing and/or chitin-containing pathogens in food.

[0096] The N-terminal amino acid sequence of purified AMCase was determined (Boot et al., 2000) (*see*, Table III, above). The N-terminal amino acid sequence allowed the cloning of the corresponding full-length mouse AMCase cDNA, (Boot et al., 2000). The full-length cDNA predicts the synthesis of a 50 kDa (pI 4.85) protein with a characteristic signal peptide (*see*, Table IV, above). Expression of this cDNA in COS cells led to secretion of a 50 kDa active mucinase/chitinase with a pI of 4.8. AMCase was found to bind to chitin particles

with high affinity. Chitin affinity chromatography was used to purify the enzyme, as described in experimental procedures. The procedure resulted in a 30.082-fold purification of an apparently homogeneous 50 kDa protein. The specific activity of the purified enzyme was 3.9 nmol 4-methylumbelliferyl-chitotrioside hydrolyzed at pH 5.2 per mg per hour, being almost identical to that of chitotriosidase. The catalytic domain of mouse AMCase is also herewith provided.

[0097] Mouse AMCase mRNA is predominantly found in stomach, submaxillary gland and also at a lower level in the lung (see, FIG. 5). Surprisingly, no mouse AMCase mRNA can be detected in the small intestine, suggesting that the protein in the intestine is probably derived from the upper parts of the gastrointestinal tract, such as the stomach.

[0098] Our findings demonstrate that AMCase in mammals is distinct from chitotriosidase: the newly discovered, discrete enzyme is referred to as acidic mammalian chitinase or AMCase. AMCase is also present in man. Screening the human EST database at the NCBI with the acidic mouse chitinase cDNA revealed the presence of a human EST clone (oq35c04.s1, Genbank acc. no. AA976830) that is highly homologous to the acidic mouse chitinase. The tissue distribution of the human mRNA was examined using a human Masterblot (Clontech). The expression pattern of this mRNA is similar to the expression pattern of the acidic mouse chitinase (FIG. 5), being highly expressed in the stomach and at a lower level in the lung. Using degenerate oligonucleotides directed against members of the chitinase family, we were able to amplify other regions of the human acidic chitinase, generating enough information to clone the full-length human acidic chitinase cDNA. Screening the Genbank database using the full-length human cDNA revealed that it was almost identical to TSA1902-L and TSA1902-S from a lung cDNA library described by Saito et al. (Saito et al., 1999). These two sequences are most probably splice variants of the acidic human chitinase mRNA. Only expression of full-length human AMCase cDNA in COS cells led to the production of a protein with chitinolytic activity. Sequence comparison of the human acidic chitinase and the mouse acidic chitinase revealed an 82% identity and a similarity of 86%. (compare Table II (SEQ ID NO:2) and Table III (SEQ ID NO:3)). The catalytic domain of human AMCase is also herewith provided.

[0099] Additional proof for the existence of two discrete genes encoding a phagocyte chitinase (chitotriosidase) and mucosal mucinase/chitinase (AMCase) is rendered by our finding that in man the former enzyme is encoded by a gene in locus 1q31 and the latter by a gene in locus 1p13.

[0100] A mucinase of the invention can be obtained by expression of a nucleic acid encoding the mucinase in a host or host cell and subsequent isolation of the mucinase from the host or host cell or medium in which the host cell is cultured. The host or host cell may be naturally expressing the mucinase. Alternatively, the host or host cell may be genetically engineered. A nucleic acid encoding the mucinase may be provided to the host or host cell.

[0101] A mucinase of the invention can also be obtained by substantially isolating or purifying the mucinase from an environment. Methods for isolating a proteinaceous molecule from an environment are known in the art (for instance, chromatography) and need no further explanation here. A sample comprising the mucinase can, for instance, be enriched for the mucinase by applying the sample onto an affinity column and collecting an elution fraction enriched for the mucinase. Enrichment can also be performed by centrifugation and subsequent separation of a fraction enriched for the mucinase. A person skilled in the art is well capable of performing alternative isolation and/or purification procedures, which are known in the art.

[0102] A nucleic acid encoding a mucinase of the invention, and/or a modified form thereof having a substantially similar mucin-hydrolyzing activity, is suitable for gene therapy. For instance, mammalian cells, preferably cells of a mucosal lining, can be provided with the nucleic acid. After that, the mucinase and/or modified form can be expressed, resulting in (increased) cleavage of mucus. In one embodiment, a cell which is transformed with the nucleic acid does not naturally produce a substantial amount of a mucinase of the invention. However, in another embodiment, the cell already produces the mucinase. In that case, production of mucinase can be enhanced by gene therapy with a nucleic acid of the invention. Gene therapy with a nucleic acid of the invention is, for instance, very suitable for inducing or enhancing mucinase expression in the lungs and/or gastrointestinal tract of a patient suffering from a disease in which mucus is involved.

[0103] Likewise, a nucleic acid encoding a mucinase of the invention which further comprises a chitin-hydrolyzing activity, and/or a modified form thereof having a substantially similar chitin-hydrolyzing activity, is suitable for gene therapy. For instance, mammalian cells, preferably cells of a mucosal lining, can be provided with the nucleic acid, resulting in (enhanced) expression of a mucinase of the invention which further comprises a chitin-hydrolyzing activity. The mucinase is capable of counteracting chitin-containing pathogens present in the mucosal lining.

[0104] The invention will now be illustrated by the following examples which merely serve to exemplify the invention and are not intended to limit the scope of the invention.

EXAMPLES

Example 1. Cloning and composition of cDNAs encoding mouse and human AMCase

Mouse AMCase

[0105] To obtain more insight into the potential occurrence of multiple mammalian chitinases, tissues of mouse and rat were examined for chitinolytic activity using the chitin-like 4-methylumbelliferyl- β -chito-oligosaccharide substrates. In extracts of stomach and intestine, a high level of activity was detected, while extracts of lung, tongue, kidney and plasma showed significant but lower activities. Isoelectric focusing (by flatbed isoelectric focusing in granulated Ultrodex gels (Pharmacia) as described by Renkema et al., 1995) of a mouse lung extract revealed a major peak of chitinolytic activity with pI 4.5 while minor peaks were found with pIs 5.5-6.5 (FIG. 1). Extracts of other mouse and rat tissues showed similar profiles of chitinolytic activity upon isoelectric focusing. The observed rodent chitinase with acidic isoelectric point (pI 4.5 form) differs strikingly from human chitotriosidase, which has an apparent neutral/basic pI.

[0106] The mouse acidic chitinase activity was found to bind to chitin particles with high affinity. Chitin affinity chromatography was used to purify the enzyme. Detergent-free extracts of mouse tissues were prepared by homogenization in 10 volumes of potassium phosphate buffer pH 6.5, using an Ultra-turrax and centrifugation for 20 minutes at 15,000 x g. The mouse intestine extract was adjusted to pH 5.0 by the addition of citric acid (0.2 M); NaCl was added to a final concentration of 2 M. A chitin column was prepared by mixing 10 grams swollen Sepharose G25 fine (Pharmacia, Uppsala, Sweden) with 300 mg of colloidal chitin (prepared as described by Shimahara et al. (Shimahara et al., 1988), followed by equilibration with phosphate-buffered saline (PBS) containing 2M NaCl. The extracts were applied onto the column with a flow speed of 0.4 ml/minute. After extensive washing, bound chitinase was eluted from the column with 8M urea, which was subsequently removed by dialysis. Protein concentrations were determined according to the method of Lowry et al.

(Lowry et al 1951) using BSA as a standard. Fractions containing chitinase activity were subjected to SDS-PAGE and Western blotting as described (Renkema et al., 1995).

[0107] The procedure resulted in a 30,000-fold purification of an apparently homogeneous 50 kDa protein. The specific activity of the purified enzyme was 3.9 nmol 4-methylumbelliferyl-chitotrioside hydrolyzed per mg per hour at pH 5.2, which is almost identical to that of human chitotriosidase.

[0108] The N-terminal amino acid sequence of purified acidic chitinase was determined as described by (Renkema et al., 1995) using a Procise 494 sequencer (Applied Biosystems Perkin Elmer, Foster City, CA, USA) (Table IV) and was found to be almost identical to that of other known members of the chitinase family. This amino acid sequence allowed the cloning of the corresponding full-length mouse acidic chitinase cDNA, as described in experimental procedures. The full-length cDNA predicts the synthesis of a 50 kDa (pI 4.85) protein with a characteristic signal peptide (Table IV). Transient expression of this cDNA in COS-1 cells was performed exactly as described previously (Boot et al., 1995) and led to the secretion of a 50 kDa active chitinase with a pI of 4.8.

[0109] Reverse transcription-polymerase chain reaction (RT-PCR) fragments were generated from mouse lung total RNA using degenerate oligonucleotides, as described (Boot et al., 1995). Obtained fragments were cloned in pGEM-T (Promega, Madison, WI, USA), sequenced and compared with the amino acid sequence established by N-terminal protein sequencing. A comparison with the GenBank mouse EST (expressed sequence tag) database using the Basic local alignment search tool (BLAST) at NCBI (National Center for Biotechnology Information) showed that several EST clones matched the mouse chitinase cDNA sequence, for example, ms33h09.y1 (GenBank Accession Number AI892792). This clone was obtained and sequenced. Anti-sense primers were generated complementary to the most 3' region of the EST clone (A-tail primer : 5'- TTTGGCTACCAATTATTGC-3') (SEQ ID NO:5) and two internal anti-sense primers (MAS1 : 5'- CAGCTACAGCAGCAGTAACCATC-3') (SEQ ID NO:6) and (MAS2 : 5'- TTCAGGGATCTCATGCCAGC-3') (SEQ ID NO:7). The MAS1 and MAS2 primers were used to clone the most 5' end of the mouse acidic chitinase cDNA using 5' rapid amplification of cDNA ends (5' RACE) and the Marathon-Ready mouse Lung cDNA kit (Clontech) according to the instructions of the manufacturer. To obtain the complete coding sequence, a 5' sense primer was generated (MS1 : 5'-CGATGGCCAAGCTACTTCTCGT-3') (SEQ ID NO:8). The total cDNA sequence was subsequently generated using MS1 and

the A-tail primer. The fragments of two independent PCR's were cloned into pGEM-T (Promega) and the nucleotide sequence of two independent clones from each PCR were sequenced from both strands by the procedure of Sanger using fluorescent nucleotides on an Applied Biosystems (ABI) 377A automated DNA sequencer following ABI protocols. The mouse AMCase protein shows considerable sequence homology to human chitotriosidase. Comparison of the amino acid sequence of both mature proteins revealed an identity of 52% and a similarity of 60%. *See*, Tables V and VI, below.

[0110] Table V. Amino acid sequence of mature (without signal peptide) mouse AMCase (SEQ ID NO:9).

```
YNLICYFTNWAQYRPGLGSFKPDDINPCLCTHILYAFAG
MQNNEITTIEWNDVTLYKAFNDLKNRNSKLKTLAIGG
WNFGTAPFTTMVSTSQRQTFTSVIKFLRQYGFGLDL
DWEYPGSRGSPQDKHLFTVLVKEMREAFEQEAIESNRP
RLMVTAAVAGGISNIQAGYEIPELSKYLDFIHVMTYDLH
GSWEGYTGENSPLKYPTETGSNAYLNVDYVMNYWKN
NGAPAEKLVGFPEYGHFTILRNPSDNGIGAPTSGDGPAG
AYTRQAGFWAYYEICTFLRSGATEVWDASQEVPYAYK
ANEWLGYDNIKFSVKAQWLKQNNFGGAMIWAIDLDD
FTGSFCDQGKFPLTSTLNKALGISTEGCTAPDVPSEPVTT
PPGSGGSSGGSSGGFCADKADGLYPVADDRNAF
WQCINGITYQQHCQAGLVFDTSCNCCNWP
```

[0111] Table VI. Amino acid sequence of human chitotriosidase (SEQ ID NO:10).

```
AKLVCYFTNWAQYRQGEARFLPKDLDPSLCTHILYAF
GMTNHQLSTTEWNDETLYQEFNGLKKMNPKLKTLAIG
GWNFGTQKFTDMVATANNRQTFVNSAIRFLRKYSFDGL
DLDWEYPGSQGSPAVDKERFTLVQDLANAFQQEAQTS
GKERLLSAAVPAGQTYVDAGYEVDKIAQNLDVFVNL
AYDFHGSWEKVIGHNSPLYKRQEEGAAASLNVDAAV
QQWLQKGTPASKLILGMPTYGRSFTLASSSDTRVGAPAT
GSGTPGPFTKEGGMLAYYEVCSWKGATKQRIQDQKVP
YIFRDNQWVGFFDDVESFKTVSYLKQKGLGGAMVWAL
DLDDFAFGFSCNQGRYPLIQTLRQELSLPYLPSTPELEVP
KPGQPSEPEHGPGSPGQDTFCQGKADGLYPNPRERSSFYS
CAAGRLFQQSCPTGLVFSNSCKCCTWN
```

[0112] Like the human chitotriosidase, the mouse enzyme is predicted to contain an N-terminal catalytic domain of about 39 kDa, a hinge region and a C-terminal chitin binding domain (*see*, Table IV, above). The mouse AMCase, like chitotriosidase, is predicted

to lack N-linked oligosaccharides, explaining the observed absence of binding to Concanavalin A (data not shown). The apparent molecular masses of identically produced recombinant human chitotriosidase and recombinant mouse AMCase are comparable when run on an SDS-PAGE gel under reducing conditions. However, under non-reducing conditions, the mouse AMCase migrates significantly slower than the human chitotriosidase (FIG. 3A). Upon gel electrophoresis (under non-reducing conditions) in polyacrylamide gels containing glycolchitin, followed by regeneration of active enzyme and detection of the local digestion of glycolchitin using Calcofluor staining, the mouse AMCase migrates slightly faster than human chitotriosidase (FIG. 3B).

Human AMCase

[0113] It was investigated whether such an acidic chitinase is also present in man. Screening the human EST database at the NCBI with the mouse acidic chitinase cDNA revealed the presence of a highly homologous human EST clone (oq35c04.s1, GenBank Accession Number, AA976830). As mouse AMCase activity was shown in the stomach, the full-length human AMCase cDNA was cloned using human stomach total RNA (Clontech) for the RT-PCR with the same degenerate primers as for the mouse AMCase. A human Marathon-Ready Lung cDNA was used to clone the most 5' end of the cDNA by 5' RACE using the following primers: HAS2 (5'-TCTGACAGCACAGAACATCCACTGCC-3') (SEQ ID NO:11) and HAS3-A-tail (5'-TTGACTGCTGATTATTGCAG-3') (SEQ ID NO:12). The total cDNA sequence was subsequently generated using HS1 (5'-GCTTCAGTCTGGTGGTGAAT-3') (SEQ ID NO:13) and HAS3-Atail. The fragments of two independent PCR's were cloned in pGEM-T (Promega) and sequenced as described above (Table II).

[0114] Screening the GenBank database using the full-length human cDNA revealed that it was almost identical to TSA1902-L (GenBank Accession Number AB025008) and TSA1902-S (GenBank Accession Number AB025009) from a lung cDNA library described by Saito et al. (Saito et al., 1999). These two sequences are most probably splice variants of the human acidic chitinase mRNA. Only expression of full-length human AMCase cDNA in COS-1 cells led to the production of a protein with chitinolytic activity (data not shown). Sequence comparison of the human acidic chitinase (*see*, Table VII, below) and the mouse acidic chitinase (*see*, Table V, above) revealed an 82% identity and a similarity of 86%.

[0115] Table VII. Amino acid sequence of mature (without signal peptide) human AMCase (SEQ ID NO:14).

YQLTCYFTNWAQYRPGLGRFMPDNIDPCLCTHLIYAFAGRQNNEITTIEWNDVTLYQAFNGLKNKNSQLKTLLAIGGWNFGTAPFTAMVSTPENRQTFTSVIKFLRQYEFDGLDFDWEYPGSRGSPQDKHLFTVLVQEMREAFEQEAKQINKPRLMVTAAVAAGISNIQSGYEIPQLSQYLDYIHVMTYDLHGSWEGYTGENSPLYKYPTDTGSNAYLNVDYVMNYWKDNGAPAEKLVGFPTYGHNFILSNPSNTGIGAPTSGAGPAGPYAKESGIWAYYEICTFLKNGATQGWDAPQEVPYAYQGNVWVGYDNIKSFDIKAQWLKHNFGGAMVWAIDLDDFTGTFCNQGKFPLISTLKKALGLQSASCTAPAQPIEPITAAPSGSGNGSGSSSSGGSSGGFCAVRANGLYPVANNRNAFWHCVNGVTYQQNCQAGLVFDTSCDCCNW

[0116] The demonstration by Saito et al. that the gene encoding TSA1902 is located on chromosome 1p13 (Saito et al., 1999) indicates that mammals contain indeed at least two discrete genes that encode functional chitinases, being chitotriosidase (locus 1q32) and AMCase (locus 1p13).

Example 2. Tissue expression of human and mouse AMCase RNA

[0117] Another major difference between human chitotriosidase and the mouse AMCase is revealed by comparison of RNA expression patterns. Total RNA was isolated using RNAzol B (Biosolve, Barneveld, The Netherlands) according to the instructions of the manufacturer. Northern blots, using 15 µg of total RNA, were performed as described (Boot et al., 1995). Mouse RNA Master Blots (Clontech, Palo Alto, CA, USA) were used to examine the tissue distribution of transcripts according to the instructions of the manufacturer. The following probes were used: the full-length mouse acidic chitinase cDNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as control. Radiolabeling and hybridization was conducted as described previously (Boot et al., 1995). Quantification of radioactivity was performed using a phosphor imager (Storm phosphor imager, Molecular Dynamics, Sunnyvale, CA, USA).

[0118] Whereas human chitotriosidase mRNA is mainly found in lymph node, bone marrow and lung, the mouse AMCase mRNA is predominantly found in, of the screened tissues, stomach, submaxillary gland and, at a lower level, in the lung (FIG. 5). Surprisingly, no mouse acidic chitinase mRNA could be detected in the small intestine. This

can be explained by an absence of mRNA, or by mRNA levels in the sample that were too low for detection with the technique used. These results suggest that the protein in the intestine is probably derived from the upper parts of the gastrointestinal tract, such as the stomach.

[0119] In rat tissues, a comparable acidic chitinase was observed. Our findings indicate that the acidic chitinase in rodents is distinct from human chitotriosidase. The discrete enzyme is therefore referred to as acidic mammalian chitinase or AMCase.

[0120] Next, the tissue distribution of this human mRNA was examined. Total RNA was isolated as described above and human RNA Master Blots (Clontech, Palo Alto, CA, USA) were probed with the human EST clone oq35c04.s1 (GenBank Accession Number AA976830) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as control to examine the tissue distribution as described above.

[0121] The expression pattern of the human AMCase mRNA is similar to the expression pattern of the mouse acidic chitinase (FIGS. 5, 6), being highly expressed in the stomach and, at a lower level, in the lung, as far as the RNA master blots are representative for these tissues. Expression in additional tissues that were not tested cannot be excluded.

Example 3. Degradation of chitin by AMCase

[0122] Several different assays revealed that the mouse acidic chitinase is able to degrade chitin and, therefore, has to be considered to be a true chitinase. Crab shell chitin (Poly-[1-4]- β -D-N-acetylglucosamine, Sigma) was used as a natural substrate to determine chitinase activity as described (Renkema et al., 1997). The chitin fragments were analyzed by fluorophore-assisted carbohydrate electrophoresis (FACE) as described by Jackson (Jackson 1990). FACE analysis revealed that recombinant mouse chitinase, like chitotriosidase, releases mainly chitobioside fragments from chitin (FIG. 32). Chitinase enzyme activity was determined in another assay with the fluorogenic substrates 4MU-chitobiose (4-methylumbelliferyl β -D-N,N'-diacetylchitobiose, Sigma, St Louis, USA) and 4MU-chitotriose (4-methylumbelliferyl β -D-N,N',N''-triacetylchitotriose, Sigma). Assay mixtures contained 0.027 mM substrate and 1 mg/ml of bovine serum albumin (BSA) in McIlvaine buffer (100 mM citric acid, 200mM sodium phosphate) at the indicated pH. The standard enzyme activity assay for human chitotriosidase with 4MU-chitotriose substrate was performed at pH 5.2, as previously described (Hollak et al., 1994). The standard AMCase enzyme activity assays with 4MU-chitobiose substrate were performed at pH 4.5. Like

chitotriosidase and some other non-mammalian chitinases, the mouse acidic chitinase activity in this assay is strongly inhibited (IC_{50} of 0.4 μ M) by the competitive chitinase inhibitor allosamidin (Milewski et al., 1992, Dickinson et al., 1989, McNab and Glover 1991). Measurements of chitin formation during regeneration of fungal spheroplasts were performed as described by Hector and Braun (Hector and Braun 1986). Briefly, spheroplasts were prepared from the *Candida albicans* strain CAi-4 (*ura3*), grown overnight in YPD medium (1% yeast extract, 2% peptone, 2% glucose) at 28°C. Cells were concentrated by centrifugation and incubated with 2.5 mg/ml zymolyase (100T, ICN Immuno Biologicals, Costa Mesa, CA, USA) in buffer containing 50 mM sodium phosphate pH 7.5, 1.2 M sorbitol and 27 mM β -mercaptoethanol for 60 minutes at 37°C. After extensive washing, spheroplasts were allowed to regenerate in 96-well microtiter plates in regeneration buffer (0.25% (w/v) MES buffer pH 6.7, containing 0.17% (w/v) Yeast Nitrogen Base (without amino acids and ammonium sulfate, Sigma), 0.15% (w/v) ammonium sulfate, 2% (w/v) glucose, 1.2 M sorbitol, 20 μ g/ml uridine) at 37 °C. Chitinase enzyme preparations were added in 3 μ g/ml. After a 2 hour incubation, 50 μ l of 300 μ g/ml Calcofluor white (Sigma) in 10 mM sodium phosphate buffer pH 7.5 containing 1.2 M sorbitol was added. After 5 minutes, the plates were washed with buffer only and fluorescence was determined using an LS 50 Perkin Elmer fluorometer (excitation 405 nm, emission 450 nm).

[0123] In addition, the mouse acidic chitinase and chitotriosidase were both able to digest chitin in the cell wall of regenerating spheroplasts of *Candida albicans*. The chitin content of the cell wall was determined with the Calcofluor white stain. When regenerating cells were incubated for 2 hours with 3 μ g per ml recombinant chitotriosidase or 3 μ g per ml recombinant mouse acidic chitinase, the chitin content was reduced by 27% and 33%, respectively. Concomitant presence of allosamidin during the incubation completely abolished the effect of both recombinant chitinases.

[0124] Finally, incubation of hyphae of *Candida albicans* with recombinant 50 kDa or 39 kDa AMCase as described by Boot et al. (1995) results in selective lysis of the growing tip, showing a fungistatic effect of AMCase similar to the effect of chitotriosidase described by Boot et al. (1995).

Example 4. pH optimum of chitinase activity of AMCase

[0125] A striking difference between chitotriosidase and AMCase is their behavior at acidic pH.

[0126] The pH dependence of chitinase activity of AMCase was determined by incubating purified enzyme at a different pH (McIlvaine buffer range 1.7-8.5) with 4-methylumbelliferyl substrates. Release of the fluorescent 4-methylumbelliferone was monitored fluorometrically (excitation 445 nm and emission 360 nm). The results are presented in FIG. 4A. The mouse acidic chitinase shows a pronounced pH optimum at pH 2.3 and a less pronounced optimum at a more neutral pH (pH 4.7). Chitotriosidase, however, shows only a broad pH optimum (see, FIG. 4A) and is completely inactivated by pre-incubation at low pH (see, FIG. 4B). In the presence of 0.5% (w/v) trichloroacetic acid (TCA), 58% of chitotriosidase is precipitated, while under similar circumstances, the mouse acidic chitinase remains in solution. At 2.5% (w/v) TCA all chitotriosidase precipitates while 26% of mouse acidic chitinase remains unprecipitated (FIG. 4C).

Example 5. Degradation of mammalian mucin by AMCase

[0127] The effect of AMCase on glycoproteins was studied by evaluating the effect of AMCase on mucin, a glycoprotein expressed on mucosal surfaces in the airways and gastrointestinal tract. Bovine submaxillary gland mucin (Sigma) 125 µg was dissolved in 40 µl 0.05M NaAc pH 5.0 in the presence or absence of 500 ng mouse AMCase. After overnight incubation at 37°C, the mucin was electrophorized on an SDS-PAGE gel (7.5% homogeneous, followed by silver staining). As is shown in FIG. 7, the mucin was degraded by treatment with the AMCase. This shows that AMCase is an endogenous regulator of mucus viscosity that can be employed in diseases in which overproduction or high viscosity of mucus is involved. Similar experiments may be performed using human AMCase to demonstrate its mucinolytic activity.

[0128] Experiments can be performed as described by Puchelle et al. (1996) to demonstrate that AMCase is capable of decreasing the viscosity of cystic fibrosis sputum and sputum derived from chronic obstructive pulmonary disease patients.

Example 6. pH optimum of mucin hydrolyzing activity of AMCase

[0129] The pH dependence of the mucin hydrolyzing activity of AMCase is determined by incubating purified enzyme at a different pH (for example, in McIlvaine buffer range 1.7-8.5) with mammalian mucin (see Example 5).

Example 7. Generation of antibodies to AMCase

[0130] Polyclonal antiserum against AMCase is raised by immunization of rabbits with recombinant human AMCase (e.g., 4 injections/animal; 20-200 µg/injection). After the final booster, the animals are bled to determine the titer of the polyclonal antiserum.

[0131] To obtain monoclonal antibodies, 6-8 wk old Balbic mice are immunized with recombinant human AMCase (for example, 4 times with 2 wk intervals with 10-100 µg/injection dissolved in Freunds complete adjuvants for the first injection, and Freunds incomplete adjuvants for subsequent immunizations). Splenocytes are isolated and fused with a fusion cell line such as Sp2/0 myeloma cells, followed by limiting dilution. Growing clones are screened using, for example, an enzyme-linked immunosorbent assay (ELISA). Therefore, 96-well plates are coated with recombinant human AMCase or with a control protein. The culture supernatant is added, followed by washing and the addition of a labeled anti-mouse antibody for detection. After limited dilution cloning of AMCase-specific antibody-producing hybridomas, stable hybridomas are obtained. From each clone cell, supernatant is collected, and by affinity chromatography using protein A sepharose columns (Pharmacia, Uppsala, Sweden) monoclonal antibodies are purified.

Example 8. A quantitative assay to detect AMCase

[0132] Using the AMCase-specific antibodies of Example 7 and recombinant human AMCase, a quantitative assay for the detection of AMCase is set up. The assay is used to quantify AMCase. In addition, the assay is able to differentiate between chitotriosidase and AMCase.

Example 9. Anti-fungal activity of AMCase in animal models

[0133] Allergic bronchopulmonary aspergillosis is a complication that is often seen in CF and asthma patients. As AMCase has an effect on mucus as well as *Aspergillus*, proof of concept is obtained in a lung infection model with *Aspergillus*, in which mouse AMCase is administered intratracheally.

Example 10. Mucolytic activity of AMCase in a mouse model for cystic fibrosis

[0134] CFTR-knockout mice are currently the only relevant disease model for human CF. The mice have the same genetic defect as CF patients. CFTR-knockout mice

display many characteristics of intestinal disease in CF but fail to develop respiratory infections or other signs of overt lung disease. To prevent massive mortality in the *CFTR*-knockout mice by intestinal obstruction, animals need to be fed a liquid diet during the weaning period. Interestingly, *CFTR*-knockout mice that also are deficient for MUC1 have a much better survival on a solid diet, indicating an important role for mucus formation in the intestine of the *CFTR*-knockout mice. Clearly, the model has its limitations for studying the effect of AMCase; however, it is a good model on which to study the effect of AMCase on gastrointestinal disease seen in CF.

Example 11. Treatment of mucin-associated human diseases

[0135] Treatment of diseases that are typically associated with the undue, inappropriate or excessive production, or the insufficient removal of mucus are treated or ameliorated with mucinase. These diseases include but are not limited to COPD and CF. In the case of CF, the indication for use of the mucinase is for both the digestive tract as well as the pulmonary signs and symptoms of excessive amounts of mucus present. Administration routes of the mucinase are such that the highest effective dose can be administered to the relevant anatomical area indicated for mucinolytic treatment.

Example 12. Treatment of topical infections by chitin-containing pathogens

[0136] A variety and myriad number of dermatological and pulmonary tract fungal infections are deemed to be indications for treatment with a mucinase of the invention.

[0137] These include but are not limited to the *Dermatophytoes (Tinea's)*, *Candidiasis*, *Aspergillosis*, *Mucomycosis* and *Pneumocystis carinii*. Patients presenting with dermatological manifestations of fungal disease can be treated by the regular application of a topical formulation of a mucinase of the invention appropriate for the relevant anatomical region infected.

REFERENCES

Almeida, I.C., Ferguson, M.A.J., Schenkman, S. and Travassos, L.R.: Lytic anti-a-galactosyl antibodies from patients with chronic chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi. *Biochem. J.* 304, 793-802 (1994).

Araujo, A.C., Souto-Padron, T. and de Souza, W.J.: Cytochemical localization of carbohydrate residues in microfilariae of wuchereria bancrofti and brugia malayi. (1993) *Histochem. Cytochem.* 41(4) 571-578.

Argueso, P., Herreras, J.M., Calonge, M., Citores, L., Pastor, J.C. and Girbes, T.: Analysis of human ocular mucus:effects of neuraminidase and chitinase enzymes. *Cornea* 17 200-207 1998.

Barnes, D.A., Bonnin, A., Huang, J.X., Gousset, L., Wu, J., Gut, W.J., Doyle, P., Dubremetz, J.F., Ward, H. and Petersen, C.: A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum mediates invasion. *Mol. Biochem. Parasitol* 96, 93-110 (1998).

Boot, R.G., Renkema, G.H., Strijland, A., van Zonneveld, A.J. and Aerts, J.M.F.G.: Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. (1995) *J. Biol. Chem.* 270, 26252-26256.

Boot, R.G., Renkema, G.H., Strijland, A., van Zonneveld, A.J. and Aerts, J.M.F.G.: Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. (1995) *J. Biol. Chem.* 270, 26252-26256.

Boot, R.G., Blommaart, E.F.C., Swart, E., Ghauharali-van der Vlught, K., Bijl, N., Moe, C., Place, A. and Aerts, J.M.F.G.: Identification of a novel acidic mammalian chitinase distinct from chitotriosidase (2001) *J. Biol. Chem.* 276, 6770-6778.

Buhrmester, C.C.: (1933) A study of the hydrogen-ion concentration, nitrogen content and viscosity of nasal secretions. *Ann.Otol.Rhinol.Laryngol.* 42:778-788.

Carraway, K.L., Price-Schiavi, S.A., Komatsu, M., Idris, N., Perez, A., Li, P., Jepson, S., Zhu, X., Carvajal, M.E. and Carraway, C.A.: Multiple facets of sialomucin complex/MUC4, a membrane mucin and ERBB2 ligand, in tumors and tissues (Y2K update). (2000) *Front Biosci* 5, D95-D107.

Celli, B.R.: Pulmonary rehabilitation in patient with COPD. Am.J.Respir.Crit Care Med. 1995 152(3):861-4.

Chernick, W.S. and Barbero, G.J.: Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. *Pediatrics*. 1959: 24: 739-745.

Choi, I., Aalkjaer, C., Boulopaep, E.L. and Boron, W.F.: (2000) An electroneutral sodium/bicarbonate cotransporter NBCn1 and associated sodium channel. *Nature* 405:571-575.

Cockrill, B.A. and Hales, C.A.: Allergic Bronchoalveolar Aspergillosis. Ann. Rev. Med. (1999), 50:303-316.

Debono, M. and Gordee, R.S.: Antibiotics that inhibit fungal cell wall development. Ann. Rev. Microbiology (1994) 48, 471-497.

Dickinson, K., Keer, V., Hitchcock, C.A. and Adams, D.J.: Chitinase activity from *candida albicans* and its inhibition by allosamidin. (1989) J. Gen. Microbiol. 135, 1417-142

Escott, G.M. and Adams, D.J.: Chitinase activity in human serum and leukocytes. (1995) Infect Immun 63(12), 4770-4773

Flach, J., Pilet, P.E. and Jolles, P.: Whats new in chitinase research? (1992)
Experientia 48, 701-716

Fuchs, H.J., Borowitz, D.S., Christiansen, D.H., Morris, E.M., Nash, M.L., Ramsey, B.W., Rosenstein, B.J., Smith, A.L. and Wohl, M.F.: Effect of aerosolized recombinant

human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. New England Journal of Medicine (1994 Sep), 331(10):637-642.

Fuhrman, J.A. and Piessens, W.F.: Chitin synthesis and sheath morphogenesis in bruglia malayi microfilariae (1985) Mol. Biochem. Parasitol. 17, 93-104.

Gendler, S.J. and Spicer, A.P.: Epithelial mucin genes. Ann. Rev. Physiol. 57, 607-634 (1995).

Gum, J.R.J.: Human mucin glycoproteins: varied structures predict diverse properties and specific functions. (1995) Biochem. Soc. Trans. 23, 795-799.

Gum, J.R., Hicks, J.W., Swallow, D.M., Lagace, R.L., Byrd, J.C., Lamport, D.T., Siddiki, B. and Kim, Y.S.: Molecular cloning of cDNAs derived from a novel human intestinal mucin gene. (1990) Biochem. Biophys. Res. Commun. 171, 407-415.

Hector, R. F. and Braun, P. C.: A 96-well epifluorescence assay for rapid assessment of compounds inhibitory to candida spp. (1986) J. Clin. Microbiol. 24, 620-624.

Hollak, C.E.M., van Weely, S., van Oers, M.H.J. and Aerts, J.M.F.G.: Markes elevation of plasma Chitotriosidase activity. A novel hallmark of Gaucher disease. (1994) J. Clin. Invest. 93, 1288-1292.

Hollak, C.E.M., van Weely, S., van Oers, M.H.J. and Aerts, J.M.F.G.: Markes elevation of plasma Chitotriosidase activity. A novel hallmark of Gaucher disease. (1994) J. Clin. Invest. 93, 1288-1292.

Hudson, M.J.H., Stamp, G.W.H., Hollingworth, M.A., Pignatelli, M. and Lalani, E.N.: MUC1 expressed in PanC1 cells decreases adhesion to type 1 collagen but increases contraction in collagen lattices. (1996) Am. J. Pathol. 148, 951-960.

Hunt, J.F., Fang, K., Malik, R., Snyder, A., Malhotra, N., Platts-Mills, T.A.E. and Gaston, B.: (2000) Endogenous airway acidification. Implications for asthma pathophysiology. *Am.J.Resp.Crit.Care Med.* 161:694-699.

Ilg, T., Handman, E., Ken, N., Stierhof, Y.D. and Bacic, A.: Mucin-like proteophosphoglycans from the protozoan parasite Leishmania. (1999) *Trends Glycosci Glycotech* 11, 53-71.

Jackson, P.: The use of polyacrylamide-gel electrophoresis for the high-resolution separation of reducing saccharides labeled with the fluorophore 8- amino naphthalene-1,3,6-trisulphonic acid. Detection of picomolar quantities by an imaging system based on a cooled charge-coupled device. (1990) *Biochem. J.* 270, 705-713.

Jeffery, P.K., Gaillard, D. and Moret, S.: Human airway secretory cells during development and in mature airway epithelium. (1992) *Eur. Respir. J.* 5, 93-104.

Jentoft, N.: Why are proteins O-glycosylated? (1990) *Trends Biochem. Sci.* 15, 291-294.

Kim, J.S., Hackley, G.H., Okamoto, K. and Rubin, B.K.: (2001) Sputum processing for evaluation of inflammatory mediators. *Pediatr. Pulmonol.* 32:152-8.

Kastrup, E.K., et al.: (eds) Respiratory inhalant products. In *Drug Facts and Comparisons*, (1998). St. Louis, Facts and Comparisons. pp 1141-1163.

Lan, M.S., Batra, S.K., Qi, W.N., Metzgar, R.S. and Hollingsworth, M.A.: Cloning and sequencing of a human pancreatic tumor mucin cDNA. (1990) *J. Biol. Chem.* 265, 15294-15299.

Komatsu, M., Tatum, L., Altman, N.H., Carothers, C.A., Carraway, K. and Carraway, L.: Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. (2000) *Int. J. Cancer* 87, 480-486.

Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J.: (1951) *J. Biol. Chem.* 193, 265-275.

McNab, R. and Glover, L.A.: Inhibition of neurospora crassa cytosolic chitinase by allosamidin (1991) *FEMS Microbiol. Lett.* 82, 79-82.

Milewski, S., O'Donnell, R.W. and Gooday, G.W.: Chemical modification studies of the active center of candida albicans chitinase and its inhibition by allosamidin (1992) *J. Gen. Microbiol.* 138, 2545-2550.

Moniaux, N., Nollet, S., Porchet, N., Degand, P., Laine, A. and Aubert, J.P.: Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. (1999) *Biochem. J.* 338, 325-333.

Neville, A.C., Parry, D.A. and Woodhead-Galloway, J.: The chitin crystallite in arthropod cuticle (1976) *J. Cell Science*, 21, 73-82.

Plant, P.K., Owen, J.L. and Elliott, M.W.: (2000). One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration. *Thorax* 55:550-554.

Potter, J., Matthews, L.W., and Lemm, J., et al.: The composition of pulmonary secretions from patients with and without cystic fibrosis. *Am.J.Dis.Child* (1960). 100:493-495.

Puchelle, E., Zahm, J.M., de Bentzmann, S., Grosskopf, C., Shak, S., Mougel, D. and Polu, J.M.: Effects of rhDNase on purulent airway secretions in chronic bronchitis. *Eur. Respir. J.* (1996) 9,765-769.

Renkema, G.H., Boot, R.G., Muijsers, A.O., Donker-Koopman, W.E. and Aerts, J.M.F.G.: Purification and characterization of human chitotriosidase, a novel member of the chitinase family proteins. (1995) *J. Biol. Chem.* 270, 2198-2202.

Renkema, G.H., Boot, R.G., Strijland, A., Donker-koopman, W.E., van den Berg, M., Muijsers, A.O. and Aerts, J.M.F.G.: Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. (1997) Eur. J. Biochem. 244, 279-28511.

Riordan, J.R., Rommens, J.M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N. and Chou, J.L.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA Science. (1989) 245:1066-73.

Saito, A., Ozaki, K., Fujiwara, T., Nakamura, Y. and Tanigami, A.: Isolation and mapping of a human lung-specific gene, TSA1902, encoding a novel chitinase family member. Gene 239 (1999) 325-331.

Schenkman, S., Ferguson, M.A.J., Heise, N., Almeida, M.L.C., Mortara, R.A. and Yoshida, N.: Mucin-like glycoproteins linked to the membrane by glycosylphosphatidylinositol anchor are the major acceptors of sialic acid in a reaction catalyzed by trans-sialidase in metacyclic forms of Trypanosoma cruzi. (1993) Mol. Biochem. Parasitol 59, 293-304.

Shahabuddin, M. and Kaslow, D.C.: Plasmodium: parasite chitinase and its role in malaria transmission (1994) Exp. Parasit. 79, 85-88.

Shak, S., Capon, D.J., Hellmiss, R., Marsters, S.A. and Baker, C.L.: Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. (1990) Proc.Natl.Acad.Sci. USA 87, 9188-9192.

Shak, S.: Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest (1995) 107:65s-70s.

Shankar, V., Pichan, P., Eddy, R.L.J., Tonk, V., Nowak, N., Sait, S.N., Shows, T.B., Schultz, R.E., Gotway, G., Elkins, R.C., Gilmore, M.S. and Sachdev, G.P.: Chromosomal localization of a human mucin gene (MUC8) and cloning of the cDNA corresponding to the carboxy terminus. (1997) Am. J. Respir. Cell Mol. Biol. 16, 232-241.

Shimahara, K. and Takiguchi, Y.: (1988) Preparation of crustacean chitin. Methods Enzymol. 161:417- 423.

Sternberg, L.R., Byrd, J.C., Yunker, C.K., Dudas, S., Hoon, V.K. and Bresalier, R.S.: Liver colonization by human colon cancer cells is reduced by antisense inhibition of MUC2 mucin synthesis. (1999) Gastroenterol. 116, 363-371.

Strong, W.B., Gut, J. and Nelson, R.G.: Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60-kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products. Infect. Immun. (2000) 68, 4117-4134.

Strous, G.J. and Dekker, J.: Mucin-type glycoproteins. (1992) Crit. Rev. Biochem. Mol. Biol. 27, 57-92.

Suzuki, M., Morimatsu, M., Yamashita, T., Iwanaga, T. and Syuto, B.: (2001) A novel serum chitinase that is expressed in bovine liver. FEBS letter 506:127-130.

Trudel, J. and Asselin, A.: Detection of chitinase activity after polyacrylamide gel electrophoresis. (1989) Anal. Biochem. 178, 362-366.

Vasconcellos, Carol A., Allen, Philip G., Wohl, Mary Ellen, Drazen, Jeffrey M., Janmey, Paul A. and Stossel, Thomas, P.: Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 263, 969-971 (1994).

Williams, S.J., McGuckin, M.A., Gotley, D.C., Eyre, H.J., Sutherland, G.R. and Antalis, T.M.: Two novel mucin genes down-regulated in colorectal cancer identified by differential display. (1999) Cancer Res. 59, 4083-4089.

Zahm, J.M., de Bentzmann, Girod, Deneuville, E., Perrot-Minnot, C.D., Pennaforte, F., Roussey, M., Shak, S. and Puchelle, E.: Dose-dependent in vitro effect of recombinant human DNA rheological and transport properties of cystic fibrosis respi mucus. Eur. Respir. J. (1995) 8:381-386.

SEQUENCE LISTING

<110> Macrozyme
Aerts, Johannes M.F.G.
Boot, Rolf G.

<120> A mammalian mucinase, its recombinant production, and its use in therapy or prophylaxis against diseases in which mucus is involved or infection diseases

<130> 2183-5136US

<140> 10/004, 219

<141> 2001-11-02

<160> 14

<170> PatentIn Ver. 2.1

<210> 1

<211> 476

<212> PBT

<213> Artificial Sequence

<223> Description of Artificial Sequence: human AMCase
amino acid sequence deduced from cDNA sequence

<400> 1

Met Thr Lys Leu Ile Leu Leu Thr Gly Leu Val Leu Ile Leu Asn Leu
1 5 10 15

Gln Leu Gly Ser Ala Tyr Gln Leu Thr Cys Tyr Phe Thr Asn Trp Ala
20 25 30

Gln Tyr Arg Pro Gly Leu Gly Arg Phe Met Pro Asp Asn Ile Asp Pro
35 40 45

Cys Leu Cys Thr His Leu Ile Tyr Ala Phe Ala Gly Arg Gln Asn Asn
50 55 60

Glu Ile Thr Thr Ile Glu Trp Asn Asp Val Thr Leu Tyr Gln Ala Phe
 65 70 75 80

Asn Gly Leu Lys Asn Lys Asn Ser Gln Leu Lys Thr Leu Leu Ala Ile
85 90 95

Gly Gly Trp Asn Phe Gly Thr Ala Pro Phe Thr Ala Met Val Ser Thr
100 105 110

Pro Glu Asn Arg Gln Thr Phe Ile Thr Ser Val Ile Lys Phe Leu Arg
 115 120 125

Gln Tyr Glu Phe Asp Gly Leu Asp Phe Asp Trp Glu Tyr Pro Gly Ser
 130 135 140

Arg Gly Ser Pro Pro Gln Asp Lys His Leu Phe Thr Val Leu Val Gln
 145 150 155 160

Glu Met Arg Glu Ala Phe Glu Gln Glu Ala Lys Gln Ile Asn Lys Pro
 165 170 175
 Arg Leu Met Val Thr Ala Ala Val Ala Ala Gly Ile Ser Asn Ile Gln
 180 185 190
 Ser Gly Tyr Glu Ile Pro Gln Leu Ser Gln Tyr Leu Asp Tyr Ile His
 195 200 205
 Val Met Thr Tyr Asp Leu His Gly Ser Trp Glu Gly Tyr Thr Gly Glu
 210 215 220
 Asn Ser Pro Leu Tyr Lys Tyr Pro Thr Asp Thr Gly Ser Asn Ala Tyr
 225 230 235 240
 Leu Asn Val Asp Tyr Val Met Asn Tyr Trp Lys Asp Asn Gly Ala Pro
 245 250 255
 Ala Glu Lys Leu Ile Val Gly Phe Pro Thr Tyr Gly His Asn Phe Ile
 260 265 270
 Leu Ser Asn Pro Ser Asn Thr Gly Ile Gly Ala Pro Thr Ser Gly Ala
 275 280 285
 Gly Pro Ala Gly Pro Tyr Ala Lys Glu Ser Gly Ile Trp Ala Tyr Tyr
 290 295 300
 Glu Ile Cys Thr Phe Leu Lys Asn Gly Ala Thr Gln Gly Trp Asp Ala
 305 310 315 320
 Pro Gln Glu Val Pro Tyr Ala Tyr Gln Gly Asn Val Trp Val Gly Tyr
 325 330 335
 Asp Asn Ile Lys Ser Phe Asp Ile Lys Ala Gln Trp Leu Lys His Asn
 340 345 350
 Lys Phe Gly Gly Ala Met Val Trp Ala Ile Asp Leu Asp Asp Phe Thr
 355 360 365
 Gly Thr Phe Cys Asn Gln Gly Lys Phe Pro Leu Ile Ser Thr Leu Lys
 370 375 380
 Lys Ala Leu Gly Leu Gln Ser Ala Ser Cys Thr Ala Pro Ala Gln Pro
 385 390 395 400
 Ile Glu Pro Ile Thr Ala Ala Pro Ser Gly Ser Gly Asn Gly Ser Gly
 405 410 415
 Ser Ser Ser Ser Gly Gly Ser Ser Gly Gly Ser Gly Phe Cys Ala Val
 420 425 430
 Arg Ala Asn Gly Leu Tyr Pro Val Ala Asn Asn Arg Asn Ala Phe Trp
 435 440 445
 His Cys Val Asn Gly Val Thr Tyr Gln Gln Asn Cys Gln Ala Gly Leu
 450 455 460
 Val Phe Asp Thr Ser Cys Asp Cys Cys Asn Trp Ala

465	470	475	
<pre> <210> 2 <211> 1625 <212> DNA <213> Artificial Sequence <220> <223> Description of Combined DNA/RNA Molecule: human AMCase cDNA sequence and deduced amino acid sequence <220> <223> Description of Artificial Sequence: human AMCase cDNA sequence and deduced amino acid sequence <220> <221> CDS <222> (104)..(1531) <400> 2 gctttccagt ctgggttgta atcctccata gtctgaagcc tttgtgataaa ccacagaatc 60 agaacatata aaaagctctg cgggactggt gctgactgca acc atg aca aag ctt 115 Met Thr Lys Leu 1 att ctc ctc aca ggt ctt gtc ctt ata ctg aat ttg cag ctc ggc tct 163 Ile Leu Leu Thr Gly Leu Val Ile Leu Asn Leu Gln Leu Gly Ser 5 10 15 20 gcc tac cag ctg aca tgc tac ttc acc aac tgg gcc cag tac cgg cca 211 Ala Tyr Gln Leu Thr Cys Tyr Phe Thr Asn Trp Ala Gln Tyr Arg Pro 25 30 35 ggc ctg ggg cgc ttc atg cct gac aac atc gac ccc tgc ctc tgt acc 259 Gly Leu Gly Arg Phe Met Pro Asp Asn Ile Asp Pro Cys Leu Cys Thr 40 45 50 cac ctg atc tac gcc ttt gct ggg agg cag aac aac gag atc acc acc 307 His Leu Ile Tyr Ala Phe Ala Gly Arg Gln Asn Asn Glu Ile Thr Thr 55 60 65 atc gaa tgg aac gat gtg act ctc tac caa gct ttc aat ggc ctg aaa 355 Ile Glu Trp Asn Asp Val Thr Leu Tyr Gln Ala Phe Asn Gly Leu Lys 70 75 80 aat aag aac agc cag ctg aaa act ctc ctg gcc att gga ggc tgg aac 403 Asn Lys Asn Ser Gln Leu Lys Thr Leu Ala Ile Gly Gly Trp Asn 85 90 95 100 ttc ggg act gcc cct ttc act gcc atg gtt tct act cct gag aac cgc 451 Phe Gly Thr Ala Pro Phe Thr Ala Met Val Ser Thr Pro Glu Asn Arg 105 110 115 cag act ttc atc acc tca gtc atc aaa ttc ctg cgc cag tat gag ttt 499 </pre>			

gac ggg ctg gac ttt gac tgg gag tac cct ggc tct cgt ggg agc cct	547
Asp Gly Leu Asp Phe Asp Trp Glu Tyr Pro Gly Ser Arg Gly Ser Pro	
135	140
	145
cct cag gac aag cat ctc ttc act gtc ctg gtg cag gaa atg cgt gaa	595
Pro Gln Asp Lys His Leu Phe Thr Val Leu Val Gln Glu Met Arg Glu	
150	155
	160
gct ttt gag cag gag gcc aag cag atc aac aag ccc agg ctg atg gtc	643
Ala Phe Glu Gln Glu Ala Lys Gln Ile Asn Lys Pro Arg Leu Met Val	
165	170
	175
	180
act gct gca gta gct gct ggc atc tcc aat atc cag tct ggc tat gag	691
Thr Ala Ala Val Ala Ala Gly Ile Ser Asn Ile Gln Ser Gly Tyr Glu	
185	190
	195
atc ccc caa ctg tca cag tac ctg gac tac atc cat gtc atg acc tac	739
Ile Pro Gln Leu Ser Gln Tyr Leu Asp Tyr Ile His Val Met Thr Tyr	
200	205
	210
gac ctc cat ggc tcc tgg gag ggc tac act gga gag aac agc ccc ctc	787
Asp Leu His Gly Ser Trp Glu Gly Tyr Thr Gly Glu Asn Ser Pro Leu	
215	220
	225
tac aaa tac ccg act gac acc ggc agc aac gcc tac ctc aat gtg gat	835
Tyr Lys Tyr Pro Thr Asp Thr Gly Ser Asn Ala Tyr Leu Asn Val Asp	
230	235
	240
tat gtc atg aac tac tgg aag gac aat gga gca cca gct gag aag ctc	883
Tyr Val Met Asn Tyr Trp Lys Asp Asn Gly Ala Pro Ala Glu Lys Leu	
245	250
	255
	260
atc gtt gga ttc cct acc tat gga cac aac ttc atc ctg agc aac ccc	931
Ile Val Gly Phe Pro Thr Tyr Gly His Asn Phe Ile Leu Ser Asn Pro	
265	270
	275
tcc aac act gga att ggt gcc ccc acc tct ggt gct ggt cct gct ggg	979
Ser Asn Thr Gly Ile Gly Ala Pro Thr Ser Gly Ala Gly Pro Ala Gly	
280	285
	290
ccc tat gcc aag gag tct ggg atc tgg gct tac tac gag atc tgt acc	1027
Pro Tyr Ala Lys Glu Ser Gly Ile Trp Ala Tyr Tyr Glu Ile Cys Thr	
295	300
	305
ttc ctg aaa aat gga gcc act cag gga tgg gat gcc cct cag gaa gtg	1075
Phe Leu Lys Asn Gly Ala Thr Gln Gly Trp Asp Ala Pro Gln Glu Val	
310	315
	320
cct tat gcc tat cag ggc aat gtg tgg gtt ggc tat gac aac atc aag	1123
Pro Tyr Ala Tyr Gln Gly Asn Val Trp Val Gly Tyr Asp Asn Ile Lys	
325	330
	335
	340
agc ttc gat att aag gctcaa tgg ctt aag cac aac aaa ttt gga ggc	1171
Ser Phe Asp Ile Lys Ala Gln Trp Leu Lys His Asn Lys Phe Gly Gly	
345	350
	355
gcc atg gtc tgg gcc att gat ctg gat gac ttc act ggc act ttc tgc	1219
Ala Met Val Trp Ala Ile Asp Leu Asp Phe Thr Gly Thr Phe Cys	

360	365	370	
-----	-----	-----	--

```

aac cag ggc aag ttt ccc cta atc tcc acc ctg aag aag gcc ctc ggc 1267
Asn Gln Gly Lys Phe Pro Leu Ile Ser Thr Leu Lys Lys Ala Leu Gly
      375           380           385

ctg cag agt gca agt tgc acg gct cca gct cag ccc att gag cca ata 1315
Leu Gln Ser Ala Ser Cys Thr Ala Pro Ala Gln Pro Ile Glu Pro Ile
      390           395           400

act gct gct ccc agt ggc agc ggg aac ggg agc ggg agt agc agc tct 1363
Thr Ala Ala Pro Ser Gly Ser Gly Asn Gly Ser Gly Ser Ser Ser Ser
      405           410           415           420

gga ggc agc tcg gga ggc agt gga ttc tgt gct gtc aga gcc aac ggc 1411
Gly Gly Ser Ser Gly Gly Ser Gly Phe Cys Ala Val Arg Ala Asn Gly
      425           430           435

ctc tac ccc gtg gca aat aac aga aat gcc ttc tgg cac tgc gtg aat 1459
Leu Tyr Pro Val Ala Asn Asn Arg Asn Ala Phe Trp His Cys Val Asn
      440           445           450

gga gtc acg tac cag cag aac tgc cag gcc ggg ctt gtc ttc gac acc 1507
Gly Val Thr Tyr Gln Gln Asn Cys Gln Ala Gly Leu Val Phe Asp Thr
      455           460           465

agc tgt gat tgc tgc aac tgg gca taaacctgac ctggctata ttcccttagag 1561
Ser Cys Asp Cys Cys Asn Trp Ala
      470           475

ttccagtctc ttttgcttag gacatgtgc ccctacctaa agtcctgcaa taaaatcagc 1621
agtc
      1625

<210> 3
<211> 1525
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Combined DNA/RNA Molecule: mouse
      AMCase cDNA sequence and deduced amino acid
      sequence

<220>
<223> Description of Artificial Sequence: mouse AMCase
      cDNA sequence and deduced amino acid sequence

<220>
<221> CDS
<222> (1)..(1419)

<400> 3
atg gcc aag cta ctt ctc gtc aca ggt ctg gct ctt ctg ctg aat gct 48
Met Ala Lys Leu Leu Leu Val Thr Gly Leu Ala Leu Leu Leu Asn Ala
      1           5           10           15

```

cag ctg ggg tct gcc tac aat ctg ata tgc tat ttc acc aac tgg gcc Gln Leu Gly Ser Ala Tyr Asn Leu Ile Cys Tyr Phe Thr Asn Trp Ala 20 25 30	96
cag tat cgg cca ggt ctg ggg agc ttc aag cct gat gac att aac ccc Gln Tyr Arg Pro Gly Leu Gly Ser Phe Lys Pro Asp Asp Ile Asn Pro 35 40 45	144
tgc ctg tgt act cac ctg atc tat gcc ttt gct ggg atg cag aac aat Cys Leu Cys Thr His Leu Ile Tyr Ala Phe Ala Gly Met Gln Asn Asn 50 55 60	192
gag atc acc acc ata gaa tgg aat gat gtt act ctc tat aaa gct ttc Glu Ile Thr Thr Ile Glu Trp Asn Asp Val Thr Leu Tyr Lys Ala Phe 65 70 75 80	240
aat gac ttg aaa aac agg aac agc aaa ctg aaa acc ctc ctg gca att Asn Asp Leu Lys Asn Arg Asn Ser Lys Leu Lys Thr Leu Leu Ala Ile 85 90 95	288
gga ggc tgg aac ttt gga act gct cct ttc act acc atg gtt tcc act Gly Gly Trp Asn Phe Gly Thr Ala Pro Phe Thr Thr Met Val Ser Thr 100 105 110	336
tct cag aac cgc cag acc ttc att acc tca gtc atc aaa ttt ctg cgt Ser Gln Asn Arg Gln Thr Phe Ile Thr Ser Val Ile Lys Phe Leu Arg 115 120 125	384
cag tat ggg ttt gat gga ctg gac ctg gac tgg gaa tac cca ggc tca Gln Tyr Gly Phe Asp Gly Leu Asp Leu Asp Trp Glu Tyr Pro Gly Ser 130 135 140	432
cgt ggg agc cct cct cag gac aag cat ctc ttc act gtc ctg gtg aag Arg Gly Ser Pro Pro Gln Asp Lys His Leu Phe Thr Val Leu Val Lys 145 150 155 160	480
gaa atg cgt gaa gct ttt gag cag gag gct att gag agc aac agg ccc Glu Met Arg Glu Ala Phe Glu Gln Glu Ala Ile Glu Ser Asn Arg Pro 165 170 175	528
aga ctg atg gtt act gct gta gct ggt ggg att tcc aac atc cag Arg Leu Met Val Thr Ala Ala Val Ala Gly Gly Ile Ser Asn Ile Gln 180 185 190	576
gct ggc tat gag atc cct gaa ctt tct aag tac ctg gat ttc atc cat Ala Gly Tyr Glu Ile Pro Glu Leu Ser Lys Tyr Leu Asp Phe Ile His 195 200 205	624
gtc atg aca tat gac ctc cat ggc tcc tgg gag ggc tac act ggg gag Val Met Thr Tyr Asp Leu His Gly Ser Trp Glu Gly Tyr Thr Gly Glu 210 215 220	672
aat agt cct ctt tac aaa tac cct act gag act ggt agc aat gcc tac Asn Ser Pro Leu Tyr Lys Tyr Pro Thr Glu Thr Gly Ser Asn Ala Tyr 225 230 235 240	720
ctc aat gtg gat tat gtc atg aac tat tgg aag aac aat gga gcc cca Leu Asn Val Asp Tyr Val Met Asn Tyr Trp Lys Asn Asn Gly Ala Pro	768

245	250	255	
gct gag aag ctc att gtt gga ttc cca gag tat gga cac acc ttc atc Ala Glu Lys Leu Ile Val Gly Phe Pro Glu Tyr Gly His Thr Phe Ile 260	265	270	816
ctg aga aac ccc tct gat aat gga att ggt gcc cct acc tct ggt gat Leu Arg Asn Pro Ser Asp Asn Gly Ile Gly Ala Pro Thr Ser Gly Asp 275	280	285	864
ggc cct gct ggc gcc tat acc aga cag gct ggg ttc tgg gcc tac tat Gly Pro Ala Gly Ala Tyr Thr Arg Gln Ala Gly Phe Trp Ala Tyr Tyr 290	295	300	912
gag att tgc acc ttt ctg aga agt gga gcc act gag gtc tgg gat gcc Glu Ile Cys Thr Phe Leu Arg Ser Gly Ala Thr Glu Val Trp Asp Ala 305	310	315	960
tcc caa gaa gtg ccc tat gcc tat aag gcc aac gag tgg ctt ggc tat Ser Gln Glu Val Pro Tyr Ala Tyr Lys Ala Asn Glu Trp Leu Gly Tyr 325	330	335	1008
gac aat atc aag agc ttc agt gtt aag gct cag tgg ctt aag cag aac Asp Asn Ile Lys Ser Phe Ser Val Lys Ala Gln Trp Leu Lys Gln Asn 340	345	350	1056
aat ttt gga ggt gcc atg atc tgg gcc att gac ctt gat gac ttc act Asn Phe Gly Gly Ala Met Ile Trp Ala Ile Asp Leu Asp Asp Phe Thr 355	360	365	1104
ggc tct ttc tgt gat cag gga aaa ttt cct ctg act tct act ttg aac Gly Ser Phe Cys Asp Gln Gly Lys Phe Pro Leu Thr Ser Thr Leu Asn 370	375	380	1152
aaa gcc ctt ggc ata tcc act gaa ggt tgc aca gct cct gac gtg cct Lys Ala Leu Gly Ile Ser Thr Glu Gly Cys Thr Ala Pro Asp Val Pro 385	390	395	1200
tcc gag cca gtg act act cct cca gga agt ggg agt ggg ggt gga agc Ser Glu Pro Val Thr Pro Pro Gly Ser Gly Ser Gly Gly Ser 405	410	415	1248
tcc gga gga agc tct gga ggc agt gga ttc tgt gcc gac aaa gca gat Ser Gly Gly Ser Ser Gly Gly Ser Gly Phe Cys Ala Asp Lys Ala Asp 420	425	430	1296
ggc ctc tac cct gtg gca gat gac aga aat gct ttt tgg cag tgc atc Gly Leu Tyr Pro Val Ala Asp Asp Arg Asn Ala Phe Trp Gln Cys Ile 435	440	445	1344
aat gga atc aca tac cag cag cat tgtcaa gca ggg ctt gtt ttt gat Asn Gly Ile Thr Tyr Gln Gln His Cys Gln Ala Gly Leu Val Phe Asp 450	455	460	1392
acc agc tgt aat tgc tgc aac tgg cca tgaacctaaat gccattcttc Thr Ser Cys Asn Cys Cys Asn Trp Pro 465	470		1439

cagaatattc tgcaactctcc tttactcctc accaaaagta actatcttcc cttaaacctt 1499
atgcaataaa attggtagcc aaaaca 1525

<210> 4
<211> 473
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: mouse AMCase
amino acid sequence deduced from cDNA sequence

<400> 4
Met Ala Lys Leu Leu Leu Val Thr Gly Leu Ala Leu Leu Leu Asn Ala
1 5 10 15

Gln Leu Gly Ser Ala Tyr Asn Leu Ile Cys Tyr Phe Thr Asn Trp Ala
20 25 30

Gln Tyr Arg Pro Gly Leu Gly Ser Phe Lys Pro Asp Asp Ile Asn Pro
35 40 45

Cys Leu Cys Thr His Leu Ile Tyr Ala Phe Ala Gly Met Gln Asn Asn
50 55 60

Glu Ile Thr Thr Ile Glu Trp Asn Asp Val Thr Leu Tyr Lys Ala Phe
65 70 75 80

Asn Asp Leu Lys Asn Arg Asn Ser Lys Leu Lys Thr Leu Leu Ala Ile
85 90 95

Ser Gln Asn Arg Gln Thr Phe Ile Thr Ser Val Ile Lys Phe Leu Arg
115 120 125

Gln Tyr Gly Phe Asp Gly Leu Asp Leu Asp Trp Glu Tyr Pro Gly Ser
130 135 140

Arg Gly Ser Pro Pro Gln Asp Lys His Leu Phe Thr Val Val Leu Val Lys
 145 150 155 160

Glu Met Arg Glu Ala Phe Glu Gln Glu Ala Ile Glu Ser Asn Arg Pro
165 170 175

Arg Leu Met Val Thr Ala Ala Val Ala Gly Gly Ile Ser Asn Ile Gln
180 185 190

Ala Gly Tyr Glu Ile Pro Glu Leu Ser Lys Tyr Leu Asp Phe Ile His
195 200 205

Val Met Thr Tyr Asp Leu His Gly Ser Trp Glu Gly Tyr Thr Gly Glu
210 215 220

Asn Ser Pro Leu Tyr Lys Tyr Pro Thr Glu Thr Gly Ser Asn Ala Tyr
 225 230 235 240

Leu Asn Val Asp Tyr Val Met Asn Tyr Trp Lys Asn Asn Gly Ala Pro
 245 250 255
 Ala Glu Lys Leu Ile Val Gly Phe Pro Glu Tyr Gly His Thr Phe Ile
 260 265 270
 Leu Arg Asn Pro Ser Asp Asn Gly Ile Gly Ala Pro Thr Ser Gly Asp
 275 280 285
 Gly Pro Ala Gly Ala Tyr Thr Arg Gln Ala Gly Phe Trp Ala Tyr Tyr
 290 295 300
 Glu Ile Cys Thr Phe Leu Arg Ser Gly Ala Thr Glu Val Trp Asp Ala
 305 310 315 320
 Ser Gln Glu Val Pro Tyr Ala Tyr Lys Ala Asn Glu Trp Leu Gly Tyr
 325 330 335
 Asp Asn Ile Lys Ser Phe Ser Val Lys Ala Gln Trp Leu Lys Gln Asn
 340 345 350
 Asn Phe Gly Gly Ala Met Ile Trp Ala Ile Asp Leu Asp Asp Phe Thr
 355 360 365
 Gly Ser Phe Cys Asp Gln Gly Lys Phe Pro Leu Thr Ser Thr Leu Asn
 370 375 380
 Lys Ala Leu Gly Ile Ser Thr Glu Gly Cys Thr Ala Pro Asp Val Pro
 385 390 395 400
 Ser Glu Pro Val Thr Thr Pro Pro Gly Ser Gly Ser Gly Ser
 405 410 415
 Ser Gly Gly Ser Ser Gly Gly Ser Gly Phe Cys Ala Asp Lys Ala Asp
 420 425 430
 Gly Leu Tyr Pro Val Ala Asp Asp Arg Asn Ala Phe Trp Gln Cys Ile
 435 440 445
 Asn Gly Ile Thr Tyr Gln Gln His Cys Gln Ala Gly Leu Val Phe Asp
 450 455 460
 Thr Ser Cys Asn Cys Cys Asn Trp Pro
 465 470

<210> 5
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: A-tail primer
 <220>
 <221> misc_feature
 <222> (1)..(22)

<400> 5
tttggctac caattttatt gc 22

<210> 6
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: anti-sense primer MAS1

<220>
<221> misc_feature
<222> (1)..(23)

<400> 6
cagctacagc agcagtaacc atc 23

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: anti-sense primer MAS2

<220>
<221> misc_feature
<222> (1)..(21)

<400> 7
ttcaggatc tcatagccag c 21

<210> 8
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: sense primer MS1

<220>
<221> misc_feature
<222> (1)..(22)

<400> 8
cgatggccaa gctacttctc gt 22

<210> 9
<211> 452
<212> PRT

<213> Mus musculus

<220>

<221> SITE

<222> (1)..(452)

<223> /note="Mouse AMCase"

<400> 9

Tyr	Asn	Leu	Ile	Cys	Tyr	Phe	Thr	Asn	Trp	Ala	Gln	Tyr	Arg	Pro	Gly
1				5				10					15		

Leu	Gly	Ser	Phe	Lys	Pro	Asp	Asp	Ile	Asn	Pro	Cys	Leu	Cys	Thr	His
								20				25		30	

Leu	Ile	Tyr	Ala	Phe	Ala	Gly	Met	Gln	Asn	Asn	Glu	Ile	Thr	Thr	Ile
							35		40			45			

Glu	Trp	Asn	Asp	Val	Thr	Leu	Tyr	Lys	Ala	Phe	Asn	Asp	Leu	Lys	Asn
						50		55			60				

Arg	Asn	Ser	Lys	Leu	Lys	Thr	Leu	Leu	Ala	Ile	Gly	Gly	Trp	Asn	Phe
						65		70		75			80		

Gly	Thr	Ala	Pro	Phe	Thr	Thr	Met	Val	Ser	Thr	Ser	Gln	Asn	Arg	Gln
						85		90		95					

Thr	Phe	Ile	Thr	Ser	Val	Ile	Lys	Phe	Leu	Arg	Gln	Tyr	Gly	Phe	Asp
						100		105			110				

Gly	Leu	Asp	Leu	Asp	Trp	Glu	Tyr	Pro	Gly	Ser	Arg	Gly	Ser	Pro	Pro
						115		120			125				

Gln	Asp	Lys	His	Leu	Phe	Thr	Val	Leu	Val	Lys	Glu	Met	Arg	Glu	Ala
						130		135			140				

Phe	Glu	Gln	Glu	Ala	Ile	Glu	Ser	Asn	Arg	Pro	Arg	Leu	Met	Val	Thr
						145		150		155		160			

Ala	Ala	Val	Ala	Gly	Gly	Ile	Ser	Asn	Ile	Gln	Ala	Gly	Tyr	Glu	Ile
						165			170			175			

Pro	Glu	Leu	Ser	Lys	Tyr	Leu	Asp	Phe	Ile	His	Val	Met	Thr	Tyr	Asp
						180		185			190				

Leu	His	Gly	Ser	Trp	Glu	Gly	Tyr	Thr	Gly	Glu	Asn	Ser	Pro	Leu	Tyr
						195		200			205				

Lys	Tyr	Pro	Thr	Glu	Thr	Gly	Ser	Asn	Ala	Tyr	Leu	Asn	Val	Asp	Tyr
						210		215			220				

Val	Met	Asn	Tyr	Trp	Lys	Asn	Asn	Gly	Ala	Pro	Ala	Glu	Lys	Leu	Ile
					225			230			235			240	

Val	Gly	Phe	Pro	Glu	Tyr	Gly	His	Thr	Phe	Ile	Leu	Arg	Asn	Pro	Ser
						245		250			255				

Asp	Asn	Gly	Ile	Gly	Ala	Pro	Thr	Ser	Gly	Asp	Gly	Pro	Ala	Gly	Ala
						260		265			270				

Tyr Thr Arg Gln Ala Gly Phe Trp Ala Tyr Tyr Glu Ile Cys Thr Phe
 275 280 285
 Leu Arg Ser Gly Ala Thr Glu Val Trp Asp Ala Ser Gln Glu Val Pro
 290 295 300
 Tyr Ala Tyr Lys Ala Asn Glu Trp Leu Gly Tyr Asp Asn Ile Lys Ser
 305 310 315 320
 Phe Ser Val Lys Ala Gln Trp Leu Lys Gln Asn Asn Phe Gly Gly Ala
 325 330 335
 Met Ile Trp Ala Ile Asp Leu Asp Asp Phe Thr Gly Ser Phe Cys Asp
 340 345 350
 Gln Gly Lys Phe Pro Leu Thr Ser Thr Leu Asn Lys Ala Leu Gly Ile
 355 360 365
 Ser Thr Glu Gly Cys Thr Ala Pro Asp Val Pro Ser Glu Pro Val Thr
 370 375 380
 Thr Pro Pro Gly Ser Gly Ser Gly Gly Ser Ser Gly Gly Ser Ser
 385 390 395 400
 Gly Gly Ser Gly Phe Cys Ala Asp Lys Ala Asp Gly Leu Tyr Pro Val
 405 410 415
 Ala Asp Asp Arg Asn Ala Phe Trp Gln Cys Ile Asn Gly Ile Thr Tyr
 420 425 430
 Gln Gln His Cys Gln Ala Gly Leu Val Phe Asp Thr Ser Cys Asn Cys
 435 440 445
 Cys Asn Trp Pro
 450

<210> 10
 <211> 445
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1)..(445)
 <223> /note="Human chitotriosidase"

<400> 10
 Ala Lys Leu Val Cys Tyr Phe Thr Asn Trp Ala Gln Tyr Arg Gln Gly
 1 5 10 15
 Glu Ala Arg Phe Leu Pro Lys Asp Leu Asp Pro Ser Leu Cys Thr His
 20 25 30
 Leu Ile Tyr Ala Phe Ala Gly Met Thr Asn His Gln Leu Ser Thr Thr
 35 40 45

Glu Trp Asn Asp Glu Thr Leu Tyr Gln Glu Phe Asn Gly Leu Lys Lys
 50 55 60
 Met Asn Pro Lys Leu Lys Thr Leu Leu Ala Ile Gly Gly Trp Asn Phe
 65 70 75 80
 Gly Thr Gln Lys Phe Thr Asp Met Val Ala Thr Ala Asn Asn Arg Gln
 85 90 95
 Thr Phe Val Asn Ser Ala Ile Arg Phe Leu Arg Lys Tyr Ser Phe Asp
 100 105 110
 Gly Leu Asp Leu Asp Trp Glu Tyr Pro Gly Ser Gln Gly Ser Pro Ala
 115 120 125
 Val Asp Lys Glu Arg Phe Thr Thr Leu Val Gln Asp Leu Ala Asn Ala
 130 135 140
 Phe Gln Gln Glu Ala Gln Thr Ser Gly Lys Glu Arg Leu Leu Leu Ser
 145 150 155 160
 Ala Ala Val Pro Ala Gly Gln Thr Tyr Val Asp Ala Gly Tyr Glu Val
 165 170 175
 Asp Lys Ile Ala Gln Asn Leu Asp Phe Val Asn Leu Met Ala Tyr Asp
 180 185 190
 Phe His Gly Ser Trp Glu Lys Val Thr Gly His Asn Ser Pro Leu Tyr
 195 200 205
 Lys Arg Gln Glu Glu Ser Gly Ala Ala Ala Ser Leu Asn Val Asp Ala
 210 215 220
 Ala Val Gln Gln Trp Leu Gln Lys Gly Thr Pro Ala Ser Lys Leu Ile
 225 230 235 240
 Leu Gly Met Pro Thr Tyr Gly Arg Ser Phe Thr Leu Ala Ser Ser Ser
 245 250 255
 Asp Thr Arg Val Gly Ala Pro Ala Thr Gly Ser Gly Thr Pro Gly Pro
 260 265 270
 Phe Thr Lys Glu Gly Gly Met Leu Ala Tyr Tyr Glu Val Cys Ser Trp
 275 280 285
 Lys Gly Ala Thr Lys Gln Arg Ile Gln Asp Gln Lys Val Pro Tyr Ile
 290 295 300
 Phe Arg Asp Asn Gln Trp Val Gly Phe Asp Asp Val Glu Ser Phe Lys
 305 310 315 320
 Thr Lys Val Ser Tyr Leu Lys Gln Lys Gly Leu Gly Gly Ala Met Val
 325 330 335
 Trp Ala Leu Asp Leu Asp Asp Phe Ala Gly Phe Ser Cys Asn Gln Gly
 340 345 350
 Arg Tyr Pro Leu Ile Gln Thr Leu Arg Gln Glu Leu Ser Leu Pro Tyr

355	360	365
Leu Pro Ser Gly Thr Pro Glu Leu Glu Val Pro Lys Pro Gly Gln Pro		
370	375	380
Ser Glu Pro Glu His Gly Pro Ser Pro Gly Gln Asp Thr Phe Cys Gln		
385	390	395
Gly Lys Ala Asp Gly Leu Tyr Pro Asn Pro Arg Glu Arg Ser Ser Phe		
405	410	415
Tyr Ser Cys Ala Ala Gly Arg Leu Phe Gln Gln Ser Cys Pro Thr Gly		
420	425	430
Leu Val Phe Ser Asn Ser Cys Lys Cys Cys Thr Trp Asn		
435	440	445

<210> 11
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer HAS2

<220>
<221> misc_feature
<222> (1)..(24)

<400> 11
tctgacagca cagaatccac tgcc 24

<210> 12
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer
HAS3-A-tail

<220>
<221> misc_feature
<222> (1)..(22)

<400> 12
ttgactgctg attttattgc ag 22

<210> 13
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer HS1

<220>
 <221> misc_feature
 <222> (1)..(22)

<400> 13
 gctttccagt ctgggtggta at 22

<210> 14
 <211> 455
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (1)..(455)
 <223> /note="Human AMCase"

<400> 14
 Tyr Gln Leu Thr Cys Tyr Phe Thr Asn Trp Ala Gln Tyr Arg Pro Gly
 1 5 10 15

Leu Gly Arg Phe Met Pro Asp Asn Ile Asp Pro Cys Leu Cys Thr His
 20 25 30

Leu Ile Tyr Ala Phe Ala Gly Arg Gln Asn Asn Glu Ile Thr Thr Ile
 35 40 45

Glu Trp Asn Asp Val Thr Leu Tyr Gln Ala Phe Asn Gly Leu Lys Asn
 50 55 60

Lys Asn Ser Gln Leu Lys Thr Leu Leu Ala Ile Gly Gly Trp Asn Phe
 65 70 75 80

Gly Thr Ala Pro Phe Thr Ala Met Val Ser Thr Pro Glu Asn Arg Gln
 85 90 95

Thr Phe Ile Thr Ser Val Ile Lys Phe Leu Arg Gln Tyr Glu Phe Asp
 100 105 110

Gly Leu Asp Phe Asp Trp Glu Tyr Pro Gly Ser Arg Gly Ser Pro Pro
 115 120 125

Gln Asp Lys His Leu Phe Thr Val Leu Val Gln Glu Met Arg Glu Ala
 130 135 140

Phe Glu Gln Glu Ala Lys Gln Ile Asn Lys Pro Arg Leu Met Val Thr
 145 150 155 160

Ala Ala Val Ala Ala Gly Ile Ser Asn Ile Gln Ser Gly Tyr Glu Ile
 165 170 175

Pro Gln Leu Ser Gln Tyr Leu Asp Tyr Ile His Val Met Thr Tyr Asp
 180 185 190

Leu His Gly Ser Trp Glu Gly Tyr Thr Gly Glu Asn Ser Pro Leu Tyr
 195 200 205

Lys Tyr Pro Thr Asp Thr Gly Ser Asn Ala Tyr Leu Asn Val Asp Tyr
 210 215 220
 Val Met Asn Tyr Trp Lys Asp Asn Gly Ala Pro Ala Glu Lys Leu Ile
 225 230 235 240
 Val Gly Phe Pro Thr Tyr Gly His Asn Phe Ile Leu Ser Asn Pro Ser
 245 250 255
 Asn Thr Gly Ile Gly Ala Pro Thr Ser Gly Ala Gly Pro Ala Gly Pro
 260 265 270
 Tyr Ala Lys Glu Ser Gly Ile Trp Ala Tyr Tyr Glu Ile Cys Thr Phe
 275 280 285
 Leu Lys Asn Gly Ala Thr Gln Gly Trp Asp Ala Pro Gln Glu Val Pro
 290 295 300
 Tyr Ala Tyr Gln Gly Asn Val Trp Val Gly Tyr Asp Asn Ile Lys Ser
 305 310 315 320
 Phe Asp Ile Lys Ala Gln Trp Leu Lys His Asn Lys Phe Gly Gly Ala
 325 330 335
 Met Val Trp Ala Ile Asp Leu Asp Asp Phe Thr Gly Thr Phe Cys Asn
 340 345 350
 Gln Gly Lys Phe Pro Leu Ile Ser Thr Leu Lys Lys Ala Leu Gly Leu
 355 360 365
 Gln Ser Ala Ser Cys Thr Ala Pro Ala Gln Pro Ile Glu Pro Ile Thr
 370 375 380
 Ala Ala Pro Ser Gly Ser Gly Asn Gly Ser Gly Ser Ser Ser Gly
 385 390 395 400
 Gly Ser Ser Gly Gly Ser Gly Phe Cys Ala Val Arg Ala Asn Gly Leu
 405 410 415
 Tyr Pro Val Ala Asn Asn Arg Asn Ala Phe Trp His Cys Val Asn Gly
 420 425 430
 Val Thr Tyr Gln Gln Asn Cys Gln Ala Gly Leu Val Phe Asp Thr Ser
 435 440 445
 Cys Asp Cys Cys Asn Trp Ala
 450 455

ABSTRACT

[0138] The invention provides a mammalian mucinase capable of hydrolyzing mucus. The mucinase is among others suitable for counteracting diseases in which mucus is involved. The diseases comprise cystic fibrosis, COPD, asthma, bronchitis, tuberculosis, tumors with altered mucus expression, and mucus-containing pathogens. The invention also provides a pharmaceutical composition comprising an effective amount of the mucinase and a method of therapeutic or prophylactic treatment of an individual against a disease in which mucus is involved. Methods for obtaining the mucinase are also herewith provided, as well as nucleic acids encoding (part of) the mucinase. In one aspect, the invention provides a diagnostic kit comprising a mucinase, a mucinase-specific antibody, a mucinase-derived peptide and/or nucleic acid encoding (part of) the mucinase.

APPENDIX B

(VERSION OF SUBSTITUTE SPECIFICATION EXCLUDING CLAIMS
WITH MARKINGS TO SHOW CHANGES MADE)

(Serial No. 10/014,219)

PATENT
Attorney Docket 5136US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EL 740547479 US

Date of Deposit with USPS: November 2, 2001

Person making Deposit: Blake Johnson

APPLICATION FOR LETTERS PATENT

for

**A MAMMALIAN MUCINASE, ITS RECOMBINANT PRODUCTION, AND ITS USE
IN THERAPY OR PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS
INVOLVED OR INFECTIOUS DISEASES**

Inventors:
J.M.F.G. Aerts
R.G. Boot

Attorney:
Allen C. Turner
Registration No. 33,041
TRASKBRITT
P.O. Box 2550
Salt Lake City, Utah 84110
(801) 532-1922

TITLE OF THE INVENTION

A MAMMALIAN MUCINASE, ITS RECOMBINANT PRODUCTION, AND ITS USE IN
THERAPY OR PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS
INVOLVED OR INFECTIOUS DISEASES

TECHNICAL FIELD

[0001] The invention relates to the field of medicine. More specifically, the invention relates to therapeutic or prophylactic treatment of an individual against a disease in which mucus is involved and/or an infection disease. The invention also relates to the preparation of a mucinase suitable for the treatment.

BACKGROUND

[0002] Mucus as protective barrier. Mucins form part of the dynamic, interactive defensive system of mammals at mucosal surfaces in, for example, the gastrointestinal tract, the respiratory tract, and reproductive organs. Mucins are highly glycosylated proteins occurring either as secretory or membrane-bound forms. They have a unique molecular structure and chemical properties. The polypeptide backbone (apomucin) is rich in hydroxy amino acids, serine and threonine, which together with glycine, alanine and proline comprise nearly 50% of total amino acid residues of the protein and are present as tandemly repeated sequences. The threonine and serine residues are the targets of O-glycosylation machinery and the extent of glycosylation is such that carbohydrates account for 50-85% of the dry weight of mucins. Secretory mucins are the major constituents of mucus secretions, lining the epithelial cells of digestive, respiratory and reproductive tracts (Gendler et al., 1995, Gum 1995). They are capable of forming gels at very low concentration by forming long thread-like polymers resulting from the formation of disulphide linkages between monomers and intramolecular interactions of sugar side chains. Membrane-bound mucins are present on the surface of various cell types and, unlike secretory mucins, do not form oligomers and are hence smaller in size than their secretory counterparts (Gendler et al., 1995, Gum 1995). The membrane-bound mucins also have O-glycosylated serine and threonine-rich regions, but they lack tandem repeat sequences. The primary function of secretory mucins is to provide protection to the apical epithelial cell layers in digestive, respiratory and urinogenital tracts

against environmental factors like acidic pH, hydrolytic enzymes and pathogens. The cell surface mucins, in addition to their protective role, have a shielding effect on various surface receptors, thereby helping in the regulation of their activity (Strous and Dekker 1992). So far, twelve human mucin genes have been identified, designated as MUC1-4, MUC5AC, MUC5B, MUC6-9, and MUC11-12 (Gendler et al., 1995, Gum 1995, Gum et al., 1990, Lan et al., 1990, Moniaux et al., 1999, Shankar et al., 1997, Williams et al., 1999). They can be divided into secreted and membrane-associated forms, each with characteristic protein domains and tissue-specific glycosylation. Eight human mucin genes have been well characterized: MUC2, MUC5AC, MUC5B, MUC6 map to 11p15.5 and encode secretory gel-forming mucins while MUC1, MUC3, MUC4, MUC7 are scattered on different chromosomes and encode membrane-bound or secreted mucins.

[0003] Historically, purified mucins have been identified by their amino and carbohydrate composition consisting of a high percentage of serine, threonine, proline, alanine, glycine, and a large proportion of O-linked oligosaccharides (up to 80% of the total mass). Biosynthetic pathways have been described for the secreted and membrane-associated mucins and their eventual degradation and turnover. Mucins are present at all mucosal surfaces throughout the body in typical combinations and relate to the demands of organ function. Patterns of MUC gene expression with gastrointestinal site-specific glycosylation are clearly important but are not yet well defined. The mucosal surface throughout the gastrointestinal tract must resist the aggressive elements from the external environment present in the diet and encountered during normal function. This defensive system is based on fundamental characteristics shared with the barrier found at other mucosal surfaces. The stable protective barrier enabling exchange between the epithelial cells of the gut lumen for the purposes of nutrition and protection is made up of a layer of secreted mucus and a cell-surface membrane glycocalyx. The mucus defensive barrier forms the first line of defense to the external environment and contains both innate and adaptive immune elements.

[0004] Mucin expression. Mucins are present at all mucosal surfaces throughout the body. The specific functional requirements for mucus at each site are reflected in the appearance of different mucins in the cells at different sites in the body. The main population of specially adapted cells producing secreted mucins are the goblet cells. The proportion of goblet cells increases through the gastrointestinal tract (GI tract) with maximal numbers in the rectum. Goblet cells in the respiratory tract are present in the trachea and, to a lesser extent, in the bronchi. They are rarely found in bronchioles less than 1 mm in diameter

(Jeffery et al., 1992). Mucins have a tissue-specific glycosylation at each site in the gastrointestinal tract. As carbohydrate constitutes the major part of all mature mucins and is represented by vast arrays of different oligosaccharide structures, the potential for multiple functions related to bulk carbohydrate or individual structures must be examined. Most of the oligosaccharides in mucins are attached by O-links. However, a much smaller number of N-linked chains are also present, linked to asparagine residues in the mucin polypeptide through an N-glycosidic bond to N-acetyl-D-glucosamine. N-linked oligosaccharides contain a branched trimannosyl-chitobiose pentasaccharide core attached to the peptide.

[0005] Mucus degradation. The adherent mucus barrier and the glycocalyx are constantly being turned over as part of their protective functions at the mucosal surface. Thus, degradation of mucus is a normal feature of an equilibrium between mucosal synthesis, secretion and the breakdown of the existing adherent gel. This balance must be regulated to ensure continual mucosal protection against potentially damaging compounds and organisms entering in the diet. The first stage in mucus degradation is conversion of the mucus gel to a viscous fluid. The viscoelastic properties of the secreted, adherent gel layer are governed by the mucins, and they are responsible for the gel-forming properties. The non-mucin components of mucus may influence gel formation or affect gel strength. They are implicated in pathological situations where alterations in the normal composition of mucus are made. Mucinase activity of bacteria has been described and is well known from observations of mucin carbohydrate release, sequestration and metabolic conversion by bacteria in the large intestine. A population of mucin oligosaccharide-degrading (MOD) bacterial strains capable of specific and complete degradation of mucins has been identified. Bacterial mucinase enzymes have been shown to act on the mucus gel to reduce it to a viscous fluid, probably through the action of proteinases or peptidases, to act further on the accessible peptide backbone, not blocked by oligosaccharide substitution, and to cleave the individual sugars from the oligosaccharide chains. Bacterial mucinase activity has been measured in fecal extracts using electrophoretic assessment of mucin degradation and by direct mucinase assays with purified biotinylated mucins.

[0006] Mucin-associated diseases. Changes in mucus are frequent in inflammatory diseases of the epithelia. High levels of secretion of the mucin proteins is a common factor in, for instance, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), chronic bronchitis, asthma, tuberculosis, and carcinomas. Conversely, in Inflammatory Bowel Disease such as Crohns disease and ulcerative colitis, the mucus barrier

is decreased. Furthermore, mucus appears to play a role in infection by mucus-containing pathogens.

[0007] Mucus obstruction in Cystic Fibrosis. Cystic Fibrosis is the most common lethal genetic disorder among Caucasians. Presently, approximately 30,000 children, adolescents, and adults in the United States are affected by this disease, as reported on the Cystic Fibrosis Foundation Web site (www.cff.org). The median age of survival is 32.3 years of age.

[0008] A variety of symptoms, the most common ones being salty-tasting sweat and skin, persistent cough, wheezing, and failure to thrive (due to intestinal defects, malnutrition and anorexia), characterize the disease. The usual complications in the respiratory tract are: hemoptysis (blood in the sputum); pneumothorax (collapsed lung); atelectasis (air resorbtion leaving the lobe or segment airless) caused by complete mucus plugging; dilated bronchioles and bronchi and weakened bronchioles and bronchi walls; fibrosis (scar tissue); and low oxygen levels. Respiratory failure in CF is usually at the end of a long process where frequently there is no longer enough healthy lung tissue left to eliminate CO₂. It is widely believed that the respiratory sequela in CF and progressive deterioration of respiratory function are the result of persistent bacterial colonization (culminating with chronic *P. aeruginosa* infections) and chronic inflammation. The major cause of high morbidity and mortality in CF remains the chronic respiratory infections (most notably with *P. aeruginosa*) which account for more than 90 percent of CF mortality.

[0009] Cystic fibrosis (CF) is a multiorgan disease that is the result of a genetic defect of a single gene. The gene, CF transmembrane conductance regulator (CFTR), was identified in 1989 (Riordan et al., 1989). The gene encodes a membrane glycoprotein that functions as a cAMP-regulated chloride channel in exocrine glands and secretory epithelia.

[0010] As a result, thick and adhesive mucus is present in the airways and gastrointestinal tract of cystic fibrosis patients, leading to respiratory symptoms, recurrent infections, and progressive lung destruction, as well as nutritional deficiencies. The viscosity of CF mucus is determined by the presence of mucins. In addition, purulent mucus of CF patients contains as much as 3-14 mg/ml DNA (Chernick and Barbero 1959, Potter et al., 1960). This DNA, derived from inflammatory cells and epithelial cells, contributes (together with actin) to the viscosity of purulent CF sputum. Therefore, mucus transport by mucociliary activity and/or cough is hampered. In addition, the viscous DNA-containing mucus may also

cause reduced effectiveness of aminoglycoside antibiotics. These two aspects of CF mucus viscosity result in persistent, recurring infections and progressive lung destruction.

[0011] As the pathogenesis of cystic fibrosis is complex, treatment for CF consists of several approaches. The pulmonary disease is managed by combinations of physiotherapy, antibiotics (especially to contain *Pseudomonas aeruginosa* infections, which is an important cause of death in CF patients), mucolytics (n-acetylcysteine, recombinant human DNase I), bronchodilators and anti-inflammatory agents such as oral corticosteroids. The nutritional support mainly consists of the administration of pancreatic enzyme preparations to help food digestion, which is hampered by obstruction of the pancreatic ducts.

[0012] The aerosol route can be used to deliver mucoactive medications locally. These mucoactive medications comprise mucolytics, mucokinetic agents, mucoregulatory medications and expectorants and ion channel modifiers.

[0013] Several studies have focused on the use of recombinant human DNase (rhuDNase) I to reduce the viscosity of cystic fibrosis sputum. In *in vitro* assays, the viscosity of purulent CF sputum as well as its adhesiveness was shown to decrease after treatment with recombinant human DNase I (Pulmozyme®, Genentech), and the mucociliary transportability of CF sputum is increased (Shak et al., 1990, Zahm et al., 1995). This is due to the degradation of DNA but also to the depolymerization of F-actin (Vanscelllos et al., 1994) Phase 3 clinical trials have shown that treatment with aerosolized recombinant human DNase I results in a 28-37% reduction in respiratory exacerbations and an improvement of 5.6-5.8% in FEV1, a measure for lung function (Fuchs et al., 1994, Shak et al., Chest 1995).

[0014] COPD. Chronic Obstructive Pulmonary Disease (COPD) is a physiologically defined group of conditions characterized by the presence of persistent airflow obstruction. COPD is defined as a disease state characterized by the presence of airflow obstruction due to chronic obstructive bronchitis or emphysema.

[0015] One of the hallmarks of bronchitis is hyperproduction of mucus as well as loss of mucociliary clearance. Even though an effect of rhuDNase has been shown to reduce chronic bronchitis sputum viscosity (Puchelle et al., 1996), mucus in chronic bronchitis contains 10-fold less DNA than in CF sputum (Kim et al., 2001). This indicates that Pulmozyme, which is a human DNase that is used to reduce viscosity of CF sputum, is not equally effective as a mucolytic for bronchitis mucus. Chronic bronchitis is currently treated with bronchodilators, β -adrenergic agents, methylxanthines, corticosteroids, and mucolytics,

mostly with n-acetylcysteine. N-acetylcysteine has mucolytic activity *in vitro*; this activity, however, has not been demonstrated convincingly *in vivo* (Celli et al., 1995)

[0016] **Asthma.** In chronic asthma, as in CF and bronchitis, decreased mucociliary clearance caused by mucus hypersecretion and/or rheological changes and permanent changes in ciliary structure and function occur. Airway inflammation plays a major role in the pathophysiology of asthma. Standard asthma treatment comprises antihistamines, bronchodilators, leukotriene inhibitors, and (gluco-)corticosteroids.

[0017] **Tuberculosis.** Another disease in which airway mucus viscosity is increased and acetylcysteine is used as a mucolytic is pulmonary tuberculosis. Tuberculosis is an infectious disease caused by *Mycobacterium tuberculosis*, which is transmitted by aerosols of saliva and mucus released by coughing. Pulmonary tuberculosis is associated with persistent cough and expectoration of bloody mucus. The disease is generally treated by long-term therapy with combinations of antibiotics.

[0018] **Intensive care medicine (respiration).** Patients in intensive care that are attached to a respirator also have problems clearing airway mucus. The airways of these patients need to be cleared regularly to prevent stasis and opportunistic infections. To this aim, these patients get antibiotics prophylactically.

[0019] **Carcinoma.** Mucins are thought to promote tumor-cell invasion and metastasis. In many human carcinomas, the expression profile of mucins is altered, with certain mucins like MUC1 being upregulated while others show a downregulated expression. The glycosylation process is disrupted in cancer, leading to aberrantly glycosylated, mostly underglycosylated mucins. In gastric carcinomas, the alterations of the mucin expression have been the subject of several studies. The expression of MUC5AC, a secretory mucin present in normal gastric mucosa, is downregulated and can be found in only 60% of the intestinal carcinomas. At the same time, the expression of MUC1 and MUC2 in gastric carcinomas was upregulated. The decrease in the amount of glycosylation of MUC1 with the progression of carcinogenesis was shown with a panel of antibodies binding with different affinities to glycosylated and unglycosylated forms of MUC1. Furthermore, in cancer cells the expression of MUC1 was distributed over the entire cell membrane, while it was limited to the apical region of normal gastric mucosa cells.

[0020] The expression pattern of the mucin genes is complex in normal airways involving six genes, mainly MUC5AC and MUC5B in mucus-producing cells and MUC4 in a wide array of epithelial cells. MUC5AC overexpression in metaplasia, dysplasia and normal

epithelium adjacent to squamous cell carcinoma provides additional arguments for a mucous cell origin of preneoplastic squamous lesions. MUC5AC and MUC5B expression is related to mucus formation in adenocarcinomas. Mucinous bronchiolalveolar carcinoma (BAC) has a particular pattern of mucin gene expression indicating that it has sustained a well-differentiated phenotype similar to the goblet cell, correlated with distinctive features, i.e., a noninvasive pattern and a better prognosis than nonBACs. MUC4 is the earlier mucin gene expressed in the foregut, before epithelial differentiation, and is expressed independently of mucus secretion both in normal adult airways and carcinomas. These findings are in favor of the histogenetic theory of non-small-cell carcinoma originating from a pluripotent mucous cell.

[0021] Several arguments suggest that mucins play a role in tumor-cell invasion and metastasis, resulting in prognostic implications. MUC1 is a transmembrane molecule with a large extracellular domain protruding high above the cell surface thought to reduce cell-cell and extracellular matrix (ECM)-cell adhesion in cancer cells (Jentoft 1990, Hudson et al., 1996) but direct evidence for a role of specific mucin genes in tumor progression is lacking. One study shows that splenic-portal inoculation in athymic mice of MUC2 antisense construct in highly metastatic human colon cancer cells resulted in a reduction in MUC2 levels and a marked decrease in liver colonization (Sternberg et al., 1999). Sialomucin complex (SMC), a rat homologue of the human mucin MUC4 isolated from highly metastatic ascites 13762 mammary adenocarcinoma cells is thought to potentiate metastasis by sterical disruption of molecular interactions for cell-cell and cell-ECM adhesions and by suppression of anti-tumor immunity by inhibition of interactions between cytotoxic lymphocytes and target tumor cells (Carraway et al., 2000). One recent study shows that *in vivo*, subcutaneous injection of SMC-overexpressing cells results in substantially greater lung metastasis than injection of SMC-repressed cells. Moreover, injection of A375 human melanoma cells followed by *in vivo* induction of SMC overexpression within the solid tumor resulted in spontaneous distant metastasis (Komatsu et al., 2000).

[0022] Mucus-containing pathogens. Mucins and mucin-like molecules have recently been described in several protozoan parasites, at different stages of the life cycle. These include kinetoplastid (*Trypanosoma*, *Leishmania*), apicomplexan (*Cryptosporidium*) and amoebic (*Entamoeba*) parasites (Schenkman et al., 1993, Almeida et al., 1994, Ilg et al., 1999, Barnes et al., 1998, Strong et al., 2000). These share many structural and compositional features with mammalian mucins, but vary in several other aspects. It is now becoming

evident that mucins in a parasite are involved in cell-cell interaction and cell surface protection, thus helping the parasite to establish infection.

[0023] Currently, several pharmaceutical compounds against diseases in which mucus is involved are used. Those compounds have, however, limited beneficial effects. A major reason for this is the fact that the targets of therapeutic compounds, like, for instance, lung epithelial cells, can hardly be reached because of the barrier of thick and adhesive mucus which is present in the airways and gastrointestinal tract of the patient. After administration of a certain pharmaceutical composition, only a small percentage of the composition is actually capable of performing its beneficial effect. Higher doses often do not improve treatment; essentially no more targets can be reached. Furthermore, higher doses often lead to more harmful side effects. A major part of administered pharmaceutical composition therefore often leaves the body before any beneficial effect could be performed.

[0024] The incapability of current therapeutic compounds to reach their target efficiently is a major drawback of current treatment.

[0025] Mucus thus provides an important defensive barrier which forms the first line of defense to the external environment. However, several diseases involve a disturbed generation of mucus, resulting in thick and adhesive mucus. This mucus forms an unwanted barrier hampering the uptake of, for instance, nutrition and/or medicines by a patient. This is, for instance, a major problem for patients suffering from cystic fibrosis, COPD, asthma, bronchitis, and tuberculosis. Uptake of nutrients in the gastrointestinal tract is insufficient because of the decreased permeability of the mucus layer covering the epithelial cells. This often results in failure to thrive. Likewise, pharmaceutical compositions are less able to reach their target, for instance, in the lungs, because of a thick mucus layer. This reduces the efficiency of current treatment. Therefore, there is a need for a means of decreasing the mucus barrier in a mammal.

SUMMARY OF THE INVENTION

[0026] The present invention provides a recombinant or substantially isolated or purified mammalian mucinase, or a modified form thereof having a substantially similar mucin-hydrolyzing activity. The invention also provides a recombinant or substantially isolated or purified mucinase, the mucinase being a mucinase having an amino acid sequence essentially corresponding to the amino acid sequence shown in FIG. 8 Table I below (SEQ ID

NO:1), or a modified form of the mucinase having a substantially similar mucin-hydrolyzing activity. A mucinase of the invention is particularly suitable for degrading mucus. The mucinase is particularly suitable of degrading mucus in a mammal, because a mammal naturally comprises a mucinase of the invention, which is endogenously present in the mammal. Therefore, a mucinase of the invention does not provoke severe side-effects and harmful immune responses in the mammal.

[0027] Table I. Human AMCase amino acid sequence (SEQ ID NO:1) deduced from cDNA sequence. The characteristic hydrophobic signal peptide (amino acids 1-21) is underlined with a single line.

```
MTKLILLTGLVLILNLQLGSAYQLTCYFTNWAQYRPGLG
RFMPDNIDPCLCTHLYAFAGRQNNEITTIEWNDVTLYQ
AFNGLKNKNSQLKTLLAIGGWNFGTAPFTAMVSTPENR
QTFITSVIKFLRQEFDGLDFDWEYPGSRGSPQDKHLFT
VLVQEMREAFEQEAKQINKPRLMVTAAVAAGISNIQSG
YEIPQLSQYLDYIHVMTYDLHGSWEGYTGENSPLYKYP
TDTGSNAYLNVDYVMNYWKDNGAPAEKLIVGFPTYGH
NFILSNPSNTGIGAPTSGAGPAGPYAKESGIWAYYEICTF
LKNGATQGWDAPEVPYAYQGNVVWGYDNIKSFDIKA
QWLKHNKFGGAMVWAIDLDDFTGTFCNQGKFPLISTLK
KALGLOQASCTAPAQPIEPITAAPSGSGNGSGSSSSGGSS
GGSGFCAVRANGLYPVANNRNAFWHCVNGVTYQQNC
QAGLVFDTSCDCCNWA
```

[0028] With a mucinase of the invention, it is now, for instance, possible to efficiently decrease an unwanted mucus barrier in the respiratory tract and/or gastrointestinal tract of a patient suffering from a disease in which mucus is involved without harmful side-effects. On the one hand, degrading mucus improves the capability of the patient to take up oxygen and/or nutrients. On the other hand, by (partially) degrading a thick mucus layer, delivery of other pharmaceutical compositions becomes easier, and mucociliary clearance improves, resulting in fewer persistent infections. It has also become possible to selectively counteract tumor cells which have a different mucus expression pattern as compared to normal cells. Additionally, it is possible to at least in part degrade microorganisms comprising mucus.

[0029] The invention also provides a mucinase produced by a host or host cell and isolated from the host or host cell or medium in which the host cell is cultured. In one embodiment, the amino acid sequence of the mucinase is encoded by a nucleotide sequence essentially corresponding to the nucleotide sequence shown in FIG. 8 Table II below (SEQ

ID NO:2). The mucinase is called AMCase. Preferably, the mucinase has a molecular weight of about 50 kDa.

[0030] **Table II.** Human AMCase cDNA sequence (SEQ ID NO:2) (GenBank Accession Number AF290004).

[0031] By "a mucinase" is meant herein a proteinaceous molecule which is capable of, at least in part, hydrolyzing a mucin. This results in the cleavage of at least one sugar moiety bond of the mucin. Preferably, a sugar moiety, such as a β .1-4 linked N-acetylglucosamine, is cleaved. In terms of the invention, by "substantially isolated or purified" is meant that the mucinase is removed from an environment in which it naturally occurs, or that a sample, comprising the mucinase, is enriched for the mucinase. The sample may be obtained from a mammal, for instance, from a mouse or a human individual, because mammals endogenously comprise a mucinase of the invention.

[0032] By "a recombinant mucinase" is meant a mucinase which has artificially been made, as opposed to mucinases which are naturally generated in living organisms. A recombinant mucinase can, for instance, be generated by expression, either *in vitro* or *in vivo*, of a vector comprising a nucleic acid sequence encoding the mucinase.

[0033] In terms of the invention, "a sequence essentially corresponding to" means that variations of the sequence are allowed, as long as the variations do not alter the properties of the sequence in kind. The properties may, however, be somewhat altered in amount. For amino acid sequences, the variations, for instance, include a conservative substitution: a substitution of an amino acid residue with another amino acid residue with generally similar properties (such as size and hydrophobicity) such that the functioning of the amino acid sequence remains the same in kind, not necessarily in amount. Additionally, an amino acid residue may be deleted without significantly altering the function of the amino acid sequence. Generally, the sequence variations will be limited to less than 35%, preferably less than 20%, more preferably less than 10%. Therefore, the variants will generally have a homology of 65%, preferably 80 %, more preferably 90%. An amino acid sequence essentially corresponding to a mucinase, for instance, has the same kind of mucin-hydrolyzing property as the mucinase, though not necessarily in amount. Likewise, a nucleotide sequence essentially corresponding to a nucleotide sequence shown in FIG-8 Table II (SEQ ID NO:2) has the same kind of properties as that of the nucleotide sequence shown in FIG-8 Table II (SEQ ID NO:2). It encodes, for instance, a mucinase.

[0034] By "a modified form of the mucinase having a substantially similar mucine-hydrolyzing activity" is meant a molecule having substantially similar mucine-hydrolyzing activity, although the modified form may differ significantly from the mucinase. The modified form may, for instance, comprise a functional part of the mucinase. In terms of the invention, a functional part of a mucinase is defined as a part which has a substantially similar mucin-hydrolyzing activity as the mucinase. The functional part could, for instance, consist of the catalytic domain of the mucinase. The modified form may also be a functional derivative, wherein several domains are deleted and/or substituted and/or added. For instance, the modified form may comprise a fusion protein. The fusion protein, which is also herewith provided, preferably comprises a mucinase of the invention and/or a functional part thereof, and a protection moiety. The protection moiety allows for a longer half-life as compared to an unprotected mucinase of the invention and/or an unprotected functional part thereof. The protection moiety, for instance, comprises at least part of an immunoglobulin chain,

preferably a constant region of the chain. In one embodiment of the invention, a fusion protein of the invention comprises a human mucinase of the invention and/or a functional part thereof. A fusion protein of the invention preferably retains mucinase biological activity, both *in vitro* and *in vivo*, and preferably has an improved pharmacokinetics when administered *in vivo* as compared to an unprotected mucinase of the invention and/or an unprotected functional part thereof. The fusion protein can also comprise several copies of a desirable domain of the mucinase, and/or an additional domain which is not derived from the mucinase.

[0035] By "a substantially similar mucin-hydrolyzing activity" is meant herein the same mucin-hydrolyzing activity in kind, not necessarily in amount. Like mucinase, a compound with a substantially similar mucin-hydrolyzing activity is capable of cleaving at least one sugar moiety bond of mucin. The substantially similar mucin-hydrolyzing activity does not necessarily comprise additional (enzymatic) activities against other kinds of compounds. If, for instance, a mucinase of the invention comprises other catalytic activities besides its mucin-cleavage activity, a compound comprising a substantially similar mucin-hydrolyzing activity does not necessarily comprise the other catalytic activities.

[0036] In one aspect, the invention provides a pharmaceutical composition comprising an effective amount of a mucinase of the invention and a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition is particularly suitable for therapeutic or prophylactic treatment of an individual against a disease in which mucus is involved, such as, for instance, cystic fibrosis, COPD, asthma, bronchitis, tuberculosis, a mucin-producing tumor and/or infection by a protozoan parasite. Preferably, the pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of a second pharmaceutical composition, such as human DNase1, a mucolytic (*e.g.*, n-acetylcysteine), an antibiotic (*e.g.*, Tobramycin), a pancreatic enzyme supplement, an antifungal drug (*e.g.*, itraconazole, caspofungin), an antihistamine, a bronchodilator, a leukotriene inhibitor, and/or a corticosteroid.

[0037] In terms of the invention, a disease in which mucus is involved means that the disease is either associated with an altered mucin expression pattern in a patient or associated with a microorganism comprising mucus such as a protozoan parasite. The altered mucin expression pattern may lead to a thick mucus layer in the respiratory tract and/or gastrointestinal tract hampering the uptake of oxygen and/or nutrients and facilitating infections. Alternatively, the altered mucin expression pattern may only be induced locally.

This is, for instance, the case with carcinoma cells having an altered expression pattern as compared to normal cells.

[0038] The invention further comprises a composition comprising a mucinase of the invention and a carrier or diluent. For instance, the composition can be a medium for culturing cells, or a cosmetic, dental or food product.

[0039] Furthermore, the invention provides a method of therapeutic or prophylactic treatment of an individual against a disease in which mucus is involved, such as cystic fibrosis, COPD, asthma, bronchitis, tuberculosis, a mucin-producing tumor and/or infection by a protozoan parasite, comprising administering to the individual a pharmaceutical composition of the invention. The mucinase present in a pharmaceutical composition of the invention is capable of cleaving mucins. Therefore, with a method of the invention, it has, for instance, become possible to decrease an unwanted mucus barrier in the respiratory tract and/or gastrointestinal tract of a patient suffering or at risk of suffering from a disease in which mucus is involved. It has also become possible to specifically bind and/or cleave mucus of tumor cells having an altered mucus expression pattern. Once bound, the tumor cell can be subject to additional treatment by conventional pharmaceuticals. As another example, it has now also become possible to protect and/or treat an individual against a mucus-comprising pathogen, by prophylaxis and/or treatment according to a method of the invention

[0040] The invention also provides a process for preparing a mucinase of the invention, or a modified form thereof having a substantially similar mucin-hydrolyzing activity, comprising growing a host or a host cell capable of producing the mucinase or modified form thereof and isolating the mucinase produced from the host or host cell or from medium in which the host cell is cultured. In one aspect of the invention, the host or host cell is genetically engineered. Preferably, the amino acid sequence of the mucinase is encoded by a nucleotide sequence essentially corresponding to the nucleotide sequence shown in FIG.-8 Table II (SEQ ID NO:2).

[0041] In another aspect of the invention, a mucinase of the invention is provided which further comprises a chitin-hydrolyzing activity. By “a chitin-hydrolyzing activity” is meant herein a capability of cleaving at least one bond of chitin. The mucinase is very suitable for degrading chitin, for instance, chitin from pathogenic microorganisms. Therefore, the invention also provides a pharmaceutical composition for therapeutic or prophylactic treatment of an individual against infection by a chitin-containing pathogen, comprising a

therapeutically or prophylactically effective amount of a mucinase of the invention and a pharmaceutically acceptable carrier or diluent. The invention also provides a method of therapeutic or prophylactic treatment of an individual against infection by a chitin-containing pathogen, comprising administering to the individual the pharmaceutical composition. The method is, for instance, very suitable for treating a CF-patient comprising *Aspergillus* species in its respiratory tract. With a method of the invention, a thick mucus layer and *Aspergillus* species can be degraded in the respiratory tract simultaneously, because of both mucus-hydrolyzing as well as chitin-hydrolyzing activity of the pharmaceutical composition. The method is also suitable for treatment of other pathogens in a mucosal lining, like, for instance, vulvovaginitis and ringworm.

[0042] A composition comprising a mucinase of the invention and a carrier or diluent is also herewith provided. For instance, the composition may be a medium for culturing cells, in particular human cells, or a cosmetic, dental, or food product. Furthermore, the invention provides a chitin-based article of manufacture comprising a chitin-hydrolyzing amount of a mucinase of the invention. The chitin-based article of manufacture may be a drug-containing carrier, an implant for controlled drug release or a transient functional implant.

[0043] An isolated host cell capable of producing a mammalian mucinase of the invention is also herewith provided, as well as a recombinant nucleic acid comprising a nucleotide sequence encoding, or complementary to a nucleotide sequence encoding, an expressible mammalian mucinase of the invention. The mucinase may comprise an amino acid sequence essentially corresponding to the amino acid sequence shown in FIG.-8 Table I (SEQ ID NO:1). Preferably, the nucleotide sequence essentially corresponds to, or essentially is complementary to, the nucleic acid sequence shown in FIG.-8 Table II (SEQ ID NO:2). By “a nucleotide sequence encoding an expressible mucinase” is meant herein a nucleotide sequence encoding a mucinase that at least in part can be obtained by transcription and/or translation of the nucleotide sequence. By “essentially complementary to a nucleic acid sequence” is meant that a particular nucleic acid can bind by hybridization to the nucleic acid sequence, especially under stringent conditions. By “essentially corresponds to the nucleic acid sequence shown in FIG.-8Table II” (SEQ ID NO:2) is meant herein that a nucleotide sequence codes for the same amino acid sequence that is encoded by the nucleic acid sequence shown in FIG.-8 Table II (SEQ ID NO:2), and/or codes for a modified form of the amino acid sequence having a substantially similar mucin-hydrolyzing activity. A

nucleotide sequence coding for the same amino acid sequence can, for instance, utilize a different codon usage.

[0044] Also provided herewith is an oligonucleotide of at least about 8 nucleotides having a nucleotide sequence corresponding to, or complementary to, a nucleotide sequence shown in FIG. 8 Table II (SEQ ID NO:2) and being capable of binding by hybridization under stringent hybridization conditions to nucleic acid coding for a mucinase of the invention. The oligonucleotide is useful for different purposes. For instance, the oligonucleotide can be used as a probe in a hybridization analysis, or as a primer in a nucleic acid amplification method such as PCR, NASBA, etc. The invention also provides a peptide of at least about 8 amino acid residues having an amino acid sequence derived from the amino acid sequence shown in FIG. 8 Table I (SEQ ID NO:1) and representing or mimicking an epitope of a mucinase of the invention, in particular those having an amino acid sequence corresponding to an amino acid sequence shown in FIG. 8 Table I (SEQ ID NO:1) and having antigenicity. Usually, such peptides will have a length of at least about 10, or even at least about 15, or at least about 40 amino acid residues. Preferably, the peptide comprises a length of about 30 amino acid residues. The peptides are, for instance, suitable for diagnostic purposes, or in immunization protocols to raise mammalian mucinase-specific antibodies.

[0045] An antibody capable of binding to a mucinase of the invention is also herewith provided. Preferably, the antibody is a monoclonal antibody. An antibody of the invention can be used for many purposes, for instance, for isolating and/or purifying (e.g., by affinity chromatography) a mucinase of the invention.

[0046] In yet another aspect, the invention provides a diagnostic kit comprising an antibody of the invention, and/or a peptide of the invention; and/or a diagnostically effective amount of a mucinase of the invention, and a conventional component of diagnostic kits for detecting an antigen or an antibody. Also provided is a diagnostic kit comprising an oligonucleotide of the invention and/or a recombinant nucleic acid of the invention, and a conventional component of diagnostic kits for detecting a nucleic acid.

[0047] Furthermore, the invention provides a method of decomposing mucin comprising contacting the mucin with a mucinase of the invention under mucin-hydrolyzing conditions. The invention also provides a method of decomposing chitin comprising contacting the chitin with a mucinase of the invention which further comprises a chitin-hydrolyzing activity, under chitin-hydrolyzing conditions.

LEGENDS OF THE DRAWINGS

[0048] FIG. 1. Isoelectric focusing profile of chitinolytic activity in mouse lung extract. Isoelectric focusing was performed as described in experimental procedures. Chitinolytic activity was measured using 4MU-chitotrioside substrate. The enzyme activity present in the different isoelectric focusing fractions is expressed as a percentage of the total activity present in all fractions.

[0049] FIG. 2. Mouse AMCase cDNA sequence and deduced amino acid sequence (SEQ ID NO: ____). The cDNA sequence (GenBank Accession Number AF290003) is indicated by the upper sequence and the deduced amino acid sequence is depicted below the nucleotide sequence. The characteristic hydrophobic signal peptide (amino acids 1-21) is underlined with a single line. The putative chitin binding domain (amino acids 426-473) is underlined with a double line. The hinge region separating the catalytic domain from the chitin binding domain is underlined with a dashed line. The part of the protein purified from mouse intestine that was determined by Edman sequencing is boxed.

[0050] FIG. 32. Degradation products with colloidal chitin as substrate. The FACE technique (described in experimental procedures) was used to visualize the cleavage products of recombinant human chitotriosidase and recombinant mouse AMCase using colloidal chitin as substrate. Lane 1, no enzyme added. Lane 2, products formed after incubation with 50 kDa recombinant human chitotriosidase with chitin. Lane 3, products formed with recombinant mouse AMCase and chitin. Lane 4, human chitotriosidase incubated without substrate. Lane 5, mouse AMCase incubated without substrate. Marker lane is indicated with M (sugar polymers are indicated on the right-hand side).

[0051] FIG. 43. Electrophoretic behavior of chitinases.
 Panel A: Purified recombinant human chitotriosidase and mouse AMCase were separated on a 12.5% SDS-PAGE gel in the presence or absence of a reducing agent and visualized by silver staining as described in experimental procedures (panel A). Lane 1, recombinant mouse AMCase under reducing conditions. Lane 2, recombinant human chitotriosidase under reducing conditions. Lane 3, recombinant human chitotriosidase under non-reducing conditions. Lane 4, recombinant mouse AMCase under non-reducing conditions. M indicates the molecular weight standards (mass (kDa) indicated at the left-hand side).

Panel B: The same purified recombinant enzymes as described in panel A were separated on a 10% SDS-PAGE gel containing glycol-chitin as described in experimental procedures. Chitinolytic activity was visualized as clearing zones in the gel. Lane 1, recombinant human

39 kDa chitotriosidase. Lane 2, recombinant human 50 kDa chitotriosidase. Lane 3, recombinant mouse AMCase (mass (kDa) indicated at the right-hand side).

[0052] FIG. 54. Effects of acidic pH.

Panel A: pH activity profile of the different chitinases. The pH optima were determined by monitoring enzyme activity at the indicated pH in McIlvaine buffer. Purified human recombinant chitotriosidase (closed lozenge), purified mouse AMCase (closed circle).

Panel B: Effects of acidic pre-incubation. Purified recombinant human chitotriosidase and mouse AMCase were pre-incubated for 30 minutes at the indicated pH in McIlvaine buffer prior to enzyme activity measurement at the assay pH (see experimental procedures). Activity prior to incubation at the indicated pH is defined as 100%.

Panel C: Precipitation by trichloroacetic acid (TCA). Purified recombinant human chitotriosidase and mouse AMCase were incubated with the indicated percentages of TCA. The amount of remaining enzyme activity after centrifugation is shown as a percentage of initial amounts.

[0053] FIG. 65. Tissue distribution of mouse AMCase mRNA.

Panel A: The relative expression levels of mouse AMCase in various mouse tissues as determined by dot blot analysis using an RNA Master Blot (Clontech) as described in experimental procedures. The highest level of expression is defined as 100%.

Panel B: Northern blot of RNA isolated from the indicated mouse tissues. 15 micrograms total of RNA was separated on an agarose gel as described in experimental procedures. The full-length mouse AMCase cDNA was used as probe. As a control for RNA loading, a glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe was used (data not shown). The position of the 18S ribosomal RNA band is indicated.

[0054] FIG. 76. Tissue distribution of human AMCase mRNA. The relative expression levels of human AMCase in various human tissues were determined by dot blot analysis using an RNA Master Blot (Clontech) using the oq35c04,s1 EST clone (GenBank Accession Number AA976830) as probe. The highest level of expression is defined as 100%. Several tissues were excluded from the figure since they did not result in a detectable signal: amygdala, caudate nucleus, cerebellum, cerebral cortex, frontal lobe, hippocampus, medulla oblongata, occipital lobe, putamen, substantia nigra, temporal lobe, thalamus, nucleus accumbens, spinal cord, fetal brain, fetal heart, fetal kidney, fetal liver, fetal spleen and fetal thymus.

[0055] FIG. 8 (SEQ ID NO:). Human AMCase cDNA sequence and deduced amino acid sequence.

Panel A: The human AMCase cDNA sequence (GenBank Accession Number AF290004) is indicated by the upper sequence and the deduced amino acid sequence is indicated below the nucleotide sequence. The characteristic hydrophobic signal peptide (amino acids 1-21) is underlined with a single line.

Panel B: Amino acid sequence comparison of mature (without signal peptide) human (h) and mouse (m) AMCase and human chitotriosidase. Residues conserved among at least two out of the three sequences are boxed.

[0056] FIG. 9₇. The effect of AMCase on glycoproteins was studied by evaluating the effect of mouse AMCase on mucin, a type of glycoproteins expressed on mucosal surfaces in the airways and gastrointestinal tract. Bovine submaxillary gland mucin (Sigma) 125 µg was dissolved in 40 µl 0.05M NaAc pH 5.0 in the presence or absence of 500 ng mouse AMCase. After overnight incubation at 37°C, the mucin was electrophorized on an SDS-PAGE gel 7.5%, followed by silver staining. As is shown in FIG. 9₇, the mucin was degraded substantially by treatment with the AMCase (left lane), but not when it was treated with control buffer (right lane).

[0057] FIG. 8. Amino acid sequence comparison of mature (without signal peptide) human (h) (SEQ ID NO:14) and mouse (m) (SEQ ID NO:9) AMCase and human chitotriosidase (SEQ ID NO:10). Residues conserved among at least two out of the three sequences are in bold.

DETAILED DESCRIPTION OF THE INVENTION

[0058] Mucus provides an important defensive barrier which forms the first line of defense to the external environment. However, several diseases involve a disturbed generation of mucus, resulting in thick and adhesive mucus. This leads, among others, to problems according to the uptake of oxygen and nutrients by a patient. Additionally, because of the thick adhesive mucus, current pharmaceutical compounds have a reduced capability to reach their targets (for instance, epithelial cells or DNA present in the mucus), and opportunistic infections occur as a result of impaired mucociliary clearance.

[0059] Furthermore, infections with mucus-containing pathogens like protozoan parasites can induce severe complications. The same applies to several other pathogens present in mucosal linings of an individual, for instance, the fungus *Aspergillus*, in the lungs.

[0060] Although pharmaceutical compositions are currently used to counteract diseases in which mucus is involved, there is yet no efficient and satisfactory method to degrade unwanted mucus.

[0061] For cystic fibrosis and COPD, the most widely used mucolytic agents are n-acetylcysteine or acetylcysteine and recombinant human DNase. Other mucolytics used in clinic include guaifenesin, carbocisteine lysine, citiolone, sobrerol, ambroxol, myrtol, iodinated glycerol, isobutyrylcysteine, and letosteine.

[0062] N-acetylcysteine is an aerosolized mucolytic agent often used as adjunctive therapy for pulmonary complications of cystic fibrosis. The viscosity of mucous secretions in the lungs is dependent upon the concentrations of mucin and DNA. N-acetylcysteine acts to split the sulfide bonds between DNA and mucins, thereby decreasing mucus viscosity. The action of N-acetylcysteine is pH dependent. Mucolytic action is significant at ranges of pH 7.9 (Kastrup et al., 1998).

[0063] Adverse effects reported with acetylcysteine include stomatitis, nausea, vomiting, hemoptysis, and severe rhinorrhea. Acetylcysteine has an unpleasant, pungent odor that may lead to an increased incidence of nausea. Bronchoconstriction has also been reported with acetylcysteine therapy. N-acetylcysteine has mucolytic activity *in vitro*; this activity has, however, not been demonstrated convincingly *in vivo* (Celli et al., 1995). A possible explanation for this finding is a pH in the airways that is lower than 7.0. Even though the normal tracheal mucus pH ranges from 6.9-9.0, in infection, pH values can become as low as pH 5.8 in mucus (Buhrmester 1933). An acidic pulmonary environment has been reported for at least two mucus-associated lung diseases, namely asthma (Hunt et al.) and cystic fibrosis (Choi et al.). A similar decreased pH may also be present in the lungs of COPD patients, as they have respiratory acidosis (Plant et al.).

[0064] DNA is a factor that contributes to viscous mucus in CF patients. This high extracellular DNA (as high as 3-14 mg/ml, Chernick and Barbero 1959, Potter et al., 1960) content further thickens airway secretions. Recombinant human DNase (Pulmozyme) has been demonstrated to reduce the viscosity of sputum in CF patients by hydrolyzing the extracellular DNA (Shak et al., 1990, Zahm et al., 1995). DNase is a highly purified solution of recombinant human deoxyribonuclease I (rhDNase), an enzyme that selectively cleaves

DNA. Studies have demonstrated that daily administration of recombinant human DNase resulted in definite improvement in pulmonary function, as assessed by FEV1, above baseline (Fuchs et al., 1994, Shak et al., 1995). Recombinant human DNase is indicated in the management of patients with CF to improve pulmonary function and decrease the frequency of respiratory infections. Safety and efficacy have not been demonstrated in children less than 5 years of age. The recommended dose of recombinant human DNase for most patients with CF is 2.5 mg by nebulization once daily. Adverse effects include voice alteration, pharyngitis, laryngitis, rash, and chest pain. As DNase only targets the DNA present in viscous sputum, the mode of action of AMCase is independent of DNase, and possibly synergistic. In addition, for indications as COPD, where less DNA is present in the sputum, AMCase is more effective.

[0065] Although pharmaceutical compositions are currently used to counteract diseases in which mucus is involved, it has to be concluded that there is an unmet need for more sophisticated agents to degrade thick, adhesive mucus and to treat and/or prevent chronic infections with pathogens in epidermal and mucosal body linings. Preferably, such agents should be highly specific and effective and should not be prone for developing resistance there against and neither cause toxic side effects.

[0066] It was previously disclosed that bacterial chitinase preparations, which are expected to be highly immunogenic when administered to humans, can degrade human ocular mucus (Argueso et al., 1998). Here it is disclosed that mammals naturally comprise a mucinase. The mammalian mucinase, endogenously present at mucosal surfaces in mammals, provides the solution for the above-mentioned problems concerning diseases in which mucus is involved. A mucinase of the invention is capable of cleaving mucus. In one embodiment, a specific mouse (nucleotide sequence SEQ ID NO:3 (see, Table III, below) and amino acid sequence SEQ ID NO:4 (see, Table IV, below)) and human mucinase (nucleotide sequence SEQ ID NO:2 (see, Table II, above) and amino acid sequence SEQ ID NO:1 (see, Table I, above)) is provided, called AMCase, which is depicted in more detail in FIGS. 2 and 8 (SEQ ID NO:—). It has a catalytically active 39 kDa domain which is connected via a hinge region with a C-terminal mucin-binding domain. To show its mucus-degrading property, we have incubated a mixture of submaxillary gland mucins with recombinant 50 kDa AMCase. The effect of the incubation was examined by analysis with SDS-PAGE and silver staining. FIG. 97 shows that a remarkable reduction in size of the mucins occurs. It was noted that the viscosity of the mucin solution was markedly reduced following incubation

with AMCase. The flow rate of the mucin solution, as measured in a vertically positioned glass pipette, was increased with almost a factor of 2.

[0066] **Table III.** Mouse AMCase cDNA sequence (SEQ ID NO:3) (GenBank Accession Number AF290003).

```

atggccaagctacttctcgcacaggctggcttcgtgaatgctcagctggggctgc
ctacaatctgatatgtatttaccaactggccagtatggccaggctggggagcttc

gaacaatgagatcaccaccatagaatggaatgtatgtactctataaaagcttcaatgactt
gaaaaacaggaacageaaactgaaaaccctcctggcaattggaggctgaaaccttggaa
ctgccccttcactaccatggttcacttcagaaccgcacccattacccatgtcat
caaatttctgcgtcagtatgggtttagtgactggactggactggaaataccaggctca
cgtgggaggccctcctcaggacaagcatcttcactgtcctgttaaggaaatgcgtgaag
ctttgagcaggaggctattgagagcaacaggcccagactgtgtactgtctgttag
ctggfggatttccaacatccaggctgctatgagatccctgaacitctaagtacctggat
ttcatccatgtcatgacatatagacccatggctccctggaggctacactgggagaata
gtcccccttacaaataccctactgagactgttagcaatgcctacccatgtggattatgtca
tgaactatttgaagaacaatggagccccagctgagaagcttattgtggattccagagt
atggacacacccatccatccatggctgataatggaaattgggcccctactatgtggat
gatggccctgtggcgcctataccagacaggctgggtctggctactatgagatttgc
acccttctgagaagtggagccactgaggtctggatgcctccaaagaagtgcctatgcc
tataaggccaaacgagtggctggctatgacaatatacaagagctcagtgttaaggctcagt
ggcttaaggcagaacaatttggaggtgccatgtctggccattgaccctgtgacttcact
ggctttctgtgatcaggaaaattccctgtacttctacttgaacaaagccctggcatat
ccactgaaggttgcacagctccgtacgtgcctccgagccagtgactactccctcaggaa
gtgggagtggggtggaaagctccggaggaaagctctggaggcagtggattctgtccga
caaagcagatggcccttacccctgtgcagatgacagaaaatcttgcactcccttactccatcaat
ggaatcacataccagcagcatgtcaagcaggcttgtttgataccagctgttaattgctg
caactggccatgaacctaattcccttacccatgtcaaaatggtagccaaaca
aaagtaactatcccttacccatgtcaaaatggtagccaaaca

```

[0067] **Table IV.** Mouse AMCase amino acid sequence (SEQ ID NO:4) deduced from cDNA sequence (SEQ ID NO:3). The characteristic hydrophobic signal peptide (amino acids 1-21) is underlined with a single line. The putative chitin-binding domain (amino acids 426-473) is underlined with a double line. The hinge region separating the catalytic domain from the chitin-binding domain is underlined with a dashed line. The part of the protein purified from mouse intesting that was determined by Edman sequencing is italicized.

```

MAKLLVTGLALLNAQLGSAYNLICYFTNWAQYRPGLG
SFKPDDINPCLCITHLIYAFAAGMQNNEITTIEWNDVTLYK
AFNDLKRNNSKLKTLAIGGWNFGTAPFTTMVSTSQNR
QTFITSVIKFLRQYGFDGLDLDWEYPGSRGSPQDKHLF
TVLVKEMREAFEQEAIESNRPRLMVTAAVAGGISNIQAG
YEIPELSKYLDFIHVMTYDLHGSWEGYTGENSPLYKYPT
ETGSNAYLNVDYVMNYWKNNGAPAEKLIVGFPEYGHT
FILRNPSDNGIGAPTSGDGPAGAYTRQAGFWAYYEICTF
LRSGATEVWDASQEVPYAYKANEWLGYDNIKSFSVKA

```

QWLKQNNFGGAMIWAIDLDDFTGSFCDQGFPLTSTLN
KALGISTEGCTAPDVPSEPVTPPGSGSGGGSSGGSSGGS
GFCADKADGLYPVADDRNAFWQCINGITYQQHCOAGL
VFDTSCNCCNWP

[0068] A thick and adhesive mucus layer in the respiratory tract and/or gastrointestinal tract of an individual with, for instance, CF, COPD, or asthma can be, at least in part, degraded by administration of a mucinase of the invention to the respiratory tract and/or gastrointestinal tract of an individual. (Partly) degradation of the thick mucus layer enhances oxygen and/or nutrient uptake by the individual. Additionally, it enhances the capability of other medicaments to reach their target and prevents the occurrence of persistent chronic infections. Because a mucinase of the invention is endogenously present in mammals, it does not provoke severe immunological reactions after additional administration of the mucinase to the mammals.

[0069] A pharmaceutical composition or commercial formulation typically comprises a certain percentage of Active Pharmaceutical Ingredient, i.e., purest achievable form of a mucinase of the invention, as well as a suitable carrier that ensures the composition to be an appropriate delivery vehicle to the area of disease. Examples are a cream or ointment for skin infections, tablet or capsule formulations for the digestive tract, and an inhalation formulation for the pulmonary airways. Appropriate doses will be formulated such that these are the Maximum Effective Dose with the appropriate safety and tolerability profile.

[0070] In order to use a mammalian mucinase, like AMCase, as a pharmaceutical agent against thick mucus layers, the mammal has to be tolerant for the mucinase. Because a mucinase of the invention occurs naturally in the mammalian body, no strong immune response is elicited by additional administration of the enzyme to the mammal.

[0071] Another requirement in the application of an enzyme as a therapeutic agent is its ability to survive and to be functional in the body. This requirement is met because a mucinase of the invention is a remarkably stable enzyme. For instance, mouse AMCase can endure incubation at acidic (pH 2) up to quite basic conditions (pH 8). The enzyme is quite resistant against various proteases.

[0072] A mucinase of the invention preferably has a low pH optimum. For instance, mouse AMCase shows a pronounced pH optimum at pH 2.3 and a less pronounced optimum at pH 4.7. A mucinase of the invention with a low pH optimum is very suitable, especially because it is pH stable, for enhancing food digestion and normal bowel movement in patients with a thick mucus layer in the gastrointestinal tract, like, for instance, cystic

fibrosis patients. It can, for instance, well perform its catalytic action in the acidic stomach, whereas many other pharmaceutical compounds are inactivated.

[0073] A mucinase of the invention can be combined with existing medicaments. Once (part of) a thick mucus layer is cleaved and/or bound by mucinase, other pharmaceuticals are more capable of reaching their targets. In one embodiment, the invention therefore provides a mucinase conjugate comprising a mucinase of the invention and a second molecule, like, for instance, a second pharmaceutical compound and/or an immunoglobulin chain. The mucinase is preferably bound to the second molecule. The conjugate is suitable for a combined therapy. For instance, the conjugate can cleave mucus in the lungs and/or gastrointestinal tract of a patient with its mucin-hydrolyzing catalytic domain, after which the second pharmaceutical compound is capable of performing its therapeutic task. Alternatively, the conjugate can bind mucus with its mucus-binding domain without cleaving the mucus, after which the second pharmaceutical compound is capable of performing its therapeutic task.

[0074] Possible AMCase combination therapies are:

CF: DNase 1 (pulmozyme, Genentech) and AMCase

Oral AMCase and pancreatic enzyme supplements

AMCase and antibiotics

AMCase and gene therapy

CF with ABPA: itraconazole (or other antifungal treatments, for ABPA itraconazole is most often used) with AMCase (+ other CF medication) +/- oral corticosteroids

Asthma: AMCase with antihistamines, bronchodilators or corticosteroids.

Asthma with ABPA: itraconazole (or other antifungal treatments, for ABPA itraconazole is most often used) with AMCase +/- antihistamines, bronchodilators or corticosteroids

ABPA without asthma or CF: oral corticosteroids and AMCase (topical administration)

Chronic obstructive pulmonary disease with bronchitis: AMCase alone, or in combination with bronchodilators, b-adrenergic agents, methylxanthines, corticosteroids, or mucolytics, (mostly with n-acetylcysteine: fluimocyl or mucomyst) is efficacious.

[0075] Systemic indications for a mucinase of the invention are also foreseen. These include but are not limited to mucus-producing benign and malignant tumors. Mucinase can be administered alone or in combination with other treatments.

[0076] A mammalian mucinase can additionally comprise chitin-hydrolyzing activity. For instance, we have found that mouse and human AMCase also comprise chitin-hydrolyzing activity. This is an important finding, because 6% of the human individuals are deficient for the only human chitin-hydrolyzing enzyme known, chitotriosidase. In those individuals, an endogenic mucinase can take over that function.

[0077] Next to cellulose, chitin is the most abundant glycopolymer on earth, being present as a structural component in coatings of many species, such as the cell wall of most fungi (Debono and Gordee 1994), the microfilarial sheath of parasitic nematodes (Fuhrman and Piessens 1985, Araujo et al., 1993), the exoskeleton of all types of arthropods (Neville et al., 1976) and in the lining of guts of many insects (Shahabuddin and Kaslow 1994). Chitinases (EC 3.2.1.14) are endo- β -1,4-N-acetylglucosaminidases that can fragment chitin and have been identified in several organisms (Flach et al., 1992). Until a few years ago it was generally assumed that man lacks the ability to produce a functional chitinase.

[0078] Chitin-containing pathogens like fungi constitute a common treat of infection of mammals. The mammalian immune system governs a broad array of defense mechanisms against systemic fungal infections. However, the incidence of life-threatening systemic fungal infections is rapidly increasing as the result of increasing active suppression of the immune system of patients during medical interventions, for example, during chemotherapies and transplantations, as well as due to viral suppression of the immune system, for example, during AIDS. Present antifungal agents show serious limitations such as the increasing resistance among the major human pathogenic fungi against existing drugs like azoles or because of the limited efficacy and toxic side effects of antifungal compounds like amphotericins. It is therefore to be concluded that there is an unmet need for more sophisticated agents to treat and/or prevent chronic infections with chitin-containing pathogens in epidermal and mucosal body linings. Preferentially, such agents should be highly specific and effective and should not be prone for developing resistance there against and neither cause toxic side effects.

[0079] The features of a mucinase of the invention which further comprises chitin-hydrolyzing activity (endogenous production in mucosal body linings, extreme acid pH stability and protease resistance, potent fungistatic action) make the mucinase an ideal candidate for use as a drug against topical/mucosal infections with chitin-containing pathogens such as fungi.

[0080] As chitin-containing pathogens such as fungi enter the body via accessible sites such as the nose, mouth, lungs, ears, eyes, skin, urethra, bladder, topical infections of these sites occur frequently. These sites are in contact with the outside world, and as a result, topical administration of antifungal drugs may be necessary to achieve optimal efficacy.

[0081] Prominent topical fungal infections for AMCase indication are, for instance, allergic bronchopulmonary aspergillosis (ABPA), vaginal infection with candida (vulvovaginitis: Low pH; a mucinase of the invention is active whereas chitotriosidase is not), dermatophytosis (ringworm of skin, scalp, nails and athlete's foot), and other topical fungal infections in body linings (including nonallergic lung aspergillosis).

[0082] Current treatment of fungal infections include allylamines (mostly topical applications) antimetabolites (oral, IV), azoles (topical, oral, IV), glucan synthesis inhibitors (IV), polyene macrolides (mostly IV, amphotericin B and derivatives, nystatin topical, pimaricin ophthalmic), and other drugs (systemic: Griseofulvin, topical: ciclopiroxolamine, haloprogin, tolnaftate, undecylenate). Many of these drugs, especially the ones for invasive and systemic infections, are hampered by serious side effects. Such side effects are less likely if a mucinase of the invention which further comprises chitin-hydrolyzing activity, which is endogenously expressed, is used as a protein drug. Thus, a mucinase of the invention which further comprises chitin-hydrolyzing activity is very suitable for treatment of lung infections in, for instance, cystic fibrosis and COPD.

[0083] Allergic bronchopulmonary aspergillosis (ABPA) is a syndrome seen in patients with severe obstructive lung disease, most commonly in asthma and cystic fibrosis (Cockrill & Hales 1999). Chronic colonization of the airways by *Aspergillus* is apparent in these patients, accompanied by *Aspergillus*-specific IgE antibody production and eosinophilia. ABPA is generally treated by using oral corticosteroids such as prednisone to suppress the inflammatory component of the disease. Antifungal therapy, such as treatment with the orally active itraconazole, has been reported. However, no controlled trials have been reported. In addition, as itraconazole is used for systemic treatment, *Aspergillus* in the airway lumen may not be treated as efficiently. Therefore, novel treatments need to be developed to treat fungal infections in these pulmonary diseases. A mucinase of the invention which further comprises chitin-hydrolyzing activity is suitable for use for this indication.

[0084] A mucinase of the invention which further comprises chitin-hydrolyzing activity is also suitable in the event of resistance to current antifungal therapies. For instance,

flucytosine resistance is common, especially when used as monotherapy for candida. Adverse effects are displayed as well.

[0085] Resistance to ketoconazole described with prolonged treatment of AIDS patients, adverse effects indications mucosal candidiasis, mycoses, histoplasmosis, dermatophytes. Resistance to flucanazole is increasing in AIDS patients, and adverse effects are displayed. The indications are mucosal candidiasis and vulvovaginal candidiasis. Resistance to itraconazole is not clear. There are few side effects. There is an indication of candida histoplasmosis, mycoses, aspergillosis, sporotrichosis, candida Terbinafine, especially to dermatophytes.

[0086] A mucinase of the invention which further comprises chitin-hydrolyzing activity can also be administered in combination with another current pharmaceutical. The invention therefore also provides a mucinase conjugate, comprising a mucinase of the invention which further comprises chitin-hydrolyzing activity and a second molecule, for instance, a second pharmaceutical compound and/or an immunoglobulin chain. Preferably, the mucinase is bound to the second molecule. The mucinase conjugate can bind chitin with its chitin-binding domain after which the second pharmaceutical compound is capable of performing its therapeutic task. The mucinase can also cleave the chitin with its chitin-hydrolyzing catalytic domain, but this is not necessary. A possible combination therapy for treatment of a fungus infection is: azoles, antimetabolites, glucan synthesis inhibitors, griseofulvin (all with intracellular activity) together with a mucinase of the invention which further comprises chitin-hydrolyzing activity, like, for instance, AMCcase. Of course, the several pharmaceutical compositions do not necessarily have to be administered at the same time. They can be administered together or separately, with either the same or different administration doses and administration intervals.

[0087] In one aspect, the invention provides a mucinase of the invention which has a low pH optimum. A major advantage of a mucinase of the invention which has a low pH optimum is that the mucinase even withstands the harsh conditions in the gastrointestinal tract and can therefore be administered orally.

[0088] A mucinase of the invention which has a low pH optimum is also suitable for use as a topical agent. For instance, athlete's foot, a topical infection caused by trichophyton or epydermophyton, involves a local decrease of pH. Therefore, a mucinase of the invention which has a low pH optimum and which has a chitin-hydrolyzing activity is particularly suitable for topical treatment of athlete's foot and for topical treatment of any

pathogen involving a low pH, like, for instance, a vaginal infection by *Candida albicans*. For instance, incubation of hyphae of *Candida albicans* with recombinant AMCase results in selective lysis of the growing tip, similar to the effect of chitotriosidase.

[0089] Additional important advantages of a mucinase of the invention which further comprises chitin-hydrolyzing activity compared to classic antifungal agents are the following. In the first place, since a mucinase of the invention which further comprises chitin-hydrolyzing activity is an endogenous protein, its administration will not result in a severe immune reaction. In the second place, resistance of fungi against chitinases has not been developed so far and seems intrinsically difficult given the fact that, despite the evolutionary pressure, plant fungal pathogens have remained sensitive to chitinases.

[0090] To counteract chitin-containing pathogens, like fungi, a mucinase of the invention which further comprises chitin-hydrolyzing activity, like AMCase, can be administered locally as a crème, for instance, on the skin. It may also be used for treatment of local ear-infections or vagina-infections, such as vulvovaginitis. Especially the latter also involves an acidic environment, in which a mucinase of the invention which further comprises chitin-hydrolyzing activity and a low pH optimum, like AMCase, is very well capable to perform its catalytic actions.

[0091] Body locations of a mucinase of the invention have led us to the conclusion that the mucinase can perform additional functions next to mucus degradation and defense against chitin-containing pathogens. For instance, the remarkably high concentration of AMCase in the gastrointestinal tract involves a role in food processing during the evolution of mammals.

[0092] A chitin-hydrolyzing capability of a mammalian mucinase, for instance, AMCase, can also be exploited as a tool to degrade injected or implanted chitin-based structures for medical purposes. For instance, drugs can be incorporated in chitin-based capsules. The concomitant presence of well-defined amounts of a mammalian mucinase, which further comprises chitin-hydrolyzing activity, in the capsule ensures a controlled release of drugs. A slow but gradual release of drugs is particularly envisioned when the drugs are trapped in a chitin matrix. The use of a the mucinase in such a system results in ultimate destruction of the chitin-based capsule and does not elicit an immunological response. The drugs used in such a system can vary from small compounds to protein and DNA fragments for the purpose of enzyme and gene therapy. Chitin (or analogues thereof) is already employed as a carrier for drugs.

[0098] Mouse AMCase mRNA is predominantly found in stomach, submaxillary gland and also at a lower level in the lung (see, FIG. 65). Surprisingly, no mouse AMCase mRNA can be detected in the small intestine, suggesting that the protein in the intestine is probably derived from the upper parts of the gastrointestinal tract, such as the stomach.

[0099] Our findings demonstrate that AMCase in mammals is distinct from chitotriosidase: the newly discovered, discrete enzyme is referred to as acidic mammalian chitinase or AMCase. AMCase is also present in man. Screening the human EST database at the NCBI with the acidic mouse chitinase cDNA revealed the presence of a human EST clone (oq35c04.s1, Genbank acc. no. AA976830) that is highly homologous to the acidic mouse chitinase. The tissue distribution of the human mRNA was examined using a human Masterblot (Clontech). The expression pattern of this mRNA is similar to the expression pattern of the acidic mouse chitinase (FIG. 65), being highly expressed in the stomach and at a lower level in the lung. Using degenerate oligonucleotides directed against members of the chitinase family, we were able to amplify other regions of the human acidic chitinase, generating enough information to clone the full-length human acidic chitinase cDNA. Screening the Genbank database using the full-length human cDNA revealed that it was almost identical to TSA1902-L and TSA1902-S from a lung cDNA library described by Saito et al. (Saito et al., 1999). These two sequences are most probably splice variants of the acidic human chitinase mRNA. Only expression of full-length human AMCase cDNA in COS cells led to the production of a protein with chitinolytic activity. Sequence comparison of the human acidic chitinase and the mouse acidic chitinase revealed an 82% identity and a similarity of 86%. (compare FIGS. 2 and 8 Table II (SEQ ID NO:2) and Table III (SEQ ID NO:3)). The catalytic domain of human AMCase is also herewith provided.

[0100] Additional proof for the existence of two discrete genes encoding a phagocyte chitinase (chitotriosidase) and mucosal mucinase/chitinase (AMCase) is rendered by our finding that in man the former enzyme is encoded by a gene in locus 1q31 and the latter by a gene in locus 1p13.

[0101] A mucinase of the invention can be obtained by expression of a nucleic acid encoding the mucinase in a host or host cell and subsequent isolation of the mucinase from the host or host cell or medium in which the host cell is cultured. The host or host cell may be naturally expressing the mucinase. Alternatively, the host or host cell may be genetically engineered. A nucleic acid encoding the mucinase may be provided to the host or host cell.

[0102] A mucinase of the invention can also be obtained by substantially isolating or purifying the mucinase from an environment. Methods for isolating a proteinaceous molecule from an environment are known in the art (for instance, chromatography) and need no further explanation here. A sample comprising the mucinase can, for instance, be enriched for the mucinase by applying the sample onto an affinity column and collecting an elution fraction enriched for the mucinase. Enrichment can also be performed by centrifugation and subsequent separation of a fraction enriched for the mucinase. A person skilled in the art is well capable of performing alternative isolation and/or purification procedures, which are known in the art.

[0103] A nucleic acid encoding a mucinase of the invention, and/or a modified form thereof having a substantially similar mucin-hydrolyzing activity, is suitable for gene therapy. For instance, mammalian cells, preferably cells of a mucosal lining, can be provided with the nucleic acid. After that, the mucinase and/or modified form can be expressed, resulting in (increased) cleavage of mucus. In one embodiment, a cell which is transformed with the nucleic acid does not naturally produce a substantial amount of a mucinase of the invention. However, in another embodiment, the cell already produces the mucinase. In that case, production of mucinase can be enhanced by gene therapy with a nucleic acid of the invention. Gene therapy with a nucleic acid of the invention is, for instance, very suitable for inducing or enhancing mucinase expression in the lungs and/or gastrointestinal tract of a patient suffering from a disease in which mucus is involved.

[0104] Likewise, a nucleic acid encoding a mucinase of the invention which further comprises a chitin-hydrolyzing activity, and/or a modified form thereof having a substantially similar chitin-hydrolyzing activity, is suitable for gene therapy. For instance, mammalian cells, preferably cells of a mucosal lining, can be provided with the nucleic acid, resulting in (enhanced) expression of a mucinase of the invention which further comprises a chitin-hydrolyzing activity. The mucinase is capable of counteracting chitin-containing pathogens present in the mucosal lining.

[0105] The invention will now be illustrated by the following examples which merely serve to exemplify the invention and are not intended to limit the scope of the invention.

EXAMPLES

Example 1. Cloning and composition of cDNAs encoding mouse and human AMCase

Mouse AMCase

[0106] To obtain more insight into the potential occurrence of multiple mammalian chitinases, tissues of mouse and rat were examined for chitinolytic activity using the chitin-like 4-methylumbelliferyl- β -chito-oligosaccharide substrates. In extracts of stomach and intestine, a high level of activity was detected, while extracts of lung, tongue, kidney and plasma showed significant but lower activities. Isoelectric focusing (by flatbed isoelectric focusing in granulated Ultrodex gels (Pharmacia) as described by Renkema et al., 1995) of a mouse lung extract revealed a major peak of chitinolytic activity with pI 4.5 while minor peaks were found with pls 5.5-6.5 (FIG. 1). Extracts of other mouse and rat tissues showed similar profiles of chitinolytic activity upon isoelectric focusing. The observed rodent chitinase with acidic isoelectric point (pI 4.5 form) differs strikingly from human chitotriosidase, which has an apparent neutral/basic pI.

[0107] The mouse acidic chitinase activity was found to bind to chitin particles with high affinity. Chitin affinity chromatography was used to purify the enzyme. Detergent-free extracts of mouse tissues were prepared by homogenization in 10 volumes of potassium phosphate buffer pH 6.5, using an Ultra-turrax and centrifugation for 20 minutes at 15,000 x g. The mouse intestine extract was adjusted to pH 5.0 by the addition of citric acid (0.2 M); NaCl was added to a final concentration of 2 M. A chitin column was prepared by mixing 10 grams swollen Sepharose G25 fine (Pharmacia, Uppsala, Sweden) with 300 mg of colloidal chitin (prepared as described by Shimahara et al. (Shimahara et al., 1988), followed by equilibration with phosphate-buffered saline (PBS) containing 2M NaCl. The extracts were applied onto the column with a flow speed of 0.4 ml/minute. After extensive washing, bound chitinase was eluted from the column with 8M urea, which was subsequently removed by dialysis. Protein concentrations were determined according to the method of Lowry et al. (Lowry et al 1951) using BSA as a standard. Fractions containing chitinase activity were subjected to SDS-PAGE and Western blotting as described (Renkema et al., 1995).

[0108] The procedure resulted in a 30,000-fold purification of an apparently homogeneous 50 kDa protein. The specific activity of the purified enzyme was 3.9 nmol 4-

methylumbelliferyl-chitotrioside hydrolyzed per mg per hour at pH 5.2, which is almost identical to that of human chitotriosidase.

[0109] The N-terminal amino acid sequence of purified acidic chitinase was determined as described by (Renkema et al., 1995) using a Procise 494 sequencer (Applied Biosystems Perkin Elmer, Foster City, CA, USA) (FIG. 2Table IV) and was found to be almost identical to that of other known members of the chitinase family. This amino acid sequence allowed the cloning of the corresponding full-length mouse acidic chitinase cDNA, as described in experimental procedures. The full-length cDNA predicts the synthesis of a 50 kDa (pI 4.85) protein with a characteristic signal peptide (FIG. 2Table IV). Transient expression of this cDNA in COS-1 cells was performed exactly as described previously (Boot et al., 1995) and led to the secretion of a 50 kDa active chitinase with a pI of 4.8.

[0110] Reverse transcription-polymerase chain reaction (RT-PCR) fragments were generated from mouse lung total RNA using degenerate oligonucleotides, as described (Boot et al., 1995). Obtained fragments were cloned in pGEM-T (Promega, Madison, WI, USA), sequenced and compared with the amino acid sequence established by N-terminal protein sequencing. A comparison with the GenBank mouse EST (expressed sequence tag) database using the Basic local alignment search tool (BLAST) at NCBI (National Center for Biotechnology Information) showed that several EST clones matched the mouse chitinase cDNA sequence, for example, ms33h09.y1 (GenBank Accession Number AI892792). This clone was obtained and sequenced. Anti-sense primers were generated complementary to the most 3' region of the EST clone (A-tail primer : 5'- TTTTGCTACCAATTATTGC-3') (SEQ ID NO:5) and two internal anti-sense primers (MAS1 : 5'-CAGCTACAGCAGCAGTAACCATC-3') (SEQ ID NO:6) and (MAS2 : 5'-TTCAGGGATCTCATAGCCAGC-3') (SEQ ID NO:7). The MAS1 and MAS2 primers were used to clone the most 5' end of the mouse acidic chitinase cDNA using 5' rapid amplification of cDNA ends (5' RACE) and the Marathon-Ready mouse Lung cDNA kit (Clontech) according to the instructions of the manufacturer. To obtain the complete coding sequence, a 5' sense primer was generated (MS1 : 5'-CGATGGCCAAGCTACTTCTCGT-3') (SEQ ID NO:8). The total cDNA sequence was subsequently generated using MS1 and the A-tail primer. The fragments of two independent PCR's were cloned into pGEM-T (Promega) and the nucleotide sequence of two independent clones from each PCR were sequenced from both strands by the procedure of Sanger using fluorescent nucleotides on an Applied Biosystems (ABI) 377A automated DNA sequencer following ABI protocols. The

mouse AMCase protein shows considerable sequence homology to human chitotriosidase. Comparison of the amino acid sequence of both mature proteins revealed an identity of 52% and a similarity of 60%. *See, Tables V and VI, below.*

[0111] **Table V.** Amino acid sequence of mature (without signal peptide) mouse AMCase (SEQ ID NO:9).

```
YNLICYFTNWAQYRPGLGSFKPDDINPCLCI  
THLIYAFAGMQNNEIITIEWNDVTLYKAFNDLK  
NRNSKLKTLLAIGGWNFGTAPFTMVSTSQNQ  
RQTFTISVIKFLRQYGF  
DGLDLWEYPGSRGSPPQDKHLFTVLVKE  
MREAFEQEAI  
ESNRPRLMVTAAVAGGISNIQAGYEIPELS  
KYLDFIHVMTYDLHGSWEGYTGENSPLYK  
YPTETGSNAYLNVDYVMNYWKNNGAPA  
EKLIVGFPEYGH  
TIFILRNPSDNGIGAPTSGDGPA  
GA  
YTRQAGFWAYYEICTFLRSGATEVWDASQEV  
PYAYKANEWLGYDNIKSFSVKAQWLKQNNF  
GGAMIAIDLDDFTGSFCDOQKFPLTSTLNK  
ALGISTEGCTAPDV  
SEPVTTPPGS  
GGGGSSGGFCADKADGLYVADDRNAFWQC  
INGITYQQHCQAGLVFDTSNC  
CCNWP
```

[0112] **Table VI.** Amino acid sequence of human chitotriosidase (SEQ ID NO:10).

```
AKLVCYFTNWAQYRQGEARFLPKDLDPSLCTH  
LIYAFAGMTNHQLSTTEWNDETLYQEFNGLKKMNP  
KLKTLLAIGGWNFGTQKFTDMVATANNRQTFVNSA  
IRFLRKYSFDGLDLDWEYPGSQGSPAVDKERFT  
TLVQDLANA  
FQQAQS  
GKERLLSAAVPAGQTYVDAGYEVDKIAQNLDFVN  
LMAYDFHGSWEKV  
TGHNSPLYKRQEEGAAASLNVDAAVQQWLQKGTP  
ASKLILGMPTYGRSFTLASSSDTRVGAPATGSG  
TPGPFTKEGGMLAYYEVCSWKGATKQR  
IQDQKVPYIFRDNQWVG  
FDDVESFKTVSYLKQKGLGGAMVWALDLDD  
FAFGFSCNQGRYPLI  
QTLRQELSLPYLPSGTPELEVKPGQPSE  
EHGPSPGQDTFCQGKADGLYPNPRERSSFYS  
CAAGRLFQQSCPTGLVFSNSCKCCTWN
```

[0113] Like the human chitotriosidase, the mouse enzyme is predicted to contain an N-terminal catalytic domain of about 39 kDa, a hinge region and a C-terminal chitin binding domain (FIG. 2*see, Table IV, above*). The mouse AMCase, like chitotriosidase, is predicted to lack N-linked oligosaccharides, explaining the observed absence of binding to Concanavalin A (data not shown). The apparent molecular masses of identically produced

recombinant human chitotriosidase and recombinant mouse AMCase are comparable when run on an SDS-PAGE gel under reducing conditions. However, under non-reducing conditions, the mouse AMCase migrates significantly slower than the human chitotriosidase (FIG. 43A). Upon gel electrophoresis (under non-reducing conditions) in polyacrylamide gels containing glycolchitin, followed by regeneration of active enzyme and detection of the local digestion of glycolchitin using Calcofluor staining, the mouse AMCase migrates slightly faster than human chitotriosidase (FIG. 43B).

Human AMCase

[0114] It was investigated whether such an acidic chitinase is also present in man. Screening the human EST database at the NCBI with the mouse acidic chitinase cDNA revealed the presence of a highly homologous human EST clone (oq35c04.s1, GenBank Accession Number, AA976830). As mouse AMCase activity was shown in the stomach, the full-length human AMCase cDNA was cloned using human stomach total RNA (Clontech) for the RT-PCR with the same degenerate primers as for the mouse AMCase. A human Marathon-Ready Lung cDNA was used to clone the most 5' end of the cDNA by 5' RACE using the following primers: HAS2 (5'-TCTGACAGCACAGAACATCCACTGCC-3') (SEQ ID NO:11) and HAS3-A-tail (5'-TTGACTGCTGATTATTGCAG-3') (SEQ ID NO:12). The total cDNA sequence was subsequently generated using HS1 (5'-GCTTTCCAGTCTGGTGGTGAAT-3') (SEQ ID NO:13) and HAS3-Atail. The fragments of two independent PCR's were cloned in pGEM-T (Promega) and sequenced as described above (Table II).

[0115] Screening the GenBank database using the full-length human cDNA revealed that it was almost identical to TSA1902-L (GenBank Accession Number AB025008) and TSA1902-S (GenBank Accession Number AB025009) from a lung cDNA library described by Saito et al. (Saito et al., 1999). These two sequences are most probably splice variants of the human acidic chitinase mRNA. Only expression of full-length human AMCase cDNA in COS-1 cells led to the production of a protein with chitinolytic activity (data not shown). Sequence comparison of the human acidic chitinase (*see, Table VII, below*) and the mouse acidic chitinase (*see, Table V, above*) revealed an 82% identity and a similarity of 86% (FIG. 8B).

[0116] Table VII. Amino acid sequence of mature (without signal peptide) human AMCase (SEQ ID NO:14).

YQLTCYFTNWAQYRPGLGRMPDNIDPCLCTHILYAFAGRQNNEITTIEWNDVTLYQAFNGLKNKNSQLKTLLAIGGWNFGTAPFTAMVSTPENRQTFITSVIKFLRQEFDGLDFDWEYPGSRGSPPKDKHLFTVLVQEMREAFEQEAKQINKPRLMVTAAVAAGISNIQSGYEIPQLSQYLDYIHVMTYDLHGSWEGYTGENSPLYKYPTDTGSNAYLNVVDYVMNYWKDNGAPAEKLVGFPTYGHNFILSNPSNTGIGAPTSGAGPAGPYAKESGIWAYYEICTFLKNGATQGWDAPQEVPYAYQGNVWVGYDNIKSFDIKAQWLKHNKFGGAMVWAIDLDDFTGTFCNQGKFPLISTLKKALGLQSASCTAPAQPIEPITAAPSGSGNGSGSSSSGGSSGGFCAVRANGLYPVANNRNAFWHCVNGVTVYQQNCQAGLVFDTSCDCCNWA

[0117] The demonstration by Saito et al. that the gene encoding TSA1902 is located on chromosome 1p13 (Saito et al., 1999) indicates that mammals contain indeed at least two discrete genes that encode functional chitinases, being chitotriosidase (locus 1q32) and AMCase (locus 1p13).

Example 2. Tissue expression of human and mouse AMCase RNA

[0118] Another major difference between human chitotriosidase and the mouse AMCase is revealed by comparison of RNA expression patterns. Total RNA was isolated using RNAzol B (Biosolve, Barneveld, The Netherlands) according to the instructions of the manufacturer. Northern blots, using 15 µg of total RNA, were performed as described (Boot et al., 1995). Mouse RNA Master Blots (Clontech, Palo Alto, CA, USA) were used to examine the tissue distribution of transcripts according to the instructions of the manufacturer. The following probes were used: the full-length mouse acidic chitinase cDNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as control. Radiolabeling and hybridization was conducted as described previously (Boot et al., 1995). Quantification of radioactivity was performed using a phosphor imager (Storm phosphor imager, Molecular Dynamics, Sunnyvale, CA, USA).

[0119] Whereas human chitotriosidase mRNA is mainly found in lymph node, bone marrow and lung, the mouse AMCase mRNA is predominantly found in, of the screened tissues, stomach, submaxillary gland and, at a lower level, in the lung (FIG. 65). Surprisingly, no mouse acidic chitinase mRNA could be detected in the small intestine. This can be explained by an absence of mRNA, or by mRNA levels in the sample that were too low for detection with the technique used. These results suggest that the protein in the

intestine is probably derived from the upper parts of the gastrointestinal tract, such as the stomach.

[0120] In rat tissues, a comparable acidic chitinase was observed. Our findings indicate that the acidic chitinase in rodents is distinct from human chitotriosidase. The discrete enzyme is therefore referred to as acidic mammalian chitinase or AMCase.

[0121] Next, the tissue distribution of this human mRNA was examined. Total RNA was isolated as described above and human RNA Master Blots (Clontech, Palo Alto, CA, USA) were probed with the human EST clone oq35c04.s1 (GenBank Accession Number AA976830) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as control to examine the tissue distribution as described above.

[0122] The expression pattern of the human AMCase mRNA is similar to the expression pattern of the mouse acidic chitinase (FIGS. 65, 76), being highly expressed in the stomach and, at a lower level, in the lung, as far as the RNA master blots are representative for these tissues. Expression in additional tissues that were not tested cannot be excluded.

Example 3. Degradation of chitin by AMCase

[0123] Several different assays revealed that the mouse acidic chitinase is able to degrade chitin and, therefore, has to be considered to be a true chitinase. Crab shell chitin (Poly-[1-4]- β -D-N-acetylglucosamine, Sigma) was used as a natural substrate to determine chitinase activity as described (Renkema et al., 1997). The chitin fragments were analyzed by fluorophore-assisted carbohydrate electrophoresis (FACE) as described by Jackson (Jackson 1990). FACE analysis revealed that recombinant mouse chitinase, like chitotriosidase, releases mainly chitobioside fragments from chitin (FIG. 32). Chitinase enzyme activity was determined in another assay with the fluorogenic substrates 4MU-chitobiose (4-methylumbelliferyl β -D-N,N'-diacetylchitobiose, Sigma, St Louis, USA) and 4MU-chitotriose (4-methylumbelliferyl β -D-N,N',N''-triacetylchitotriose, Sigma). Assay mixtures contained 0.027 mM substrate and 1 mg/ml of bovine serum albumin (BSA) in McIlvaine buffer (100 mM citric acid, 200mM sodium phosphate) at the indicated pH. The standard enzyme activity assay for human chitotriosidase with 4MU-chitotriose substrate was performed at pH 5.2, as previously described (Hollak et al., 1994). The standard AMCase enzyme activity assays with 4MU-chitobiose substrate were performed at pH 4.5. Like chitotriosidase and some other non-mammalian chitinases, the mouse acidic chitinase activity in this assay is strongly inhibited (IC_{50} of 0.4 μ M) by the competitive chitinase inhibitor

allosamidin (Milewski et al., 1992, Dickinson et al., 1989, McNab and Glover 1991). Measurements of chitin formation during regeneration of fungal spheroplasts were performed as described by Hector and Braun (Hector and Braun 1986). Briefly, spheroplasts were prepared from the *Candida albicans* strain CAi-4 (*ura3*), grown overnight in YPD medium (1% yeast extract, 2% peptone, 2% glucose) at 28°C. Cells were concentrated by centrifugation and incubated with 2.5 mg/ml zymolyase (100T, ICN Immuno Biologicals, Costa Mesa, CA, USA) in buffer containing 50 mM sodium phosphate pH 7.5, 1.2 M sorbitol and 27 mM β-mercaptoethanol for 60 minutes at 37°C. After extensive washing, spheroplasts were allowed to regenerate in 96-well microtiter plates in regeneration buffer (0.25% (w/v) MES buffer pH 6.7, containing 0.17% (w/v) Yeast Nitrogen Base (without amino acids and ammonium sulfate, Sigma), 0.15% (w/v) ammonium sulfate, 2% (w/v) glucose, 1.2 M sorbitol, 20 µg/ml uridine) at 37 °C. Chitinase enzyme preparations were added in 3 µg/ml. After a 2 hour incubation, 50 µl of 300 µg/ml Calcofluor white (Sigma) in 10 mM sodium phosphate buffer pH 7.5 containing 1.2 M sorbitol was added. After 5 minutes, the plates were washed with buffer only and fluorescence was determined using an LS 50 Perkin Elmer fluorometer (excitation 405 nm, emission 450 nm).

[0124] In addition, the mouse acidic chitinase and chitotriosidase were both able to digest chitin in the cell wall of regenerating spheroplasts of *Candida albicans*. The chitin content of the cell wall was determined with the Calcofluor white stain. When regenerating cells were incubated for 2 hours with 3 µg per ml recombinant chitotriosidase or 3 µg per ml recombinant mouse acidic chitinase, the chitin content was reduced by 27% and 33%, respectively. Concomitant presence of allosamidin during the incubation completely abolished the effect of both recombinant chitinases.

[0125] Finally, incubation of hyphae of *Candida albicans* with recombinant 50 kDa or 39 kDa AMCase as described by Boot et al. (1995) results in selective lysis of the growing tip, showing a fungistatic effect of AMCase similar to the effect of chitotriosidase described by Boot et al. (1995).

Example 4. pH optimum of chitinase activity of AMCase

[0126] A striking difference between chitotriosidase and AMCase is their behavior at acidic pH.

[0127] The pH dependence of chitinase activity of AMCase was determined by incubating purified enzyme at a different pH (McIlvaine buffer range 1.7-8.5) with 4-

methylumbelliferyl substrates. Release of the fluorescent 4-methylumbelliferone was monitored fluorometrically (excitation 445 nm and emission 360 nm). The results are presented in FIG. 54A. The mouse acidic chitinase shows a pronounced pH optimum at pH 2.3 and a less pronounced optimum at a more neutral pH (pH 4.7). Chitotriosidase, however, shows only a broad pH optimum (see FIG. 54A) and is completely inactivated by pre-incubation at low pH (see FIG. 54B). In the presence of 0.5% (w/v) trichloroacetic acid (TCA), 58% of chitotriosidase is precipitated, while under similar circumstances, the mouse acidic chitinase remains in solution. At 2.5% (w/v) TCA all chitotriosidase precipitates while 26% of mouse acidic chitinase remains unprecipitated (FIG. 54C).

Example 5. Degradation of mammalian mucin by AMCase

[0128] The effect of AMCase on glycoproteins was studied by evaluating the effect of AMCase on mucin, a glycoprotein expressed on mucosal surfaces in the airways and gastrointestinal tract. Bovine submaxillary gland mucin (Sigma) 125 µg was dissolved in 40 µl 0.05M NaAc pH 5.0 in the presence or absence of 500 ng mouse AMCase. After overnight incubation at 37°C, the mucin was electrophorized on an SDS-PAGE gel (7.5% homogeneous, followed by silver staining). As is shown in FIG. 97, the mucin was degraded by treatment with the AMCase. This shows that AMCase is an endogenous regulator of mucus viscosity that can be employed in diseases in which overproduction or high viscosity of mucus is involved. Similar experiments may be performed using human AMCase to demonstrate its mucinolytic activity.

[0129] Experiments can be performed as described by Puchelle et al. (1996) to demonstrate that AMCase is capable of decreasing the viscosity of cystic fibrosis sputum and sputum derived from chronic obstructive pulmonary disease patients.

Example 6. pH optimum of mucin hydrolizing activity of AMCase

[0130] The pH dependence of the mucin hydrolyzing activity of AMCase is determined by incubating purified enzyme at a different pH (for example, in McIlvaine buffer range 1.7-8.5) with mammalian mucin (see Example 5).

Example 7. Generation of antibodies to AMCase

[0131] Polyclonal antiserum against AMCase is raised by immunization of rabbits with recombinant human AMCase (e.g., 4 injections/animal; 20-200 µg/injection). After the final booster, the animals are bled to determine the titer of the polyclonal antiserum.

[0132] To obtain monoclonal antibodies, 6-8 wk old Balbic mice are immunized with recombinant human AMCase (for example, 4 times with 2 wk intervals with 10-100 µg/injection dissolved in Freunds complete adjuvans for the first injection, and Freunds incomplete adjuvans for subsequent immunizations). Splenocytes are isolated and fused with a fusion cell line such as Sp2/0 myeloma cells, followed by limiting dilution. Growing clones are screened using, for example, an enzyme-linked immunosorbent assay (ELISA). Therefore, 96-well plates are coated with recombinant human AMCase or with a control protein. The culture supernatant is added, followed by washing and the addition of a labeled anti-mouse antibody for detection. After limited dilution cloning of AMCase-specific antibody-producing hybridomas, stable hybridomas are obtained. From each clone cell, supernatant is collected, and by affinity chromatography using protein A sepharose columns (Pharmacia, Uppsala, Sweden) monoclonal antibodies are purified.

Example 8. A quantitative assay to detect AMCase

[0133] Using the AMCase-specific antibodies of Example 7 and recombinant human AMCase, a quantitative assay for the detection of AMCase is set up. The assay is used to quantify AMCase. In addition, the assay is able to differentiate between chitotriosidase and AMCase.

Example 9. Anti-fungal activity of AMCase in animal models

[0134] Allergic bronchopulmonary aspergillosis is a complication that is often seen in CF and asthma patients. As AMCase has an effect on mucus as well as *Aspergillus*, proof of concept is obtained in a lung infection model with *Aspergillus*, in which mouse AMCase is administered intratracheally.

Example 10. Mucolytic activity of AMCase in a mouse model for cystic fibrosis

[0135] CFTR-knockout mice are currently the only relevant disease model for human CF. The mice have the same genetic defect as CF patients. CFTR-knockout mice display many characteristics of intestinal disease in CF but fail to develop respiratory

infections or other signs of overt lung disease. To prevent massive mortality in the *CFTR*-knockout mice by intestinal obstruction, animals need to be fed a liquid diet during the weaning period. Interestingly, *CFTR*-knockout mice that also are deficient for MUC1 have a much better survival on a solid diet, indicating an important role for mucus formation in the intestine of the *CFTR*-knockout mice. Clearly, the model has its limitations for studying the effect of AMCase; however, it is a good model on which to study the effect of AMCase on gastrointestinal disease seen in CF.

Example 11. Treatment of mucin-associated human diseases

[0136] Treatment of diseases that are typically associated with the undue, inappropriate or excessive production, or the insufficient removal of mucus are treated or ameliorated with mucinase. These diseases include but are not limited to COPD and CF. In the case of CF, the indication for use of the mucinase is for both the digestive tract as well as the pulmonary signs and symptoms of excessive amounts of mucus present. Administration routes of the mucinase are such that the highest effective dose can be administered to the relevant anatomical area indicated for mucinolytic treatment.

Example 12. Treatment of topical infections by chitin-containing pathogens

[0137] A variety and myriad number of dermatological and pulmonary tract fungal infections are deemed to be indications for treatment with a mucinase of the invention.

[0138] These include but are not limited to the *Dermatophytes (Tinea's)*, *Candidiasis*, *Aspergillosis*, *Mucomycosis* and *Pneumocystis carinii*. Patients presenting with dermatological manifestations of fungal disease can be treated by the regular application of a topical formulation of a mucinase of the invention appropriate for the relevant anatomical region infected.

REFERENCES

Almeida, I.C., Ferguson, M.A.J., Schenkman, S. and Travassos, L.R.: Lytic anti-a-galactosyl antibodies from patients with chronic chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of *Trypanosoma cruzi*. Biochem. J. 304, 793-802 (1994).

Araujo, A.C., Souto-Padron, T. and de Souza, W.J.: Cytochemical localization of carbohydrate residues in microfilariae of *wuchereria bancrofti* and *brugia malayi*. (1993) Histochem. Cytochem. 41(4) 571-578.

Argueso, P., Herreras, J.M., Calonge, M., Citores, L., Pastor, J.C. and Girbes, T.: Analysis of human ocular mucus: effects of neuraminidase and chitinase enzymes. *Cornea* 17: 200-207 1998.

Barnes, D.A., Bonnin, A., Huang, J.X., Gousset, L., Wu, J., Gut, W.J., Doyle, P., Dubremetz, J.F., Ward, H. and Petersen, C.: A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum mediates invasion. Mol. Biochem. Parasitol. 96, 93-110 (1998).

Boot, R.G., Renkema, G.H., Strijland, A., van Zonneveld, A.J. and Aerts, J.M.F.G.: Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. (1995) J. Biol. Chem. 270, 26252-26256.

Boot, R.G., Renkema, G.H., Strijland, A., van Zonneveld, A.J. and Aerts, J.M.F.G.: Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. (1995) *J. Biol. Chem.* 270, 26252-26256.

Boot, R.G., Blommaart, E.F.C., Swart, E., Ghauharali-van der Vlught, K., Bijl, N., Moe, C., Place, A. and Aerts, J.M.F.G.: Identification of a novel acidic mammalian chitinase distinct from chitotriosidase (2001) *J. Biol. Chem.* 276, 6770-6778.

Buhrmester, C.C.: (1933) A study of the hydrogen-ion concentration, nitrogen content and viscosity of nasal secretions. Ann.Otol.Rhinol.Laryngol. 42:778-788.

Carraway, K.L., Price-Schiavi, S.A., Komatsu, M., Idris, N., Perez, A., Li, P., Jepson, S., Zhu, X., Carvajal, M.E. and Carraway, C.A.: Multiple facets of sialomucin complex/MUC4, a membrane mucin and ERBB2 ligand, in tumors and tissues (Y2K update). (2000) *Front Biosci* 5, D95-D107.

Celli, B.R.: Pulmonary rehabilitation in patient with COPD. *Am.J.Respir.Crit Care Med.* 1995 152(3):861-4.

Chernick, W.S. and Barbero, G.J.: Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis. *Pediatrics.* 1959; 24: 739-745.

Choi, I., Aalkjaer, C., Boulpaep, E.L. and Boron, W.F.: (2000) An electroneutral sodium/bicarbonate cotransporter NBCn1 and associated sodium channel. *Nature* 405:571-575.

Cockrill, B.A. and Hales, C.A.: Allergic Bronchoalveolar Aspergillosis. *Ann. Rev. Med.* (1999). 50:303-316.

Debono, M. and Gordee, R.S.: Antibiotics that inhibit fungal cell wall development. *Ann. Rev. Microbiology* (1994) 48, 471-497.

Dickinson, K., Keer, V., Hitchcock, C.A. and Adams, D.J.: Chitinase activity from candida albicans and its inhibition by allosamidin. (1989) *J. Gen. Microbiol.* 135, 1417-142.

Escott, G.M. and Adams, D.J.: Chitinase activity in human serum and leukocytes. (1995) *Infect. Immun.* 63(12), 4770-4773.

Flach, J., Pilet, P.E. and Jolles, P.: Whats new in chitinase research? (1992) *Experientia* 48, 701-716.

Fuchs, H.J., Borowitz, D.S., Christiansen, D.H., Morris, E.M., Nash, M.L., Ramsey, B.W., Rosenstein, B.J., Smith, A.L. and Wohl, M.E.: Effect of aerosolized recombinant

human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. New England Journal of Medicine (1994 Sep), 331(10):637-642.

Fuhrman, J.A. and Piessens, W.F.: Chitin synthesis and sheath morphogenesis in *bruglia malayi* microfilariae (1985) Mol. Biochem. Parasitol. 17, 93-104.

Gendler, S.J. and Spicer, A.P.: Epithelial mucin genes. Ann. Rev. Physiol. 57, 607-634 (1995).

Gum, J.R.J.: Human mucin glycoproteins: varied structures predict diverse properties and specific functions. (1995) Biochem. Soc. Trans. 23, 795-799.

Gum, J.R., Hicks, J.W., Swallow, D.M., Lagace, R.L., Byrd, J.C., Lampert, D.T., Siddiki, B. and Kim, Y.S.: Molecular cloning of cDNAs derived from a novel human intestinal mucin gene. (1990) Biochem. Biophys. Res. Commun. 171, 407-415.

Hector, R. F. and Braun, P. C.: A 96-well epifluorescence assay for rapid assessment of compounds inhibitory to candida spp. (1986) J. Clin. Microbiol. 24, 620-624.

Hollak, C.E.M., van Weely, S., van Oers, M.H.J. and Aerts, J.M.F.G.: Markes elevation of plasma Chitotriosidase activity. A novel hallmark of Gaucher disease. (1994) J. Clin. Invest. 93, 1288-1292.

Hollak, C.E.M., van Weely, S., van Oers, M.H.J. and Aerts, J.M.F.G.: Markes elevation of plasma Chitotriosidase activity. A novel hallmark of Gaucher disease. (1994) J. Clin. Invest. 93, 1288-1292.

Hudson, M.J.H., Stamp, G.W.H., Hollingworth, M.A., Pignatelli, M. and Lalani, E.N.: MUC1 expressed in PanC1 cells decreases adhesion to type I collagen but increases contraction in collagen lattices. (1996) Am. J. Pathol. 148, 951-960.

Hunt, J.F., Fang, K., Malik, R., Snyder, A., Malhotra, N., Platts-Mills, T.A.E. and Gaston, B.: (2000) Endogenous airway acidification. Implications for asthma pathophysiology. Am.J.Resp.Crit.Care Med. 161:694-699.

Ilg, T., Handman, E., Ken, N., Stierhof, Y.D. and Bacic, A.: Mucin-like proteophosphoglycans from the protozoan parasite Leishmania. (1999) Trends Glycosci Glycotech 11, 53-71.

Jackson, P.: The use of polyacrylamide-gel electrophoresis for the high-resolution separation of reducing saccharides labeled with the fluorophore 8- amino naphthalene-1,3,6-trisulphonic acid. Detection of picomolar quantities by an imaging system based on a cooled charge-coupled device. (1990) Biochem. J. 270, 705-713.

Jeffery, P.K., Gaillard, D. and Moret, S.: Human airway secretory cells during development and in mature airway epithelium. (1992) Eur. Respir. J. 5, 93-104.

Jentoft, N.: Why are proteins O-glycosylated? (1990) Trends Biochem. Sci. 15, 291-294.

Kim, J.S., Hackley, G.H., Okamoto, K. and Rubin, B.K.: (2001) Sputum processing for evaluation of inflammatory mediators. Pediatr. Pulmonol. 32:152-8.

Kastrup, E.K., et al.: (eds) Respiratory inhalant products. In Drug Facts and Comparisons, (1998). St. Louis, Facts and Comparisons. pp 1141-1163.

Lan, M.S., Batra, S.K., Qi, W.N., Metzgar, R.S. and Hollingsworth, M.A.: Cloning and sequencing of a human pancreatic tumor mucin cDNA. (1990) J. Biol. Chem. 265, 15294-15299.

Komatsu, M., Tatum, L., Altman, N.H., Carothers, C.A., Carraway, K. and Carraway, L.: Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. (2000) Int. J. Cancer 87, 480-486.

Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J.: (1951) *J. Biol. Chem.* 193, 265-275.

McNab, R. and Glover, L.A.: Inhibition of neurospora crassa cytosolic chitinase by allosamidin (1991) *FEMS Microbiol. Lett.* 82, 79-82.

Milewski, S., O'Donnell, R.W. and Gooday, G.W.: Chemical modification studies of the active center of candida albicans chitinase and its inhibition by allosamidin (1992) *J. Gen. Microbiol.* 138, 2545-2550.

Moniaux, N., Nollet, S., Porchet, N., Degand, P., Laine, A. and Aubert, J.P.: Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. (1999) *Biochem. J.* 338, 325-333.

Neville, A.C., Parry, D.A. and Woodhead-Galloway, J.: The chitin crystallite in arthropod cuticle (1976) *J. Cell Science*, 21, 73-82.

Plant, P.K., Owen, J.L. and Elliott, M.W.: (2000). One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration. *Thorax* 55:550-554.

Potter, J., Matthews, L.W., and Lemm, J., et al.: The composition of pulmonary secretions from patients with and without cystic fibrosis. *Am.J.Dis.Child* (1960). 100:493-495.

Puchelle, E., Zahm, J.M., de Bentzmann, S., Grosskopf, C., Shak, S., Mougel, D. and Polu, J.M.: Effects of rhDNase on purulent airway secretions in chronic bronchitis. *Eur. Respir. J.* (1996) 9,765-769.

Renkema, G.H., Boot, R.G., Muijsers, A.O., Donker-Koopman, W.E. and Aerts, J.M.F.G.: Purification and characterization of human chitotriosidase, a novel member of the chitinase family proteins. (1995) *J. Biol. Chem.* 270, 2198-2202.

Renkema, G.H., Boot, R.G., Strijland, A., Donker-koopman, W.E., van den Berg, M., Muijsers, A.O. and Aerts, J.M.F.G.: Synthesis, sorting, and processing into distinct isoforms of human macrophage chitotriosidase. (1997) Eur. J. Biochem. 244, 279-28511.

Riordan, J.R., Rommens, J.M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N. and Chou, J.L.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA Science. (1989) 245:1066-73.

Saito, A., Ozaki, K., Fujiwara, T., Nakamura, Y. and Tanigami, A.: Isolation and mapping of a human lung-specific gene, TSA1902, encoding a novel chitinase family member. Gene 239 (1999) 325-331.

Schenkman, S., Ferguson, M.A.J., Heise, N., Almeida, M.L.C., Mortara, R.A. and Yoshida, N.: Mucin-like glycoproteins linked to the membrane by glycosylphosphatidylinositol anchor are the major acceptors of sialic acid in a reaction catalyzed by trans-sialidase in metacyclic forms of Trypanosoma cruzi. (1993) Mol. Biochem. Parasitol 59, 293-304.

Shahabuddin, M. and Kaslow, D.C.: Plasmodium: parasite chitinase and its role in malaria transmission (1994) Exp. Parasit. 79, 85-88.

Shak, S., Capon, D.J., Hellmiss, R., Marsters, S.A. and Baker, C.L.: Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. (1990) Proc.Natl.Acad.Sci. USA 87, 9188-9192.

Shak, S.: Aerosolized recombinant human DNase I for the treatment of cystic fibrosis. Chest (1995) 107:65s-70s.

Shankar, V., Pichan, P., Eddy, R.L.J., Tonk, V., Nowak, N., Sait, S.N., Shows, T.B., Schultz, R.E., Gotway, G., Elkins, R.C., Gilmore, M.S. and Sachdev, G.P.: Chromosomal localization of a human mucin gene (MUC8) and cloning of the cDNA corresponding to the carboxy terminus. (1997) Am. J. Respir. Cell Mol. Biol. 16, 232-241.

Shimahara, K. and Takiguchi, Y.: (1988) Preparation of crustacean chitin. Methods Enzymol. 161:417- 423.

Sternberg, L.R., Byrd, J.C., Yunker, C.K., Dudas, S., Hoon, V.K. and Bresalier, R.S.: Liver colonization by human colon cancer cells is reduced by antisense inhibition of MUC2 mucin synthesis. (1999) Gastroenterol. 116, 363-371.

Strong, W.B., Gut, J. and Nelson, R.G.: Cloning and sequence analysis of a highly polymorphic Cryptosporidium parvum gene encoding a 60-kilodalton glycoprotein and characterization of its 15- and 45-kilodalton zoite surface antigen products. Infect. Immun. (2000) 68, 4117-4134.

Strous, G.J. and Dekker, J.: Mucin-type glycoproteins. (1992) Crit. Rev. Biochem. Mol. Biol. 27, 57-92.

Suzuki, M., Morimatsu, M., Yamashita, T., Iwanaga, T. and Syuto, B.: (2001) A novel serum chitinase that is expressed in bovine liver. FEBS letter 506:127-130.

Trudel, J. and Asselin, A.: Detection of chitinase activity after polyacrylamide gel electrophoresis. (1989) Anal. Biochem. 178, 362-366.

Vasconcellos, Carol A., Allen, Philip G., Wohl, Mary Ellen, Drazen, Jeffrey M., Janmey, Paul A. and Stossel, Thomas, P.: Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 263, 969-971 (1994).

Williams, S.J., McGuckin, M.A., Gotley, D.C., Eyre, H.J., Sutherland, G.R. and Antalis, T.M.: Two novel mucin genes down-regulated in colorectal cancer identified by differential display. (1999) Cancer Res. 59, 4083-4089.

Zahm, J.M., de Bentzmann, Girod, Deneuville, E., Perrot-Minnot, C.D., Pennaforte, F., Roussey, M., Shak, S. and Puchelle, E.: Dose-dependent in vitro effect of recombinant human DNA rheological and transport properties of cystic fibrosis respi mucus. Eur. Respir. J. (1995) 8:381-386.

SEQUENCE LISTING

<110> Macrozyme
Aerts, Johannes M.F.G.
Boot, Rolf G.

<120> A mammalian mucinase, its recombinant production, and
its use in therapy or prophylaxis against diseases in
which mucus is involved or infection diseases

<130> 2183-5136US

<140> 10/004,219
<141> 2001-11-02

<160> 14

<170> PatentIn Ver. 2.1

<210> 1
<211> 476
<212> PRT
<213> Artificial Sequence

<223> Description of Artificial Sequence: human AMCase
amino acid sequence deduced from cDNA sequence

<u><400> 1</u>		
Met Thr Lys Leu Ile Leu Leu Thr Gly Leu Val Leu Ile Leu Asn Leu		
1	5	10
Gln Leu Gly Ser Ala Tyr Gln Leu Thr Cys Tyr Phe Thr Asn Trp Ala		
20	25	30
Gln Tyr Arg Pro Gly Leu Gly Arg Phe Met Pro Asp Asn Ile Asp Pro		
35	40	45
Cys Leu Cys Thr His Leu Ile Tyr Ala Phe Ala Gly Arg Gln Asn Asn		
50	55	60
Glu Ile Thr Thr Ile Glu Trp Asn Asp Val Thr Leu Tyr Gln Ala Phe		
65	70	75
Asn Gly Leu Lys Asn Lys Asn Ser Gln Leu Lys Thr Leu Leu Ala Ile		
85	90	95
Gly Gly Trp Asn Phe Gly Thr Ala Pro Phe Thr Ala Met Val Ser Thr		
100	105	110
Pro Glu Asn Arg Gln Thr Phe Ile Thr Ser Val Ile Lys Phe Leu Arg		
115	120	125
Gln Tyr Glu Phe Asp Gly Leu Asp Phe Asp Trp Glu Tyr Pro Gly Ser		
130	135	140
Arg Gly Ser Pro Pro Gln Asp Lys His Leu Phe Thr Val Leu Val Gln		
145	150	155
		160

Glu Met Arg Glu Ala Phe Glu Gln Glu Ala Lys Gln Ile Asn Lys Pro
 165 170 175
 Arg Leu Met Val Thr Ala Ala Val Ala Ala Gly Ile Ser Asn Ile Gln
 180 185 190
 Ser Gly Tyr Glu Ile Pro Gln Leu Ser Gln Tyr Leu Asp Tyr Ile His
 195 200 205
 Val Met Thr Tyr Asp Leu His Gly Ser Trp Glu Gly Tyr Thr Gly Glu
 210 215 220
 Asn Ser Pro Leu Tyr Lys Tyr Pro Thr Asp Thr Gly Ser Asn Ala Tyr
 225 230 235 240
 Leu Asn Val Asp Tyr Val Met Asn Tyr Trp Lys Asp Asn Gly Ala Pro
 245 250 255
 Ala Glu Lys Leu Ile Val Gly Phe Pro Thr Tyr Gly His Asn Phe Ile
 260 265 270
 Leu Ser Asn Pro Ser Asn Thr Gly Ile Gly Ala Pro Thr Ser Gly Ala
 275 280 285
 Gly Pro Ala Gly Pro Tyr Ala Lys Glu Ser Gly Ile Trp Ala Tyr Tyr
 290 295 300
 Glu Ile Cys Thr Phe Leu Lys Asn Gly Ala Thr Gln Gly Trp Asp Ala
 305 310 315 320
 Pro Gln Glu Val Pro Tyr Ala Tyr Gln Gly Asn Val Trp Val Gly Tyr
 325 330 335
 Asp Asn Ile Lys Ser Phe Asp Ile Lys Ala Gln Trp Leu Lys His Asn
 340 345 350
 Lys Phe Gly Gly Ala Met Val Trp Ala Ile Asp Leu Asp Asp Phe Thr
 355 360 365
 Gly Thr Phe Cys Asn Gln Gly Lys Phe Pro Leu Ile Ser Thr Leu Lys
 370 375 380
 Lys Ala Leu Gly Leu Gln Ser Ala Ser Cys Thr Ala Pro Ala Gln Pro
 385 390 395 400
 Ile Glu Pro Ile Thr Ala Ala Pro Ser Gly Ser Gly Asn Gly Ser Gly
 405 410 415
 Ser Ser Ser Ser Gly Ser Ser Gly Gly Ser Gly Phe Cys Ala Val
 420 425 430
 Arg Ala Asn Gly Leu Tyr Pro Val Ala Asn Asn Arg Asn Ala Phe Trp
 435 440 445
 His Cys Val Asn Gly Val Thr Tyr Gln Gln Asn Cys Gln Ala Gly Leu
 450 455 460
 Val Phe Asp Thr Ser Cys Asp Cys Cys Asn Trp Ala

465

470

475

<210> 2
<211> 1625

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Combined DNA/RNA Molecule: human
AMCase cDNA sequence and deduced amino acid
sequence

<220>

<223> Description of Artificial Sequence: human AMCase
cDNA sequence and deduced amino acid sequence

<220>

<221> CDS

<222> (104)...(1531)

<400> 2

gctttccagt ctgggttgta atcctccata gtctgaagcc tttgtataaa ccacagaatc 60
agaacatata aaaagctctg cgggacttgt gctgactgca acc atg aca aag ctt 115
Met Thr Lys Leu
1

att ctc ctc aca ggt ctt gtc ctt ata ctg aat ttg cag ctc ggc tct 163
Ile Leu Leu Thr Gly Leu Val Leu Ile Leu Asn Leu Gln Leu Gly Ser
5 10 15 20

gcc tac cag ctg aca tgc tac ttc acc aac tgg gcc cag tac cgg cca 211
Ala Tyr Gln Leu Thr Cys Tyr Phe Thr Asn Trp Ala Gln Tyr Arg Pro
25 30 35

ggc ctg ggg cgc ttc atg cct gac aac atc gac ccc tgc ctc tgt acc 259
Gly Leu Gly Arg Phe Met Pro Asp Asn Ile Asp Pro Cys Leu Cys Thr
40 45 50

cac ctg atc tac gcc ttt qct ggg agg cag aac aac gag atc acc acc 307
His Leu Ile Tyr Ala Phe Ala Gly Arg Gln Asn Asn Glu Ile Thr Thr
55 60 65

atc gaa tgg aac gat gtg act ctc tac caa gct ttc aat ggc ctg aaa 355
Ile Glu Trp Asn Asp Val Thr Leu Tyr Gln Ala Phe Asn Gly Leu Lys
70 75 80

aat aag aac agc cag ctg aaa act ctc ctg gcc att gga ggc tgg aac 403
Asn Lys Asn Ser Gln Leu Lys Thr Leu Leu Ala Ile Gly Gly Trp Asn
85 90 95 100

ttc ggg act gcc cct ttc act gcc atg gtt tct act cct qag aac cgc 451
Phe Gly Thr Ala Pro Phe Thr Ala Met Val Ser Thr Pro Glu Asn Arg
105 110 115

cag act ttc atc acc tca gtc atc aaa ttc ctg cgc cag tat gag ttt 499

gac ggg ctg qac ttt gac tgg gag tac cct ggc tct cgt ggg agc cct	547
<u>Asp Gly Leu Asp Phe Asp Trp Glu Tyr Pro Gly Ser Arg Gly Ser Pro</u>	
135	140
145	
cct cag gac aag cat ctc ttc act gtc ctg gtg cag gaa atg cgt gaa	595
<u>Pro Gln Asp Lys His Leu Phe Thr Val Leu Val Gln Glu Met Arg Glu</u>	
150	155
160	
gct ttt gag cag gag gcc aag cag atc aac aag ccc agg ctg atg gtc	643
<u>Ala Phe Glu Gln Glu Ala Lys Gln Ile Asn Lys Pro Arg Leu Met Val</u>	
165	170
175	180
act gct gca gta gct gct ggc atc tcc aat atc cag tct ggc tat gag	691
<u>Thr Ala Ala Val Ala Ala Gly Ile Ser Asn Ile Gln Ser Gly Tyr Glu</u>	
185	190
195	
atc ccc caa ctg tca cag tac ctg gac tac atc cat gtc atg acc tac	739
<u>Ile Pro Gln Leu Ser Gln Tyr Leu Asp Tyr Ile His Val Met Thr Tyr</u>	
200	205
210	
gac ctc cat ggc tcc tgg gag ggc tac act gga gag aac agc ccc ctc	787
<u>Asp Leu His Gly Ser Trp Glu Gly Tyr Thr Gly Glu Asn Ser Pro Leu</u>	
215	220
225	
tac aaa tac ccg act gac acc ggc agc aac gcc tac ctc aat gtg gat	835
<u>Tyr Lys Tyr Pro Thr Asp Thr Gly Ser Asn Ala Tyr Leu Asn Val Asp</u>	
230	235
240	
tat gtc atg aac tac tgg aag gac aat gga gca cca gct gag aag ctc	883
<u>Tyr Val Met Asn Tyr Trp Lys Asp Asn Gly Ala Pro Ala Glu Lys Leu</u>	
245	250
255	260
atc gtt gga ttc cct acc tat gga cac aac ttc atc ctg agc aac ccc	931
<u>Ile Val Gly Phe Pro Thr Tyr Gly His Asn Phe Ile Leu Ser Asn Pro</u>	
265	270
275	
tcc aac act gga att ggt gcc ccc acc tct ggt gct ggt cct gct ggg	979
<u>Ser Asn Thr Gly Ile Gly Ala Pro Thr Ser Gly Ala Gly Pro Ala Gly</u>	
280	285
290	
ccc tat gcc aag gag tct ggg atc tgg gct tac tac gag atc tgt acc	1027
<u>Pro Tyr Ala Lys Glu Ser Gly Ile Trp Ala Tyr Tyr Glu Ile Cys Thr</u>	
295	300
305	
ttc ctg aaa aat gga gcc act cag gga tgg gat gcc cct cag gaa gtg	1075
<u>Phe Leu Lys Asn Gly Ala Thr Gln Gly Trp Asp Ala Pro Gln Glu Val</u>	
310	315
320	
cct tat gcc tat cag ggc aat gtg tgg gtt ggc tat gac aac atc aag	1123
<u>Pro Tyr Ala Tyr Gln Gly Asn Val Trp Val Gly Tyr Asp Asn Ile Lys</u>	
325	330
335	340
agc ttc gat att aag gct caa tgg ctt aag cac aac aaa ttt gga ggc	1171
<u>Ser Phe Asp Ile Lys Ala Gln Trp Leu Lys His Asn Lys Phe Gly Gly</u>	
345	350
355	
gcc atg gtc tgg gcc att gat ctg gat gac ttc act ggc act ttc tgc	1219
<u>Ala Met Val Trp Ala Ile Asp Leu Asp Asp Phe Thr Gly Thr Phe Cys</u>	

360	365	370
aac cag ggc aag ttt ccc cta atc tcc acc ctg aag aag gcc ctc ggc Asn Gln Gly Lys Phe Pro Leu Ile Ser Thr Leu Lys Lys Ala Leu Gly		1267
375	380	385
ctg cag agt gca agt tgc acg gct cca gct cag ccc att gag cca ata Leu Gln Ser Ala Ser Cys Thr Ala Pro Ala Gln Pro Ile Glu Pro Ile		1315
390	395	400
act gct gct ccc agt ggc agc ggg aac ggg agc ggg agt agc agc tct Thr Ala Ala Pro Ser Gly Ser Gly Asn Gly Ser Ser Ser Ser Ser		1363
405	410	415
425	430	435
gga ggc agc tcg gga ggc agt gga ttc tgt gct gtc aga gcc aac ggc Gly Gly Ser Ser Gly Gly Ser Gly Phe Cys Ala Val Arg Ala Asn Gly		1411
455	460	465
ctc tac ccc gtg gca aat aac aga aat gcc ttc tgg cac tgc gtg aat Leu Tyr Pro Val Ala Asn Asn Arg Asn Ala Phe Trp His Cys Val Asn		1459
440	445	450
gga gtc acg tac cag cag aac tgc cag gcc ggg ctt gtc ttc gac acc Gly Val Thr Tyr Gln Gln Asn Cys Gln Ala Gly Leu Val Phe Asp Thr		1507
455	460	465
agc tgt gat tgc aac tgg gca taaacctgac ctgggtctata ttcccttagag Ser Cys Asp Cys Cys Asn Trp Ala		1561
470	475	
ttccagtctc ttttgcttag gacatgtgc ccctacctaa agtcctgcaa taaaatcagc		1621
agtc		1625

<210> 3
<211> 1525
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Combined DNA/RNA Molecule: mouse
AMCase cDNA sequence and deduced amino acid
sequence

<220>
<223> Description of Artificial Sequence: mouse AMCase
cDNA sequence and deduced amino acid sequence

<220>
<221> CDS
<222> (1)..(1419)

<400> 3
atg gcc aag cta ctt ctc gtc aca ggt ctg qct ctt ctg ctg aat gct 48
Met Ala Lys Leu Leu Leu Val Thr Gly Leu Ala Leu Leu Leu Asn Ala
1 5 10 15

cag ctg ggg tct gcc tac aat ctg ata tgc tat ttc acc aac tgg gcc	96
Gln Leu Gly Ser Ala Tyr Asn Leu Ile Cys Tyr Phe Thr Asn Trp Ala	
20	25
30	
cag tat cgg cca ggt ctg ggg agc ttc aag cct gat gac att aac ccc	144
Gln Tyr Arg Pro Gly Leu Gly Ser Phe Lys Pro Asp Asp Ile Asn Pro	
35	40
45	
tgc ctg tgt act cac ctg atc tat gcc ttt gct ggg atg cag aac aat	192
Cys Leu Cys Thr His Leu Ile Tyr Ala Phe Ala Gly Met Gln Asn Asn	
50	55
60	
gag atc acc acc ata gaa tgg aat gat gtt act ctc tat aaa gct ttc	240
Glu Ile Thr Thr Ile Glu Trp Asn Asp Val Thr Leu Tyr Lys Ala Phe	
65	70
75	80
aat gac ttg aaa aac agg aac agc aaa ctg aaa acc ctc ctg gca att	288
Asn Asp Leu Lys Asn Arg Asn Ser Lys Leu Lys Thr Leu Leu Ala Ile	
85	90
95	
gga ggc tgg aac ttt gga act gct cct ttc act acc atg gtt tcc act	336
Gly Gly Trp Asn Phe Gly Thr Ala Pro Phe Thr Thr Met Val Ser Thr	
100	105
110	
tct cag aac cgc cag acc ttc att acc tca gtc atc aaa ttt ctg cgt	384
Ser Gln Asn Arg Gln Thr Phe Ile Thr Ser Val Ile Lys Phe Leu Arg	
115	120
125	
cag tat ggg ttt gat gga ctg gac ctg gac tgg gaa tac cca ggc tca	432
Gln Tyr Gly Phe Asp Gly Leu Asp Leu Asp Trp Glu Tyr Pro Gly Ser	
130	135
140	
cgt ggg agc cct cct cag gac aag cat ctc ttc act gtc ctg gtg aag	480
Arg Gly Ser Pro Pro Gln Asp Lys His Leu Phe Thr Val Leu Val Lys	
145	150
155	160
gaa atg cgt gaa gct ttt gag cag gag gct att gag agc aac agg ccc	528
Glu Met Arg Glu Ala Phe Glu Gln Glu Ala Ile Glu Ser Asn Arg Pro	
165	170
175	
aga ctg atg gtt act gct gta gct ggt ggg att tcc aac atc cag	576
Arg Leu Met Val Thr Ala Ala Val Ala Gly Gly Ile Ser Asn Ile Gln	
180	185
190	
gct ggc tat gag atc cct gaa ctt tct aag tac ctg gat ttc atc cat	624
Ala Gly Tyr Glu Ile Pro Glu Leu Ser Lys Tyr Leu Asp Phe Ile His	
195	200
205	
gtc atg aca tat gac ctc cat ggc tcc tgg gag ggc tac act ggg gag	672
Val Met Thr Tyr Asp Leu His Gly Ser Trp Glu Gly Tyr Thr Gly Glu	
210	215
220	
aat agt cct ctt tac aaa tac cct act gag act ggt agc aat gcc tac	720
Asn Ser Pro Leu Tyr Lys Tyr Pro Thr Glu Thr Gly Ser Asn Ala Tyr	
225	230
235	240
ctc aat gtg gat tat gtc atg aac tat tgg aag aac aat gga gcc cca	768
Leu Asn Val Asp Tyr Val Met Asn Tyr Trp Lys Asn Asn Gly Ala Pro	

245	250	255
<u>gct gag aag ctc att gtt gga ttc cca gag tat gga cac acc ttc atc</u>		
<u>Ala Glu Lys Leu Ile Val Gly Phe Pro Glu Tyr Gly His Thr Phe Ile</u>		<u>816</u>
<u>260</u>	<u>265</u>	<u>270</u>
<u>ctg aga aac ccc tct gat aat gga att ggt gcc cct acc tct ggt gat</u>		
<u>Leu Arg Asn Pro Ser Asp Asn Gly Ile Gly Ala Pro Thr Ser Gly Asp</u>		<u>864</u>
<u>275</u>	<u>280</u>	<u>285</u>
<u>ggc cct gct ggc gcc tat acc aga cag gct ggg ttc tgg gcc tac tat</u>		
<u>Gly Pro Ala Gly Ala Tyr Thr Arg Gln Ala Gly Phe Trp Ala Tyr Tyr</u>		<u>912</u>
<u>290</u>	<u>295</u>	<u>300</u>
<u>gag att tgc acc ttt ctg aga agt gga gcc act gag gtc tgg gat gcc</u>		
<u>Glu Ile Cys Thr Phe Leu Arg Ser Gly Ala Thr Glu Val Trp Asp Ala</u>		<u>960</u>
<u>305</u>	<u>310</u>	<u>315</u>
<u>320</u>		
<u>tcc caa gaa gtg ccc tat gcc tat aag gcc aac gag tgg ctt ggc tat</u>		
<u>Ser Gln Glu Val Pro Tyr Ala Tyr Lys Ala Asn Glu Trp Leu Gly Tyr</u>		<u>1008</u>
<u>325</u>	<u>330</u>	<u>335</u>
<u>gac aat atc aag agc ttc agt gtt aag gct cag tgg ctt aag cag aac</u>		
<u>Asp Asn Ile Lys Ser Phe Ser Val Lys Ala Gln Trp Leu Lys Gln Asn</u>		<u>1056</u>
<u>340</u>	<u>345</u>	<u>350</u>
<u>aat ttt gga ggt gcc atg atc tgg gcc att gac ctt gat gac ttc act</u>		
<u>Asn Phe Gly Gly Ala Met Ile Trp Ala Ile Asp Leu Asp Asp Phe Thr</u>		<u>1104</u>
<u>355</u>	<u>360</u>	<u>365</u>
<u>ggc tct ttc tgt gat cag gga aaa ttt cct ctg act tct act ttg aac</u>		
<u>Gly Ser Phe Cys Asp Gln Gly Lys Phe Pro Leu Thr Ser Thr Leu Asn</u>		<u>1152</u>
<u>370</u>	<u>375</u>	<u>380</u>
<u>aaa gcc ctt ggc ata tcc act gaa ggt tgc aca gct cct gac gtg cct</u>		
<u>Lys Ala Leu Gly Ile Ser Thr Glu Gly Cys Thr Ala Pro Asp Val Pro</u>		<u>1200</u>
<u>385</u>	<u>390</u>	<u>395</u>
<u>400</u>		
<u>tcc gag cca gtg act act cct cca gga agt ggg agt ggg ggt gga agc</u>		
<u>Ser Glu Pro Val Thr Thr Pro Pro Gly Ser Gly Ser Gly Gly Ser</u>		<u>1248</u>
<u>405</u>	<u>410</u>	<u>415</u>
<u>tcc gga gga agc tct gga ggc agt gga ttc tgt gcc gac aaa gca gat</u>		
<u>Ser Gly Gly Ser Ser Gly Gly Ser Gly Phe Cys Ala Asp Lys Ala Asp</u>		<u>1296</u>
<u>420</u>	<u>425</u>	<u>430</u>
<u>ggc ctc tac cct gtg gca gat gac aga aat gct ttt tgg cag tgc atc</u>		
<u>Gly Leu Tyr Pro Val Ala Asp Asp Arg Asn Ala Phe Trp Gln Cys Ile</u>		<u>1344</u>
<u>435</u>	<u>440</u>	<u>445</u>
<u>aat gga atc aca tac cag cag cat tgtcaa gca ggg ctt gtt ttt gat</u>		
<u>Asn Gly Ile Thr Tyr Gln Gln His Cys Gln Ala Gly Leu Val Phe Asp</u>		<u>1392</u>
<u>450</u>	<u>455</u>	<u>460</u>
<u>acc agc tgt aat tgc tgc aac tgg cca tgaacctaat gccattttc</u>		
<u>Thr Ser Cys Asn Cys Cys Asn Trp Pro</u>		<u>1439</u>
<u>465</u>	<u>470</u>	

cagaaatttc tgcactctcc ttactcctc accaaaagta actatcttcc cttaacctt 1499
atgcaataaa attggtagcc aaaaca 1525

<210> 4
<211> 473

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: mouse AMCase
amino acid sequence deduced from cDNA sequence

<400> 4

Met Ala Lys Leu Leu Leu Val Thr Gly Leu Ala Leu Leu Leu Asn Ala			
1	5	10	15

Gln Leu Gly Ser Ala Tyr Asn Leu Ile Cys Tyr Phe Thr Asn Trp Ala		
20	25	30

Gln Tyr Arg Pro Gly Leu Gly Ser Phe Lys Pro Asp Asp Ile Asn Pro		
35	40	45

Cys Leu Cys Thr His Leu Ile Tyr Ala Phe Ala Gly Met Gln Asn Asn		
50	55	60

Glu Ile Thr Thr Ile Glu Trp Asn Asp Val Thr Leu Tyr Lys Ala Phe			
65	70	75	80

Asn Asp Leu Lys Asn Arg Asn Ser Lys Leu Lys Thr Leu Leu Ala Ile		
85	90	95

Gly Gly Trp Asn Phe Gly Thr Ala Pro Phe Thr Thr Met Val Ser Thr		
100	105	110

Ser Gln Asn Arg Gln Thr Phe Ile Thr Ser Val Ile Lys Phe Leu Arg		
115	120	125

Gln Tyr Gly Phe Asp Gly Leu Asp Leu Asp Trp Glu Tyr Pro Gly Ser		
130	135	140

Arg Gly Ser Pro Pro Gln Asp Lys His Leu Phe Thr Val Leu Val Lys			
145	150	155	160

Glu Met Arg Glu Ala Phe Glu Gln Glu Ala Ile Glu Ser Asn Arg Pro		
165	170	175

Arg Leu Met Val Thr Ala Ala Val Ala Gly Gly Ile Ser Asn Ile Gln		
180	185	190

Ala Gly Tyr Glu Ile Pro Glu Leu Ser Lys Tyr Leu Asp Phe Ile His		
195	200	205

Val Met Thr Tyr Asp Leu His Gly Ser Trp Glu Gly Tyr Thr Gly Glu		
210	215	220

Asn Ser Pro Leu Tyr Lys Tyr Pro Thr Glu Thr Gly Ser Asn Ala Tyr			
225	230	235	240

Leu	Asn	Val	Asp	Tyr	Val	Met	Asn	Tyr	Trp	Lys	Asn	Asn	Gly	Ala	Pro
					245				250					255	
Ala	Glu	Lys	Leu	Ile	Val	Gly	Phe	Pro	Glu	Tyr	Gly	His	Thr	Phe	Ile
					260				265				270		
Leu	Arg	Asn	Pro	Ser	Asp	Asn	Gly	Ile	Gly	Ala	Pro	Thr	Ser	Gly	Asp
					275			280				285			
Gly	Pro	Ala	Gly	Ala	Tyr	Thr	Arg	Gln	Ala	Gly	Phe	Trp	Ala	Tyr	Tyr
					290			295			300				
Glu	Ile	Cys	Thr	Phe	Leu	Arg	Ser	Gly	Ala	Thr	Glu	Val	Trp	Asp	Ala
					305			310			315			320	
Ser	Gln	Glu	Val	Pro	Tyr	Ala	Tyr	Lys	Ala	Asn	Glu	Trp	Leu	Gly	Tyr
					325				330				335		
Asp	Asn	Ile	Lys	Ser	Phe	Ser	Val	Lys	Ala	Gln	Trp	Leu	Lys	Gln	Asn
					340			345				350			
Asn	Phe	Gly	Gly	Ala	Met	Ile	Trp	Ala	Ile	Asp	Leu	Asp	Asp	Phe	Thr
					355			360			365				
Gly	Ser	Phe	Cys	Asp	Gln	Gly	Lys	Phe	Pro	Leu	Thr	Ser	Thr	Leu	Asn
					370			375			380				
Lys	Ala	Leu	Gly	Ile	Ser	Thr	Glu	Gly	Cys	Thr	Ala	Pro	Asp	Val	Pro
					385			390			395			400	
Ser	Glu	Pro	Val	Thr	Thr	Pro	Pro	Gly	Ser	Gly	Ser	Gly	Gly	Ser	
					405				410			415			
Ser	Gly	Gly	Ser	Ser	Gly	Gly	Ser	Gly	Phe	Cys	Ala	Asp	Lys	Ala	Asp
					420				425			430			
Gly	Leu	Tyr	Pro	Val	Ala	Asp	Asp	Arg	Asn	Ala	Phe	Trp	Gln	Cys	Ile
					435			440			445				
Asn	Gly	Ile	Thr	Tyr	Gln	Gln	His	Cys	Gln	Ala	Gly	Leu	Val	Phe	Asp
					450			455			460				
Thr	Ser	Cys	Asn	Cys	Cys	Asn	Trp	Pro							
					465			470							

<210> 5
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: A-tail primer

<220>
<221> misc feature
<222> (1) (22)

<400> 5
ttttggctac caattttatt gc

22

<210> 6
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: anti-sense
primer MAS1

<220>
<221> misc feature
<222> (1)..(23)

<400> 6
cagctacagc agcagtaacc atc

23

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: anti-sense
primer MAS2

<220>
<221> misc feature
<222> (1)..(21)

<400> 7
ttcaggggatc tcatagccag c

21

<210> 8
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: sense primer
MS1

<220>
<221> misc feature
<222> (1)..(22)

<400> 8
cgatggccaa gctacttctc gt

22

<210> 9
<211> 452
<212> PRT

<213> Mus musculus

<220>

<221> SITE

<222> (1)..(452)

<223> /note="Mouse AMCase"

<400> 9

Tyr	Asn	Leu	Ile	Cys	Tyr	Phe	Thr	Asn	Trp	Ala	Gln	Tyr	Arg	Pro	Gly
1				5				10					15		

Leu	Gly	Ser	Phe	Lys	Pro	Asp	Asp	Ile	Asn	Pro	Cys	Leu	Cys	Thr	His
				20				25				30			

Leu	Ile	Tyr	Ala	Phe	Ala	Gly	Met	Gln	Asn	Asn	Glu	Ile	Thr	Thr	Ile
				35			40				45				

Glu	Trp	Asn	Asp	Val	Thr	Leu	Tyr	Lys	Ala	Phe	Asn	Asp	Leu	Lys	Asn
	50				55			60							

Arg	Asn	Ser	Lys	Leu	Lys	Thr	Leu	Leu	Ala	Ile	Gly	Gly	Trp	Asn	Phe
	65				70			75				80			

Gly	Thr	Ala	Pro	Phe	Thr	Thr	Met	Val	Ser	Thr	Ser	Gln	Asn	Arg	Gln
	85				90				95						

Thr	Phe	Ile	Thr	Ser	Val	Ile	Lys	Phe	Leu	Arg	Gln	Tyr	Gly	Phe	Asp
	100				105				110						

Gly	Leu	Asp	Leu	Asp	Trp	Glu	Tyr	Pro	Gly	Ser	Arg	Gly	Ser	Pro	Pro
	115				120			125							

Gln	Asp	Lys	His	Leu	Phe	Thr	Val	Leu	Val	Lys	Glu	Met	Arg	Glu	Ala
	130				135			140							

Phe	Glu	Gln	Glu	Ala	Ile	Glu	Ser	Asn	Arg	Pro	Arg	Leu	Met	Val	Thr
145				150			155		160						

Ala	Ala	Val	Ala	Gly	Gly	Ile	Ser	Asn	Ile	Gln	Ala	Gly	Tyr	Glu	Ile
				165				170		175					

Pro	Glu	Leu	Ser	Lys	Tyr	Leu	Asp	Phe	Ile	His	Val	Met	Thr	Tyr	Asp
	180				185			190							

Leu	His	Gly	Ser	Trp	Glu	Gly	Tyr	Thr	Gly	Glu	Asn	Ser	Pro	Leu	Tyr
	195				200			205							

Lys	Tyr	Pro	Thr	Glu	Thr	Gly	Ser	Asn	Ala	Tyr	Leu	Asn	Val	Asp	Tyr
	210			215			220								

Val	Met	Asn	Tyr	Trp	Lys	Asn	Asn	Gly	Ala	Pro	Ala	Glu	Lys	Leu	Ile
225				230			235		240						

Val	Gly	Phe	Pro	Glu	Tyr	Gly	His	Thr	Phe	Ile	Leu	Arg	Asn	Pro	Ser
	245				250			255							

Asp	Asn	Gly	Ile	Gly	Ala	Pro	Thr	Ser	Gly	Asp	Gly	Pro	Ala	Gly	Ala
	260			265			270								

Tyr Thr Arg Gln Ala Gly Phe Trp Ala Tyr Tyr Glu Ile Cys Thr Phe
 275 280 285

Leu	Arg	Ser	Gly	Ala	Thr	Glu	Val	Trp	Asp	Ala	Ser	Gln	Glu	Val	Pro
290						295						300			

Tyr Ala Tyr Lys Ala Asn Glu Trp Leu Gly Tyr Asp Asn Ile Lys Ser
 305 310 315 320

Phe Ser Val Lys Ala Gln Trp Leu Lys Gln Asn Asn Phe Gly Gly Ala
 325 330 335

Met Ile Trp Ala Ile Asp Leu Asp Asp Phe Thr Gly Ser Phe Cys Asp
340 345 350

Gln	Gly	Lys	Phe	Pro	Leu	Thr	Ser	Thr	Leu	Asn	Lys	Ala	Leu	Gly	Ile
				355				360						365	

Ser	Thr	Glu	Gly	Cys	Thr	Ala	Pro	Asp	Val	Pro	Ser	Glu	Pro	Val	Thr
370					375						380				

Thr Pro Pro Gly Ser Gly Ser Gly Gly Gly Ser Ser Ser Gly Gly Ser Ser
385 390 395 400

Gly Gly Ser Gly Phe Cys Ala Asp Lys Ala Asp Gly Leu Tyr Pro Val
 405 410 415

Ala Asp Asp Arg Asn Ala Phe Trp Gln Cys Ile Asn Gly Ile Thr Tyr
420 425 430

Gln Gln His Cys Gln Ala Gly Leu Val Phe Asp Thr Ser Cys Asn Cys
435 440 445

Cys Asn Trp Pro
450

<210> 10

<211> 445

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

$\langle 222 \rangle$ (1) .. (445)

<223> /note="Human chitotriosidase"

<400> 10

Ala Lys Leu Val Cys Tyr Phe Thr Asn Trp Ala Gin Tyr Arg Gln Gly
 1 5 10 15

Glu Ala Arg Phe Leu Pro Lys Asp Leu Asp Pro Ser Leu Cys Thr His
 20 25 30

Leu Ile Tyr Ala Phe Ala Gly Met Thr Asn His Gin Leu Ser Thr Thr
35 40 45

Glu	Trp	Asn	Asp	Glu	Thr	Leu	Tyr	Gln	Glu	Phe	Asn	Gly	Leu	Lys	Lys
50				55				60							
Met	Asn	Pro	Lys	Leu	Lys	Thr	Leu	Leu	Ala	Ile	Gly	Gly	Trp	Asn	Phe
65				70				75					80		
Gly	Thr	Gln	Lys	Phe	Thr	Asp	Met	Val	Ala	Thr	Ala	Asn	Asn	Arg	Gln
				85				90				95			
Thr	Phe	Val	Asn	Ser	Ala	Ile	Arg	Phe	Leu	Arg	Lys	Tyr	Ser	Phe	Asp
				100				105				110			
Gly	Leu	Asp	Leu	Asp	Trp	Glu	Tyr	Pro	Gly	Ser	Gln	Gly	Ser	Pro	Ala
				115				120			125				
Val	Asp	Lys	Glu	Arg	Phe	Thr	Thr	Leu	Val	Gln	Asp	Leu	Ala	Asn	Ala
				130				135			140				
Phe	Gln	Gln	Glu	Ala	Gln	Thr	Ser	Gly	Lys	Glu	Arg	Leu	Leu	Leu	Ser
				145				150			155		160		
Ala	Ala	Val	Pro	Ala	Gly	Gln	Thr	Tyr	Val	Asp	Ala	Gly	Tyr	Glu	Val
				165				170			175				
Asp	Lys	Ile	Ala	Gln	Asn	Leu	Asp	Phe	Val	Asn	Leu	Met	Ala	Tyr	Asp
				180				185			190				
Phe	His	Gly	Ser	Trp	Glu	Lys	Val	Thr	Gly	His	Asn	Ser	Pro	Leu	Tyr
				195				200			205				
Lys	Arg	Gln	Glu	Glu	Ser	Gly	Ala	Ala	Ala	Ser	Leu	Asn	Val	Asp	Ala
				210				215			220				
Ala	Val	Gln	Gln	Trp	Leu	Gln	Lys	Gly	Thr	Pro	Ala	Ser	Lys	Leu	Ile
				225				230			235		240		
Leu	Gly	Met	Pro	Thr	Tyr	Gly	Arg	Ser	Phe	Thr	Leu	Ala	Ser	Ser	Ser
				245				250			255				
Asp	Thr	Arg	Val	Gly	Ala	Pro	Ala	Thr	Gly	Ser	Gly	Thr	Pro	Gly	Pro
				260				265			270				
Phe	Thr	Lys	Glu	Gly	Gly	Met	Leu	Ala	Tyr	Tyr	Glu	Val	Cys	Ser	Trp
				275				280			285				
Lys	Gly	Ala	Thr	Lys	Gln	Arg	Ile	Gln	Asp	Gln	Lys	Val	Pro	Tyr	Ile
				290				295			300				
Phe	Arg	Asp	Asn	Gln	Trp	Val	Gly	Phe	Asp	Asp	Val	Glu	Ser	Phe	Lys
				305				310			315		320		
Thr	Lys	Val	Ser	Tyr	Leu	Lys	Gln	Lys	Gly	Leu	Gly	Gly	Ala	Met	Val
				325				330			335				
Trp	Ala	Leu	Asp	Leu	Asp	Asp	Phe	Ala	Gly	Phe	Ser	Cys	Asn	Gln	Gly
				340				345			350				
Arg	Tyr	Pro	Leu	Ile	Gln	Thr	Leu	Arg	Gln	Glu	Leu	Ser	Leu	Pro	Tyr

355	360	365
<u>Leu Pro Ser Gly Thr Pro Glu Leu Glu Val Pro Lys Pro Gly Gln Pro</u>		
370	375	380
<u>Ser Glu Pro Glu His Gly Pro Ser Pro Gly Gln Asp Thr Phe Cys Gln</u>		
385	390	395
<u>Gly Lys Ala Asp Gly Leu Tyr Pro Asn Pro Arg Glu Arg Ser Ser Phe</u>		
405	410	415
<u>Tyr Ser Cys Ala Ala Gly Arg Leu Phe Gln Gln Ser Cys Pro Thr Gly</u>		
420	425	430
<u>Leu Val Phe Ser Asn Ser Cys Lys Cys Cys Thr Trp Asn</u>		
435	440	445

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer HAS2

<220>

<221> misc feature

<222> (1)...(24)

<400> 11

tctgacagca cagaatccac tgcc

24

<210> 12

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer
HAS3-A-tail

<220>

<221> misc feature

<222> (1)...(22)

<400> 12

ttgactgctg attttattgc ag

22

<210> 13

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer HS1

<220>
<221> misc feature
<222> (1)..(22)

<400> 13
gctttccagt ctggtgtga at

22

<210> 14
<211> 455
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (1)..(455)
<223> /note="Human AMCase"

<400> 14
Tyr Gln Leu Thr Cys Tyr Phe Thr Asn Trp Ala Gln Tyr Arg Pro Gly
1 5 10 15

Leu Gly Arg Phe Met Pro Asp Asn Ile Asp Pro Cys Leu Cys Thr His
20 25 30

Leu Ile Tyr Ala Phe Ala Gly Arg Gln Asn Asn Glu Ile Thr Thr Ile
35 40 45

Glu Trp Asn Asp Val Thr Leu Tyr Gln Ala Phe Asn Gly Leu Lys Asn
50 55 60

Lys Asn Ser Gln Leu Lys Thr Leu Leu Ala Ile Gly Gly Trp Asn Phe
65 70 75 80

Gly Thr Ala Pro Phe Thr Ala Met Val Ser Thr Pro Glu Asn Arg Gln
85 90 95

Thr Phe Ile Thr Ser Val Ile Lys Phe Leu Arg Gln Tyr Glu Phe Asp
100 105 110

Gly Leu Asp Phe Asp Trp Glu Tyr Pro Gly Ser Arg Gly Ser Pro Pro
115 120 125

Gln Asp Lys His Leu Phe Thr Val Leu Val Gln Glu Met Arg Glu Ala
130 135 140

Phe Glu Gln Glu Ala Lys Gln Ile Asn Lys Pro Arg Leu Met Val Thr
145 150 155 160

Ala Ala Val Ala Ala Gly Ile Ser Asn Ile Gln Ser Gly Tyr Glu Ile
165 170 175

Pro Gln Leu Ser Gln Tyr Leu Asp Tyr Ile His Val Met Thr Tyr Asp
180 185 190

Leu His Gly Ser Trp Glu Gly Tyr Thr Gly Glu Asn Ser Pro Leu Tyr
195 200 205

Lys Tyr Pro Thr Asp Thr Gly Ser Asn Ala Tyr Leu Asn Val Asp Tyr
210 215 220
Val Met Asn Tyr Trp Lys Asp Asn Gly Ala Pro Ala Glu Lys Leu Ile
225 230 235 240
Val Gly Phe Pro Thr Tyr Gly His Asn Phe Ile Leu Ser Asn Pro Ser
245 250 255
Asn Thr Gly Ile Gly Ala Pro Thr Ser Gly Ala Gly Pro Ala Gly Pro
260 265 270
Tyr Ala Lys Glu Ser Gly Ile Trp Ala Tyr Tyr Glu Ile Cys Thr Phe
275 280 285
Leu Lys Asn Gly Ala Thr Gln Gly Trp Asp Ala Pro Gln Glu Val Pro
290 295 300
Tyr Ala Tyr Gln Gly Asn Val Trp Val Gly Tyr Asp Asn Ile Lys Ser
305 310 315 320
Phe Asp Ile Lys Ala Gln Trp Leu Lys His Asn Lys Phe Gly Gly Ala
325 330 335
Met Val Trp Ala Ile Asp Leu Asp Asp Phe Thr Gly Thr Phe Cys Asn
340 345 350
Gln Gly Lys Phe Pro Leu Ile Ser Thr Leu Lys Lys Ala Leu Gly Leu
355 360 365
Gln Ser Ala Ser Cys Thr Ala Pro Ala Gln Pro Ile Glu Pro Ile Thr
370 375 380
Ala Ala Pro Ser Gly Ser Gly Asn Gly Ser Ser Ser Ser Gly
385 390 395 400
Gly Ser Ser Gly Gly Ser Gly Phe Cys Ala Val Arg Ala Asn Gly Leu
405 410 415
Tyr Pro Val Ala Asn Asn Arg Asn Ala Phe Trp His Cys Val Asn Gly
420 425 430
Val Thr Tyr Gln Gln Asn Cys Gln Ala Gly Leu Val Phe Asp Thr Ser
435 440 445
Cys Asp Cys Cys Asn Trp Ala
450 455

ABSTRACT

[0139] The invention provides a mammalian mucinase capable of hydrolyzing mucus. The mucinase is among others suitable for counteracting diseases in which mucus is involved. The diseases comprise cystic fibrosis, COPD, asthma, bronchitis, tuberculosis, tumors with altered mucus expression, and mucus-containing pathogens. The invention also provides a pharmaceutical composition comprising an effective amount of the mucinase and a method of therapeutic or prophylactic treatment of an individual against a disease in which mucus is involved. Methods for obtaining the mucinase are also herewith provided, as well as nucleic acids encoding (part of) the mucinase. In one aspect, the invention provides a diagnostic kit comprising a mucinase, a mucinase-specific antibody, a mucinase-derived peptide and/or nucleic acid encoding (part of) the mucinase.



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Aerts et al.

Serial No.: 10/004,219

Filed: November 2, 2001

For: A MAMMALIAN MUCINASE, ITS RECOMBINANT PRODUCTION, AND ITS USE IN THERAPY OR PROPHYLAXIS AGAINST DISEASES IN WHICH MUCUS IS INVOLVED OR INFECTIOUS DISEASE

Examiner: To be assigned

Group Art Unit: 1645

Attorney Docket No.: 2183-5136US

CERTIFICATE OF MAILING

I hereby certify that this correspondence along with any attachments referred to or identified as being attached or enclosed is being deposited with the United States Postal Service as First Class Mail (under 37 C F R § 18(a)) on the date of deposit shown below with sufficient postage and in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

May 29, 2002

Date of Deposit

Betty Vowles

Signature of registered practitioner or other person having reasonable basis to expect mailing to occur on date of deposit shown pursuant to 37 C F R § 18(a)(1)(ii)

Betty Vowles

Typed/printed name of person whose signature is contained above

SUBMISSION OF PROPOSED DRAWING AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.121(d), Applicant hereby requests approval by the Examiner of the proposed drawing amendments to figures 2-8. The drawing changes are the removal of as-filed drawing figures 2 and 8A (the listings previously shown in these figures being incorporated into the text of the specification) and the renumbering of the remaining drawing figures in accordance therewith. As-filed drawing figure 8B has been renumbered as figure 8 and the font size thereof increased in compliance with 37 C.F.R. § 1.84.

Serial No.: 10/004,219

Further, a typographical error in as-filed drawing figure 6B (now figure 5B) has been corrected. Specifically, "Small" has been amended to instead read "Small". This amendment is shown on the attached sheet with red ink markings indicating the proposed change thereto.

Applicant does not believe that any fee is required to accompany this Submission of Proposed Drawing Amendment. However, should such a fee be required, please debit Deposit Account No. 20-1469 for the amount of such fee.

Respectfully submitted,



Tawni L. Wilhelm
Registration No. 47,456
Attorney for Applicants
TRASKBRITT, PC
P. O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: (801) 532-1922

Date: May 29, 2002

ACT/TLW/bv